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Abstract
The effective control of porcine reproductive and respiratory syndrome virus 
(PRRSV), which causes substantial economic losses to the pig industry worldwide, 
is challenged by complicated host-pathogen interactions and delayed immunity. 
This study aimed to characterise myeloid immune cells associated with PRRSV 
(monocytes, macrophages, dendritic cells), and to assess their susceptibility to 
infection, in order to help identify underlying mechanisms that might facilitate 
PRRSV success. Cellular expression of putative PRRSV receptors CD 163 
(scavenger receptor) and CD 169 (sialic-acid binding lectin), was central to 
investigations.
Porcine monocytes isolated from peripheral blood were treated with various 
cytokines and macrophage activating factors before infection with Eastern European 
PRRSV strain Lena. IL-10 and dexamethasone (dexa) significantly up-regulated 
PRRSV replication, which correlated with increased CD 163/CD 169. M-CSF 
differentiated monocyte derived macrophages (MoMos) were stimulated with 
activators for classical (LPS/IFN-y) or alternative (IL-4) activation. GM-CSF and 
IL-4 generated monocyte derived dendritic cells (MoDCs) were activated with a 
maturation cocktail containing EPS, IFN-y, IL-lp, IL-6, TNF-a and PGE2. Dexa 
and IL-10 were added to MoMos and MoDCs to further assess their significance. 
Cells were characterised by morphology, phenotype and function, and PRRSV 
replication measured using flow cytometry and RT-qPCR.
Analysis of porcine macrophage subsets highlighted some divergence from 
described human counterparts. MoDCs, however, appeared similar to mouse and 
human DCs, showing a MHCIIhlCD80/86hlCD14low phenotype upon maturation. 
Infection studies revealed similar replication across activation states, and dexa and
IL-10 significantly increased MoM0 susceptibility. MoDCs showed low replication, 
which was independent of CD 163/CD 169.
These novel findings demonstrate the high variability of porcine myeloid 
cells. PRRSV tropism was not restricted to macrophages, and not always dependent 
on CD 163/CD 169. Cortisol appeared not to be associated with immunosuppression 
of myeloid cells, but supported PRRSV replication in monocytes and macrophages, a 
finding significant for future PRRSV control strategies and perhaps relevant to other 
porcine infectious diseases.
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Chapter I
Introduction
1. INTRODUCTION
1.1. Porcine reproductive and respiratory syndrome
Porcine reproductive and respiratory syndrome (PRRS) is an infectious 
disease of swine, which is endemic in the United Kingdom as well as in most other 
pork producing countries worldwide (World Organisation for Animal Health, 2012). 
PRRS, caused by PRRS virus (PRRSV), was first described in North America in 
1987 and shortly afterwards in Europe, including the in UK, in 1991 (Collins et ah, 
1992; Edwards et ah, 1992). PRRSV has since spread worldwide, inflicting 
significant economic losses to the global swine industry. The ability of PRRSV to 
cause reproductive failure in breeding pigs and respiratory problems in young pigs 
leads to inevitable significant losses of pig production; estimated costs of up to 
US$560 million a year have been reported as a result of PRRSV infection in USA 
(Neumann et ah, 2005). In The Netherlands, an outbreak of PRRSV lasting 18 
weeks was estimated to cost €379 per sow (Nieuwenhuis et ah, 2012). It remains a 
difficult challenge to eradicate PRRSV, as disease control is complicated by many 
variable factors in the genetic diversity of the virus, its pathogenesis and in host 
susceptibility to PRRSV. The emergence of highly pathogenic strains of PRRSV in 
2006 had a damaging effect on the swine industry in China, and demonstrated the 
ability of the virus to evolve into even more pathogenic variants (Tian et ah, 2007). 
In order to prevent any further damage to global pig industries, more efficient 
strategies of disease control are urgently required. In order to help achieve these, the 
complete pathogenesis of the disease and an improved understanding the underlying 
mechanisms of the host immune responses to PRRSV need to be established.
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PRRSV infects all ages of swine, with infections that vary from mild 
infection resulting in some production losses, to highly pathogenic infection leading 
to high mortality throughout herds (Rossow, 1998). In reproducing pigs, various 
breeding problems can occur in the sow; abortions, still births, mummified pigs, 
premature farrowings and reduced birth weight are all common features of PRRS, 
and in the boar, seminal quality is reduced (Prieto and Castro, 2005; Wensvoort et 
al., 1992). PRRSV infection in young pigs primarily results in respiratory problems, 
including coughing and dyspnea, along with fever and lack of appetite, resulting in 
reduced growth (Pejsak et al., 1997). Secondary infections to PRRSV, such as 
Mycoplasma hyopneumonia and Bordetella bronchisceptica, are also common in 
PRRSV infected animals, and increases mortality rates (Thacker et al., 1999).
The main route of transmission is by direct contact between pigs, however, 
various other routes exist; PRRSV has been isolated from semen, blood, saliva, 
faeces, aerosols, milk and colostrum (Swenson et al., 1994; Wagstrom et al., 1997; 
Wills et al., 1997a). Transplacental PRRSV transmission between sows and piglets 
can also occur (Christianson et al., 1992). It is characteristic o î Arteriviridae viruses 
to cause persistent infections (Snijder and Meulenberg, 1998), which PRRSV is able 
to do so for several months once the acute stage of infection has subsided, which can 
be up to 157 days post-infection (p.i) (Wills et al., 1997b). The ability of PRRSV to 
persist varies between virus strains, and is likely to also be affected by host genetic 
differences (Vincent et al., 2005). It would appear, however, that all ages of pig 
remain infected for at least several weeks, during which time pigs provide a 
longstanding source of infection for other pigs (Allende et al., 2000; Mengeling et 
al., 1994).
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PRRSV is able to spread rapidly between herds due to the variety of routes 
by which it can be transmitted. Control of PRRSV is currently by the combination 
of vaccination and adapted husbandry practices introduced at farm level (Papatsiros, 
2012). As an enveloped virus, PRRSV is particularly susceptible to desiccation and 
detergent, and its survival, therefore, is presumed to be limited to some extent by 
husbandry practices. However, this is not expected to provide complete control of 
the disease alone and seemingly requires combination with improved vaccination 
strategies.
Despite a poor understanding of the host immune response to PRRSV, 
several PRRSV vaccines are commercially available, including both modified-live 
virus (MLV) and inactivated-virus vaccines (Murtaugh et al., 2002; Vanhee et al., 
2009). The vaccines serve to reduce reproductive failure in sows and gilts and 
reduce viraemia and respiratory syndrome in young pigs, however, their efficacy is 
less than ideal due to the complexity of the host immune response and their inability 
to protect against the wide scope of circulating PRRSV strains (Mateu and Diaz, 
2008; Murtaugh et al., 2002). Consequently, there remains an ongoing obstacle in 
developing a single vaccine which can fully protect against all PRRSV strains, and 
therefore providing sustainable control against the disease (Diaz et al., 2005).
1.1.1. PRRS taxonomy and structure
Prior to the identification of the causative agent, PRRS was known as 
‘mystery swine disease’ or ‘blue ear disease’ due to the erythematous blanching rash 
observed on the ears of some infected pigs (Paton et al., 1991; Wensvoort et al., 
1991b). The virus of PRRS was identified by Wensvoort and colleagues as Lelystad
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virus in 1991, following virus isolation from experimentally infected pigs 
(Wensvoort et al., 1991b). It was named by the International Committee on 
Taxonomy of Viruses (ICTY) as PRRS virus (PRRSV), and is classed as an RNA 
virus belonging to the order Nidovirales, family Arteriviridae, and genus Arterivirus 
(van Regenmortel, 2000). Other members of the Arteriviridae family include equine 
arteritis virus (EAV), lactate dehydrogenase -elevating virus (LDEV), and simian 
haemorrhagic fever virus (SHFV).
PRRSV exhibits a high degree of genetic and antigenic variability. There are 
two genotypes of PRRSV described; the European genotype, PRRSV-l, and the 
North American genotype, PRRSV-2 (Meng et al., 1995) (Figure 1.1). Both 
genotypes cause the same disease, but viraemia or severity of the disease is 
influenced by virus genotype (Petry et al., 2005). PRRSV-2 is more commonly 
associated with higher virulence and more pathogenic disease than PRRSV-l, and 
comprises of many highly pathogenic strains, which induce high mortality rates 
(Johnson et al., 2004; Shang et al., 2013). Sequence analysis has shown that the two 
genotypes share only approximately 60% nucleotide identity (Allende et al., 1999), 
thus vaccination with one genotype fails to protect against infection with the other 
genotype (Labarque et al., 2003; van Woensel et al., 1998) and it has been argued 
that the two genotypes are in fact similar but distinct species. Furthermore, within 
each of the two genotypes there are many isolates exhibiting significant sequence 
variations (Chang et al., 2002; Frossard et al., 2012) (Table 1.1, Figure 1.1). Highly 
pathogenic strains of PRRSV, which emerged in China in 2006, caused severe 
disease in both young and adult pigs and induced high mortality rates (20-100%) 
(Tian et al., 2007). Infected pigs were highly contagious, resulting in the rapid 
transmission of the disease to many neighbouring provinces (Zhou et al., 2008).
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This highlighted the unpredictable genetic stability of PRRSV and its potential to 
become an even greater problem in swine industries worldwide. Table 1.1 
summarises some PRRSV strains which are of significance to PRRSV-l 
investigations, including Lena, a highly pathogenic strain selected for use in this 
study, Lelystad, a prototype strain used in many in vivo studies, and H2, a British 
stain often used as a positive control in diagnostic tests.
A
Isolate Geographical Origin Year Isolated Subtype Suggested pathogenicity
Lena Belarus 2007'* 1.3 H igh
Lelystad Netherlands 19912* 1.1 Medium
H2 UK 19913* 1.1 Low
B
Percentage identity
Lelystad Lena H2 VR2332
Lelystad 80.8 99.2 63.2
Lena 19.2 80.8 63.6
H2 0.8 19.2 63.0
VR2332 36.8 36.4 37.0
Table 1.1. Summary of PRRSV strains significant to PRRSV-l studies. A shows some 
basic features o f three relevant PRRSV-l strains, where 1 *(Kamiychuk et al., 2010), 
2*(Wensvoort et al., 1991a), 3* (personal communications, AHVLA, Weybridge) and B 
describes how they are related to one another and to a prototype PRRSV-2 strain VR2332, 
according to sequencing o f the ORF5 nucleotide, kindly provided by Jean-Pierre Frossard, 
AHVLA, 2014.
6
Genotype 1 Genotype 2
0.05
H2.Lelystad
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•  UK
• Europe 
•A sia  
«Americas
Figure 1.1. Phylogenetic tree displaying some relevant PRRSV isolates. The
distribution o f three relevant genotype 1 (PRRSV-l) isolates (Lena, Lelystad and H2) in 
relation to Genotpye 2 (PRRSV-2) strains, according to sequencing o f the ORF5 nucleotide. 
Colours denote the origin o f isolates; UK (blue), Europe (red), Asia (purple) and America 
(green). Figure kindly provided by Jean-Pierre Frossard (AHVLA), 2014.
PRRSV is a small, spherical, enveloped, 13-15 kb single stranded positive- 
sense RNA virus (Benfield et al., 1992; Morrison et al., 1992). The virion is 50-60 
nm in diameter with two large open reading frames (ORF la  and ORF lb) which 
encode non-structural polyproteins, and seven smaller open reading frames (ORF2- 
ORF7), which encode structural proteins of the virus (Nielsen et al., 2001; Stade)ek 
et al., 2002). The major structural proteins are the nucleocapsid (N) protein, the 
membrane protein (M), and the major envelope glycoprotein (GP5) (Dea et al., 
2000). The minor structural proteins include GP2a, GP2b, GP3, and GP4 (Wu et al., 
2001; Wu et al., 2005) (Figure 1.2). As an enveloped virus, the PRRSV N protein is 
protected by the surrounding lipid-bilayer envelope, which is composed o f various 
structural proteins, the small envelope protein E, the M protein, and the minor 
structural proteins listed above (Van Breedam et al., 2010a). As with other
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enveloped viruses, many of the envelope components are thought to play a role in 
viral fusion with host cells and their consequent entry into the cell. This is later 
discussed with regard to PRRSV entry.
Figure 1.2. PRRSV virus structure. PRRSV major structural proteins consist o f the 
nucleocapsid (N) protein, the membrane protein (M) and the major envelope glycoprotein 
(GP5). The minor structural proteins include GP2a, GP2b, GP3, and GP4. Image obtained 
from http://www.prrs.ugent.be/ (Laboratorium voor Virologie, 2009)
1.1.2. PRRSV tropism
Like other members of the Arteriviridae family, PRRSV has a restricted cell 
tropism and predominantly infects cells o f the myeloid lineage (Snijder and 
Meulenberg, 1998). In vivo studies have shown a preference of PRRSV for infection 
of alveolar macrophages (Haynes et al., 1997). It is noticed in diagnostic 
laboratories like the Animal Health and Veterinary Laboratories Agency (AHVLA), 
however, that alveolar macrophages show high levels of variability in their 
susceptibility to infection in vitro (unpublished data). In addition to alveolar 
macrophages, PRRSV has also been isolated from macrophages located in other
N dimer
M/GP5
GP3
GP4
GP2
tissues, including the spleen, liver, Peyer's patches, thymus and placenta (Duan et al., 
1997a, b; Kamiychuk and Nauwynck, 2009; Larochelle et al., 1996; Lawson et al., 
1997; Sur et al., 1996). Macrophage precursor cells, i.e. bone marrow cells and 
peripheral blood monocytes, however, are reported to be refractory to infection 
(Duan et al., 1997a, b), as are peritoneal macrophages (Teifke et al., 2001). In 
addition, the African green monkey kidney cell line MA-104 and cells derived 
thereof (MARC-145) have been shown to sustain PRRSV-2 infection, while a cell- 
line suitable for PRRSV-1 propagation has not been identified (Kim et al., 1993; 
Mengeling et al., 1995).
PRRSV is also reported to infect dendritic cells (DCs), although the literature 
is conflicting. Whilst PRRSV-2 is well reported to infect monocyte derived DCs 
(MoDCs) (Flores-Mendoza et al., 2008; Park et al., 2008; Wang et al., 2007), and 
bone marrow derived DCs (BMDC) (Chang et al., 2008), reports of PRRSV-1 
infection of DCs are few (Silva-Campa et al., 2010).
1.1.3. PRRSV entry via CD163 and CD169
PRRSV entry into cells is thought to occur via receptor-mediated 
endocytosis, involving several suggested receptors and co-receptors expressed on 
myeloid cells. These include heparin sulphate, tetraspanin CD151, simian vimentin, 
CD 163 and sioaloadhesin (CD 169) (Calvert et al., 2007; Delputte and Nauwynck, 
2004; Delputte et al., 2002; Kim et al., 2006; Shanmukhappa et al., 2007; 
Vanderheijden et al., 2003). Although the above factors are reported to be involved 
in PRRSV entry, they are not all considered to be required for entry to occur. It is 
only the latter two receptors, CD 163 and CD 169, that have recently been reported to
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be essential particularly for PRRSV-1 entry, each having a specific role in PRRSV 
replication in the macrophage (Van Breedam et al., 2010a).
Sialoadhesin, also known as CD 169, is also a type 1 transmembrane protein 
restricted to macrophages, and belongs to a family of sialic-acid binding lectins 
known as siglecs (Munday et al., 1999). Its importance in PRRSV infection was 
highlighted when transfected into non-permissive cell lines, resulting in the 
attachment and internalisation of PRRSV via clathrin-mediated endocytosis 
(Vanderheijden et al., 2003). It was concluded that sialic acids present on the 
M/GP5 glycoprotein complexes present in the viral envelope of PRRSV were 
directly binding to sialoadhesin on host cells (Van Breedam et al., 2010b), however, 
the lack of nucleocapsid dissembly or productive infection o f  these cells suggested 
the requirement of an additional factor in PRRSV replication. It is also recognised 
that as the M/GP5 glycoprotein of PRRSV that binds CD 169 in a sialic-acid 
dependent manner is a conservative glycoprotein (Van Breedam et al., 2010b), 
CD 169 is likely to be involved in the attachment of all PRRSV strains.
It is proposed by Van Breedam and colleagues that the additional factor 
required for PRRSV replication is CD 163 (Van Breedam et al., 2010a), a type 1 
transmembrane glycoprotein scavenger receptor, expressed mainly on monocytes 
and macrophages (Hogger et al., 1998). Its expression on human macrophages acts 
to clear haemogolobin-heptaglobin complexes (Buechler et al., 2000). It is described 
that its expression on non-permissive cells enables them to become infected with 
PRRSV, demonstrated by the transfection of CD 163 into various cell lines (Calvert 
et al., 2007). The role of CD 163 has been implicated with the later stages of PRRSV 
entry, thereby considered essential for the genome release stage of replication, and
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potentially requiring interaction with the minor envelope glycoproteins GP2a and 
GP4 (Das et al., 2010).
1.2. Immune response to PRRSV
Respiratory viruses initiate host innate immune responses which involve cells 
such as alveolar macrophages, natural killer (NK) cells, DCs, and cytokine responses 
including type I interferon (IFN-a/IFN-f3) in the lung (Vareille et al., 2011). 
Together, these cells and factors influence the initial infection and regulate the 
adaptive immune response. PRRSV has been suggested to initiate a weak innate 
immune responses, and therefore, a compromised adaptive immune response, 
resulting in prolonged viraemia and persistent infection (Mateu and Diaz, 2008). 
Conversely, strains that induce a significant inflammation seem to be effectively 
cleared as recently demonstrated for both Lena and another PRRSV-1 isolate, SU- 
IBel (Morgan et al., 2013; Weesendorp et al., 2013). Due to its ability to persist, it 
was hypothesised that PRRSV is able to elicit immunosuppression and 
immunomodulation of the host innate and adaptive immune responses (Diaz et al., 
2005; Drew, 2000). Such suppression of host immunity would be in line with the 
increased susceptibility to secondary infections as observed in PRRSV, albeit such 
direct immunosuppression is difficult to measure (Mateu and Diaz, 2008).
PRRSV pathogenesis can be described in two stages, consisting of the early 
acute stage and the late persistent stage. The early stage is characterised by the 
presence of the clinical signs described above, and high levels of viral replication in 
PAMs and other tissue macrophages (Pol et al., 1991). The later stage of persistence 
is associated with significantly lower levels of viral replication and while clinical 
signs are less evident, virus is readily transmitted to naïve pigs and hence further
increases economic losses (Allende et al., 2000; Benfleld et al., 2000; Xiao et al., 
2004).
Whilst pigs are able to develop both humoral and T-cell associated cell 
mediated immune responses following PRRSV infection, the exact mechanisms of 
viral clearance are not yet fully understood, and the wide diversity of circulating 
PRRSV field strains gives rise to the possibility of strain-specific host responses to 
PRRSV. A rapid anti-PRRSV antibody response can be detected by ELISA in serum 
from 7-9 days p.i (Yoon et al., 1992), but these antibodies are unable to neutralise 
PRRSV (Yoon et al., 1994). Moreover, the simultaneous presence of PRRSV and 
PRRSV specific antibodies during this early viraemic stage highlights the inability of 
antibodies to protect against PRRSV (Albina, 1997; Loemba et al., 1996; Molitor et 
al., 1997). Along with this non-protective anti-PRRSV antibody response a 
polyclonal activation of B cells has been suggested (Drew, 2000; Lamontagne et al.,
2003), possibly including auto-antibodies which act on host proteins rather than 
neutralising PRRSV (Lemke et al., 2004). Neutralising antibodies, demonstrated to 
provide complete protection against a variety of viruses such as respiratory syncytial 
virus (RSV) and influenza (Prince et al., 1985), were suggested to play some role in 
PRRSV protection (Lopez and Osorio, 2004). However, the role of neutralising 
antibodies is unlikely to be a significant one in the case of PRRSV, given that the 
response is slow and irregular; PRRSV neutralising antibodies do not appear in all 
cases and not until 4 weeks p.i or longer (Meier et al., 2003; Yoon et al., 1994). It 
was shown, however, that inactivated PRRSV vaccines which do not induce 
neutralising antibodies are not protective. In contrast, it is suggested that attenuated 
vaccines, which have shown some protection, do induce some levels of neutralising 
antibodies, but this is not a proven direct correlation (Lopez and Osorio, 2004).
12
Furthermore, the onset of neutralising antibodies following experimental PRRSV 
infection has shown some correlation with clearance of the virus from circulation 
and from tissues (Labarque et al., 2000). The observation that the earliest antibodies 
produced following PRRSV infection are directed against N protein, followed by 
those directed against M protein and finally those against surface GP5 protein 
(Nelson et al., 1994), the latter containing a major neutralisation epitope (Nelson et 
al., 1994; Pirzadeh and Dea, 1997, 1998), supports the theory that the neutralising 
antibody response is delayed, but relevant. By the time neutralising antibodies 
appear, PRRSV, however, has had the chance to disseminate across the organism 
and hide in various tissues.
As the humoral immunity to PRRSV appears not to be sufficient in the 
immediate clearance of PRRSV infection, it is speculated that cellular immunity 
plays a more significant role in PRRSV protection (Vezina et al., 1996; Wills et al., 
1997b). PRRSV infected pigs show a T-cell specific mediated response, which is 
sometimes delayed until 4 weeks p.i, but can be detected up to 14 weeks p.i 
(Bautista and Molitor, 1997; Lopez Fuertes et al., 1999). CD4+ T helper cells, 
targeted against PRRSV M/GP5 proteins, were identified as the major effector cells 
in the T-cell proliferation response induced by PRRSV (Bautista and Molitor, 1997; 
Bautista et al., 1999). Whilst a CD8+ T-cell response is also reported, another study 
reports the highest T-cell response, measured by Interferon (IFN)-y production, is by 
y/8 T-cells (Batista et al., 2004). Whether these cell-mediated responses are 
protective is unlcear; one study which reports PRRSV specific CD4+ and CD8+ T- 
cell detection from 2 weeks p.i onwards, suggests there is no correlation of this 
response with virus loads in lymphoid tissue, neither in acute or persistent stages 
(Xiao et al., 2004).
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Cell mediated (T-cell) responses are often measured by their production of 
IFN-y, which is also considered a main component of the cytokine response to 
PRRSV (Lopez Fuertes et al., 1999). IFN-y, secreted by T helper 1, T cytotoxic cells 
or y/ô-T-cells, has direct antiviral activity, and is important in the protection against 
many cytopathic viruses due to its ability to inhibit viral replication (Bautista and 
Molitor, 1999; Finke et al., 1995). IFN-y is also involved in regulating the 
expression of molecules involved in antigen processing and presentation, such as 
proteasomes and MHC, required for further T-cell stimulation and recognition by 
cytotoxic T-cells (Boehm et al., 1997). Earlier studies investigating the IFN-y 
response following infection with either PRRSV-1 or PRRSV-2 genotypes have 
indicated in that this response is also delayed (Xiao et al., 2004). Following 
infection or vaccination with PRRSV, IFN-y secreting cells are variable during the 
first week p.i, followed by a sudden increase at 3-4 weeks following vaccination 
(Lopez Fuertes et al., 1999; Meier et al., 2003). In particular, PRRSV has been 
suggested to increase the number of IFN-y producing y/Ô-T-cells (Olin et al., 2005). 
IFN-y has been detected in serum, peripheral blood mononuclear cells (PBMCs) and 
cells of the broncho-alveolar lavage (BAL) (Gomez-Laguna et al., 2010; 
Weesendorp et al., 2013; Wesley et al., 2006), and has been shown to inhibit the 
replication of PRRSV in PAMs and MARC-145 cells in vitro (Albina et al., 1998; 
Bautista and Molitor, 1999; Rowland et al., 2001). Interestingly, two recent parallel 
experiments have shown that strains of PRRSV genotype 1.3, which are highly 
pathogenic, induce a high IFN-y response and the virus is cleared within 4 weeks, 
while PRRSV-1 strains which are less pathogenic went into a persistent state 
(Morgan et al., 2013; Weesendorp et al., 2013).
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In addition to its anti-viral effect on PRRSV, IFN-y release may have 
multiple roles in benefiting protection against PRRSV (Rowland et al., 2001). IFN-y 
is an efficient natural modulator promoting an adaptive Th-1 immune response (Cull 
et al., 2002; Darwich et al., 2010; Mo smarm et al., 1986). IFN-y promotes NK and 
cytotoxic T-cell activity, and induces the classical activation of macrophages, which 
as discussed later on, results in pro-inflammatory macrophages (Mosser and 
Edwards, 2008).
In addition to IFN-y, type I IFNs (such as IFN-a/IFN-|3), produced by 
leukocytes and particularly by plasmacytoid DC (pDc) in response to viral infection, 
are essential in mounting efficient antiviral innate and adaptive immune responses 
(Mogensen, 2009). Whilst PRRSV has shown to be highly susceptible to the 
antiviral effects of IFN-a in vitro (Loving et al., 2007; Luo et al., 2011; Sang et al., 
2011), and in vivo (Brockmeier et al., 2012), the synthesis of IFN-a by PAMs and 
MoDCs remains low or nonexistent throughout PRRSV infection (Albina et al., 
1998; Lee et al., 2004; Van Reeth et al., 1999; Zhang et al., 2012), demonstrating 
that these cells are unable to sense PRRSV infection and respond by IFN-a 
production. It was, however, also suggested that different PRRSV isolates may have 
different effects on IFN-a induction or inhibition (Lee et al., 2004) and systemic 
IFN-a production and IFN-a secreting cells have been observed following infection 
with various isolates (Albina et al., 1998; Brockmeier et al., 2012; Dwivedi et al., 
2012; Gomez-Laguna et al., 2010; Liu et al., 2010), suggesting that certain cell types 
are able to sense infection. Intriguingly, an earlier study indicated that PRRSV-2 
genotype inhibits its secretion from plasmacytoid DCs (pDCs), high producers of 
IFN-a (Calzada-Nova et al., 2010; Calzada-Nova et al., 2011). These findings, 
however, have not been reproducible by another study demonstrating IFN-a
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secretion in response to both PRRSV-1 and PRRSV-2 genotypes from pDCs via the 
TLR7 pathway (Baumann et al., 2013). These studies highlight the controversy still 
surrounding PRRSV research. In particular, at least four non-structural proteins 
(Nspl, Nsp2, Nsp4 and N sp ll) have been characterised to contain suppressive 
activities against IFN-a (Kim et al., 2010). As IFN-a has the ability to activate 
APCs, increase antibody and cytotoxic T-cell responses, and direct Thelper (Th)l 
differentiation (Cepica and Derbyshire, 1986), the inadequate induction of IFN-a by 
PRRSV is likely to have a direct effect on the resulting adaptive immune response.
As well as IFNs, other cytokines are thought to be involved in the PRRSV 
immune response. Chiou and colleagues found that following PRRSV infection, 
synthesis of TNF-a was significantly reduced in alveolar macrophages (Chiou et al., 
2000). The same finding was observed by Lopez-Fuertes and colleagues (Lopez- 
Fuertes et al., 2000). As TNF-a is an important immune mediator, which activates 
leukocytes for microbial killing, stimulates IL-1 and IT-6 production in 
macrophages, and is an important activator of DCs (Kuby, 2007), it is thought that 
its suppression may undermine not only the normal role of macrophages, but also the 
wider immune response. Host and breed differences may also be important, as 
suggested by Ait-Ali and colleagues who showed that reduced virus replication in 
macrophages from the Landrace breed was conversely associated with up-regulation 
of TNF-a and IT-8 mRNA (Ait-Ali et al., 2007).
IT-8, along with IT-1(3 has also been reported in serum following PRRSV 
infection by Tunney and colleagues, and both of these innate cytokines are linked 
with viral clearance (Tunney et al., 2010). There is also evidence of IT-12 (Topez 
Fuertes et al., 1999), and IT-6 secretion in serum following PRRSV infection (Asai 
et al., 1999). Whilst IT-12 is involved in the stimulation of T-cells and activity of
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NK cells, IL-6 is involved in the polyclonal activation of B-cells and T-cells, so 
production of both would initiate humoral and cell-mediated immune responses 
(Kuby, 2007). PRRSV can also induce IL-4 in serum, which induces the alternative 
activation of macrophages, resulting in wound repair macrophages which may aid 
the repair of damaged lung tissue (Dwivedi et al., 2012; Gordon and Martinez, 
2010). The multiple functions of these factors, therefore, are certain to aid PRRSV 
protection in the host.
In contrast to cytokines which may protect against PRRSV, IL-10 has been 
suggested to be induced by PRRSV as a proposed mechanism of evasion of the 
protective innate and adaptive immune responses. IL-10, produced mainly from 
cells of monocyte/macrophage lineage, Th-2 and regulatory T-cells, and some B 
cells (de Waal Malefyt et al., 1991; Moore et al., 2001; O'Garra and Vieira, 2004), 
can induce anti-inflammatory responses via the IL-10 receptor and activation of 
Signal transducer and activator of transcription (STAT)3 pathway (Moore et al., 
2001; Murray, 2006). By its action on DCs and macrophages, IL-10 acts a potent 
suppressor of immune responses, including the suppression of the type 1 induction of 
pDCs (Duramad et al., 2003; Lannes and Summerfield, 2013). IL-10 production is 
considered necessary to dampen the virus-induced inflammatory response in order to 
prevent severe tissue damage (Sun et al., 2011; Trandem et al., 2011a; Trandem et 
al., 2011b). Some viruses, such as herpesvirus and cytomegalovirus, have evolved 
methods to promote the early production of IL-10 in order to antagonise the 
protective antiviral immune response (Humphreys et al., 2007; Suvas et al., 2004). 
Whilst it is thought that PRRSV is likely to elicit the same mechanism, the induction 
of IL-10 by PRRSV is not clearly established and appears to be strain dependent 
(Darwich et al., 2010; Klinge et al., 2009). It is thought that it is the interaction of
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PRRSV structural N protein with macrophages and DCs which mediates the 
induction of IL-10 by PRRSV (Wongyanin et al., 2009; Yoo et ah, 2010). Several 
reports suggested that PRRSV induces IL-10 during the early stages of infection 
which is supported by reports of an inverse correlation between IL-10 and IFN-y 
levels (Diaz et ah, 2006; Mateu and Diaz, 2008; Suradhat et ah, 2003). However, IL- 
10 may influence T-cells towards a Th2 response, although PRRSV specific Th2 
responses have not yet been shown. Furthermore, there is no indication that strains 
inducing IL-10 and TGF-p (another factor relevant for regulatory T-cells) are any 
more pathogenic than those not inducing IL-10, as the direct effects of IL-10 on 
PRRSV replication have not been shown. Interestingly, one study did show that a 
highly virulent PRRSV strain did not induce IL-10 production (Subramaniam et ah, 
2011).
NK cells also have some significance in PRRSV infection. NKs typically 
play a role in the early stages of viral infection, by killing infected cells via 
granzyme and perforin degranulation (Lodoen and Lanier, 2006). NKs can also 
produce high levels of IFN-y and various chemokines against pathogens (Biron et ah, 
1999). NK cytoxicity against PRRSV, however, is dampened, and PRRSV appears 
to show reduced susceptibility to the low levels of NK cytoxicity that exist (Dwivedi 
et ah, 2012; Jung et ah, 2009). This is thought to be another evasion mechanism by 
PRRSV by which NK mediated lysis of PRRSV infected PAMs is inhibited (Cao et 
ah, 2013).
The effect of PRRSV on the above cytokine responses are likely to have 
many consequences on the antigen presentation cells (APCs) associated with 
PRRSV. For example, IFN-y and IFN-a can activate APCs, and IL-10 can inhibit 
the differentiation and activation of DC (Liu et ah, 2013). It is likely, therefore, that
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PRRSV modulates the antigen presentation to, and activation of, T lymphocytes. 
Moreover, PRRSV has demonstrated an ability to directly modulate the expression 
of important molecules on APCs. An example of this is the down-regulation of 
MHC-I expression on lung DCs (Loving et al., 2007), and the down-regulation of 
MHC-I, MHC-II and CD 14 expression on MoDCs following in vitro PRRSV 
infection (Wang et al., 2007). This down-regulation of MHC-I, MHC-II and CD 14 
expression on MoDCs was correlated with decreased T-cell proliferative responses, 
suggesting that PRRSV infected DCs are less efficient at presenting antigens to T- 
cells (Wang et al., 2007).
The delayed humoral and T-cell mediated responses to PRRSV, along with 
the mediating effects on cytokine production and on APCs, are together likely to be 
responsible for the delayed clearance of the virus and consequently persistent 
infection. Viruses that cause persistent infections frequently incorporate evasion 
strategies, in particular ones which block the production of or inhibit activation of 
proteins up-regulated by IFN, which is fitting with the current PRRSV pathogenesis 
(Carrigan and Knox, 1990; Moskophidis et al., 1994). Furthermore, PRRSV also 
decreases the total leukocyte population in peripheral blood, including, monocytes 
and eosinophils, several days after infection (Che et al., 2011), an effect likely to 
undermine the immune response of pigs against secondary infections.
During the persistent stage of PRRSV, virus is detected in primary lymphoid 
tissue, where viral loads are reportedly at least 1000-fold lower than in the early p.i 
acute stage (Xiao et al., 2004). These viral load levels, however, are reportedly not 
as low as true steady-state persistent infection (Allende et al., 2000). Forkhead box 
p3 (Foxp3) T-regulatory cells (Tregs), also implicated in the immunosuppression by 
PRRSV, are known for their role in establishing persistent infections such as HIV
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(Kinter et al., 2004). There is a reported infiltration of Tregs into the lungs of 
PRRSV infected animals, resulting in increased IL-10 and TGF-p production and 
further modulating the immune response (Didierlaurent et al., 2007).
The shedding of PRRSV is reported during the persistent infection of older 
animals (sows), and virus can go on to infect naïve animals up to 45-86 days p.i 
(Bierk et al., 2001). PRRSV is eventually cleared from the body, at approximately 
150 days p.i (Allende et al., 2000). Whilst convalescent animals have shown some 
protective immunity against the homologous strains, they are not protected against 
new strains (Meng, 2000; Mengeling et al., 1999). This highlights the problem 
regarding the heterogeneity of PRRSV and in identifying a vaccination control 
strategy, which protects against all strains of the virus.
1.3. Myeloid cells associated with PRRSV
The myeloid cells associated with PRRSV collectively belong to the 
mononuclear phagocyte system (MPS), which was identified by Van Furth and 
colleagues (van Furth et al., 1972). The MPS consists of blood monocytes and their 
bone marrow progenitors, macrophages, and DCs, and is thought to make up 10-15% 
of the total cells in most organs (Bonifer and Hume, 2008). Mononuclear 
phagocytes express a variety of receptors involved in the recognition of diverse 
microbial ligands, which allows them to act as important effector cells in 
inflammation and host innate and adaptive responses (Pluddemann et al., 2011; 
Taylor et al., 2005).
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1.3.1. Monocytes
Monocytes are primary immune cells which are derived from CD34+ 
myeloid progenitor cells in the bone marrow and circulate in blood, bone marrow 
and spleen (Auffray et al., 2009; Swirski et al., 2009). Circulating monocytes act as 
innate immune surveillance cells, expressing chemokine receptors and pathogen 
recognition receptors (PRRs), which mediate their activation and migration to 
tissues. They do this by their recognition of chemokines, tissue injury, or pathogen 
signals. Upon such recognition, monocytes can take up antigens, and migrate to 
lymphoid organs via lymphatics where they are exposed to several proteins, 
cytokines, and growth factors which result in further differentiation into 
macrophages or specialised cells such as dendritic cells and osteoclasts (Muller and 
Randolph, 1999; Tacke and Randolph, 2006; Volkman and Gowans, 1965). Whilst 
it is considered their main function to act as a systemic reservoir of myeloid 
precursors for the replenishment of these cells, monocytes also carry out specific 
effector functions during inflammation, such as the production of inflammatory 
cytokines such as TNF-a (Auffray et al., 2009; Belge et al., 2002; Geissmann et al., 
2010).
It has long been recognised that monocytes are a heterogeneous population, 
varying in their size, granularity and morphology (Gordon and Taylor, 2005). The 
discovery of antigenic markers has helped identify further heterogeneity in 
monocytes subsets, giving clues to differential physiological functions of monocyte 
subsets. Human monocytes can be distinguished into two subsets according to their 
expression of CD 14 and CD 16; CD 14*" CD 16 cells, known as classical monocytes, 
comprise the majority of circulating monocytes, and CD14+CD16+ cells, which have
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a phenotype more akin to mature tissue macrophages, represent 10% of the 
circulating monocytes (Passlick et al., 1989; Ziegler-Heitbrock et ah, 1993).
Although circulating monocytes in their steady state are generally considered 
to be non-proliferating (Auffray et ah, 2009; Geissmann et ah, 2010), their increased 
heterogeneity has also been associated with the suggestion that monocytes are able to 
proliferate. This has been demonstrated by a sub-population of small monocytes in 
response to haematopoietic growth factors, such as macrophage-colony stimulating 
factor (M-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF) and 
IL-3 (Cheung and Hamilton, 1992; Elliott et ah, 1989; Finnin et ah, 1999; 
Gendelman et ah, 1988). In addition, there is some debate regarding the exact 
mechanisms involved during monocyte differentiation to macrophages, and whether 
proliferation occurs during differentiation (Geissmann et ah, 2008).
The differentiation of monocytes to macrophages is driven by M-CSF, which 
acts via a cell surface tyrosine kinase receptor known as colony stimulating factor 
receptor 1 (CSF-1R), expressed on cells of the mononuclear phagocyte lineage 
(Stanley et ah, 1997). M-CSF is a haematopoietic growth factor, which mediates the 
survival, proliferation, differentiation and function of mononuclear phagocytes 
(Becker et ah, 1987; Brugger et ah, 1991), and is produced by monocytes and 
macrophages themselves, as well as various other cells including fibroblasts, 
endothelial cells, epithelial cells, B and T-cells (Fixe and Praloran, 1998; Popova et 
ah, 2011). It is thought that during inflammation, vast amounts of M-CSF are 
produced for the increased generation of macrophages required for the immune 
response. M-CSF also allows the study of macrophages in vitro, as the addition of 
M-CSF to monocytes results in the differentiation of macrophages (Gordon and 
Taylor, 2005; van Furth et ah, 1972).
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1.3.2. Porcine Monocytes and PRRSV
The characterisation of porcine monocytes is quite limited in comparison to 
that of human or mouse monocytes, although the role of myeloid cells in PRRSV 
infection and other important pathogens has driven the requirement for more studies 
of these cells in pigs. Unlike human monocytes, porcine monocytes are 
predominantly CD16+, and have instead been divided into two sub-populations based 
on the expression of CD 163 (Chamorro et al., 2000; Sanchez et al., 1999). CD163+ 
are thought to resemble human classical monocytes (CD14+CD16+) and have 
increased APC function compared to CD 163' (Chamorro et al., 2005; Sanchez et al., 
1999).
Despite the reported expression of putative PRRSV receptor CD 163, 
peripheral blood monocytes have previously been deemed unsusceptible to PRRSV 
infection in vitro, however, bone marrow derived monocytes have shown 
susceptibility after one day in culture (Duan et al., 1997a). Confusingly, it is argued 
that monocytes are refractory to PRRSV due to their absence of the putative PRRSV 
receptors CD 163 and CD 169, and in particular, low levels of expression of CD 169 
by monocytes, which are reported as PRRSV-1 receptors (Delputte et al., 2007). 
Whilst the data concerning monocyte infection with PRRSV is conflicting, it is 
interesting to note that other viruses of the Arteriviridae family, such as lactate 
dehydrogenase-elevating virus (LDV) and simian haemorrhagic fever virus 
(SHMV), which have a common cell tropism for monocytes/macrophages, show 
restricted in vitro replication in primary cultures of host macrophages only (Gravell 
et al., 1986; Plagemann and Moennig, 1992).
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1.3.3. Macrophages
As circulating monocytes enter peripheral tissues, they undergo maturation 
into resident macrophages or other terminal cells of the MPS (Van Furth et al., 
1973). Macrophages are important effector cells in the immediate defence against 
foreign antigens due to their wide scope of functions, including the uptake of 
microbial particles, killing mechanisms by the production of several mediators, and 
the processing and presentation of antigens to T-cells (Hamilton, 1993). 
Macrophages are distributed widely across tissues and many specialised subtypes 
exist according to anatomical location and function. These include osteoclasts in 
bone, alveolar macrophages in the lung, histiocytes in interstitial connective tissue 
and Kupffer cells in the liver (Lewis, 1992). Alveolar macrophages, located at the 
interphase between air and lung tissue, are central in the immediate defence of 
respiratory pathogens given that they are the first cells to initiate contact with inhaled 
pathogens (Eddens and Kolls, 2012). They therefore play a role in the regulation of 
inflammatory reactions in the lung (Hauschildt and Kleine, 1995). This is thought to 
also be the case with PRRSV infection, given that highest viral loads of PRRSV are 
detected in these cells following infection (Duan et al., 1997b).
Many of the functions of macrophages require receptor mediated microbial 
recognition before they can occur. Macrophages are, therefore, equipped with a 
distinct set of surface or soluble pathogen-recognition receptors (PRRs) (Geissmann 
et al., 2010; Janeway, 1989). PRRs enable macrophages to detect bacterial, fungal or 
viral pathogens when scanning the extracellular environment, where they are able to 
recognise conserved microbial structures on pathogens, collectively referred to as 
pathogen associated molecular patterns (PAMPs) (Janeway and Medzhitov, 2002). 
Many PRRs are associated with bacterial pathogens, such as scavenger receptor (SR-
24
A) which binds ligands such as bacterial lipopolysaccharide (LPS), bacterial CpG 
DNA and bacterial surface proteins (Dunne et al., 1994; Peiser et al., 2006; Zhu et 
al., 2001). Other known receptors associated with pathogen uptake include the 
mannose receptor (CD206), linked with Dengue virus infection and DC-SIGN 
(CD209), implicated in both Dengue and HIV infection (Miller et al., 2008). 
Macrophages also express Fey receptors (FcyRs) and complement receptors which 
are involved in the recognising and uptake of opsonised particles. In 
particular, FcyR and complement receptor 3 (CR3) are well characterised phagocytic 
receptors expressed by macrophages which bind immunoglobulin G (IgG)-opsonised 
particles or complement coated particles respectively (Aderem and Underhill, 1999; 
Garcia-Garcia and Rosales, 2002; Swanson and Hoppe, 2004).
Macrophages also express toll-like receptors (TLRs) on their surface, which 
are one of the most extensively studied classes of PRRs. TLRs recognise PAMPs 
from various viruses, pathogenic bacteria or fungus. TLR4, recognises LPS on gram 
negative bacteria, and envelope proteins from respiratory syncytial virus (RSV) 
(Murawski et al., 2009). Upon engagement of TLRs with individual PAMPs, a 
number of different signalling pathways are triggered. Following TLR recognition, 
adaptor molecules such as MyD88, are recruited, which can determine the specificity 
of the immune response (O'Neill and Bowie, 2007). Recruitment of such adaptor 
molecules activate downstream signalling cascades, which ultimately activate 
transcription factors able to regulate the expression of genes involved in 
inflammation and antimicrobial host defences, and the production of pro- 
inflammatory mediators (Akira et al., 2006). TLRs are also involved in uptake of 
microbial particles, in particular via phagocytosis (Blander, 2007).
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The uptake of the microbial particles follows immediately after macrophage 
receptor recognition of pathogens. The method of uptake depends on the size of the 
particle, and whilst macrophages usually use phagocytosis for microbial uptake, 
smaller viruses are thought to enter via endocytosis, macropinocytosis, or fusion 
(Flannagan et al., 2009). Phagocytosis is an actin-dependent mechanism by which 
large microbial particles, usually greater than 0.5 pm in diameter, are ingested 
(Aderem and Underhill, 1999). After internalisation of the microbial particle into the 
cell phagosome, the fusion of the phagosome with lysosomes (intracellular granules) 
forms a phagolysosome (Stuart and Ezekowitz, 2005). It is within the 
phagolysosome where the enzymatic digestion or killing of the internalised contents 
occurs, by a combination of non-oxidative or oxidative mechanisms (Lewis, 1992). 
Non-oxidative killing mechanisms include the production of anti-microbial peptides 
(AMPs), such as cathelicidins, defensins and other degradative proteases (Rogan et 
al., 2006). The oxygen-dependent ‘respiratory burst’ of macrophages following 
phagocytosis involves the non-mitochondrial generation of the antimicrobial reactive 
oxygen species (ROS), free radicals which trigger the apoptosis of cells (lies and 
Forman, 2002). Macrophages are also able to produce type I IFNs, which can aid 
protection against viral replication (Smith and Wagner, 1967). Further killing 
mechanisms, such as the production of inducible nitric oxide synthase (iNOS), occur 
following macrophage activation, as discussed further on in this chapter.
The processing and presentation of antigen by macrophages follows 
microbial uptake. This is another important function of macrophages, by which they 
assist the initiation of the cell mediated immune response. This function is 
dependent on MHCII, by which glycoproteins are encoded to help recycle antigen 
peptides to the cell surface, where the MHCII-peptide complex is recognised by
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circulating CD4 expressing T-cells (Lewis, 1992). Intracellular processing of 
antigen by macrophages can also result in the association of peptides with MHCI 
molecules, resulting in the cross-presentation to CD8+ T-cells (Kovacsovics- 
Bankowski et al., 1993). T-cells are not activated by the interaction with the 
MHC/peptide complex alone, but require a second signal in the form of IL-1, which 
stimulates T-cell growth and differentiation by the induction of IL-2 production and 
IL-2 receptors (Lichtman et al., 1988).
1.3.4. Macrophage activation
Macrophage activation results in the polarisation of macrophages into 
different functional subsets, determined by the surrounding environmental signals 
and hence the current disease situation. Whilst macrophages in a steady state have 
intrinsic anti-inflammatory functions, activated macrophage subsets are likely to 
individually contribute to more specific functional roles in immune responses 
(Gordon and Taylor, 2005).
Activated macrophages were discovered in the 1960s with the identification 
of bigger and more ‘angry’ macrophages required for the killing of Listeria 
monocytogenes (Adams and Hamilton, 1984; Mackaness, 1964). Further research 
broadened the understanding of macrophage activation as the acquisition of 
competence for enhanced microbicidal or tumourcidal activity (Lewis, 1992). It 
later became apparent that activated macrophages themselves where more 
heterogeneous than previously appreciated, and that more than one form of 
macrophage activation existed. Extensive research has been carried out in 
determining macrophage subsets in both human and mouse species, and the
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application of microarray technology has enabled genome-wide analysis outlining 
macrophage sub-populations. Two established macrophage subsets are now 
described, referred to as M l and M2 macrophages, differentiated by classical or 
alternative activation respectively (Gordon, 2003; Nathan, 1991).
Classical (M l) activation of macrophages requires two signals in the form of 
IFN-y and from TLR ligation which induces endogenous tumour necrosis factor 
(TNF)-ct production (Mosser, 2003). Firstly, IFN-y induces a ‘primed’ state of 
macrophages, meaning that although they are not cytolytic, they can readily become 
so following pulses with the second signal, which is usually lipopolysaccharide 
(LPS), which binds to TLR4. Macrophage TLR ligation with LPS is shown to result 
in the ‘fully activated’ state of macrophages (Dalton et al., 1993). Thus, in vitro, Ml 
macrophages can be generated following treatment with IFN-y, and exposure to a 
microbe or microbial product such as LPS (Held et al., 1999; Nathan, 1991). In vivo, 
in a type-1 disease environment, where Ml macrophages are efficient effector cells, 
IFN-y may be produced by innate or adaptive cells, such as plasmacytoid dendritic 
cells (pDCs), natural killer (NK) cells, or Thl cells (Chan et al., 1991; Colonna et al.,
2004).
Such classical activation of macrophages induces the modulation of genes via 
the induction of a combination of transcription factors. These include the signal 
transducer and activator of transcription (STAT) molecules, which are activated by 
IFN-y ligation, and nuclear factor-xB (NFkB) and mitogen-activated protein kinases 
(MAPKs), which can be activated in response to TLR or TNF receptor ligation 
(O'Shea and Murray, 2008). It is these gene changes that determine the role of Ml 
macrophages, which is predominantly to kill intracellular pathogens in Thl cellular 
immune responses (Mosser and Edwards, 2008). Their increased bacteriocidal
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ability is by virtue of the production of inducible nitric oxide synthase (iNOS) which 
uses L-arginine as a substrate to produce cytotoxic nitric oxide (NO) (MacMicking et 
al., 1997). M l macrophages are also able to act as inducer and effector immune cells 
due to their increased production of pro-inflammatory cytokines such as IL-ip, TNF, 
IL-6 IL-12 and IL-23, and low production of anti-inflammatory IL-10, (Mantovani et 
al., 2005; Verreck et al., 2004).
Alternative activation of macrophages was discovered later than classical 
activation. It was found that alternative activation occurred via the stimulation of 
macrophages with IL-4, which was found to up-regulate expression of the mannose 
receptor (CD206) (Stein et al., 1992). Although this was an indication of activation, 
the resulting macrophage was clearly distinct from the classic activated macrophage 
as it did not produce NO and had a poor ability to kill intracellular pathogens 
(Modolell et al., 1995). It was later discovered that IL-13, which shares the same IL- 
4 receptor alpha (IL-4Ra) chain as IL-4, also induces the same alternatively activated 
macrophage (Gordon, 2003). Both IL-4 and IL-13 are produced in a Th2 type 
response, particularly in response to allergens, by several different innate immune 
cells, including basophils, mast cells, and even macrophages themselves (Mohrs et 
al., 2005; Varin and Gordon, 2009).
Alternatively activated macrophages, now known as M2 macrophages, are 
primarily associated with mechanisms of immunosuppression and wound repair, in 
contrast to the microbial killing roles of classically activated macrophages (Gordon,
2003). Although known for their increased phagocytosis (via their increased 
expression of mannose receptor CD206), M2 macrophages have reduced killing 
abilities due to low NO production (Munder et al., 1998; Stein et al., 1992). Low 
NO levels by M2 macrophages are explained by the induction of arginase by IL-4,
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which competes with inducible NO synthase (iNOS) and consequently results in low 
NO production (Modolell et al., 1995; Rutschman et al., 2001). Furthermore, M2 
macrophages produce components involved in the synthesis of extracellular matrix, 
which contribute to tissue repair (Gratchev et al., 2001).
Since M2 macrophages produce more anti-inflammatory cytokines, such as 
IL-10 and TGF-p, and low levels of pro-inflammatory cytokines IL-12 and IL-23 
they have also been suggested to be involved in shutting the immune system off 
(Mantovani et al., 2005). However, M2 macrophages further produce chemokines 
which promote the recruitment and activation of eosinophils, mast cells, and 
basophils as a further source of Th2 cytokines, essentially changing the nature of the 
immune reaction (Gordon and Martinez, 2010). The signalling pathways activated 
by ligation of the IL-4Ra are thought to involve STAT6, which plays a central role 
in the regulation of genes responsible for the increased production of chemokines by 
M2 macrophages, although other STATs can participate (Bhattacharjee et al., 2006).
Although the term ‘alternative’ macrophage suggests that it is the only other 
way macrophages can be activated, it is likely that there are some factors which 
drive macrophages to a phenotype which does not strictly conform to either M l or 
M2 subtypes. Through ligation with FcyRs, IgG complexes are reported to induce 
‘type II activated macrophages’, which have an anti-inflammatory profile due to 
their abrogation of IL-12 production, increased IL-10 production, and their ability to 
skew the T-cell response to a Th2 response (Anderson and Mosser, 2002; Gerber and 
Mosser, 2001). Furthermore, it is reported that alternative activation of macrophages 
also occurs with IL-10, glucocorticoids and vitamin D3 hormones, and although the 
same ‘M2’ nomenclature is often applied to these cells, it is unlikely that they all 
share identical properties as those activated using IL-4/IL-13 (Mantovani et al.,
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2004). IL-10 (produced by CD4+ Th2 cells, macrophages, and B cells) acts on 
distinct receptor to that of IL-4/IL-13, and therefore does not have the same effect on 
macrophage gene expression (Moore et al., 2001). It is reported to down-regulate 
MHCII expression, and is shown to have variable effects on mannose receptor 
expression (Gordon, 2003).
Macrophage activation is implicated in the success of many pathogens as 
many are able to interfere with the signalling of macrophage activation. Leishmania 
spp and Mycobacterium spp infect macrophages, and are able to halt their activation 
in response to IFN-y (Nandan et al., 2000; Ting et al., 1999). On the other hand, 
fibrosis following gamma herpes virus infection in mice, is thought to be due to 
induced alternative activation of macrophages (Gangadharan et al., 2008). There are 
cases, however, where the modulation of macrophage activation by a pathogen does 
not contribute to its success. For example, respiratory syncytial virus (RSV) induces 
alternative activation of macrophages, which is shown to be beneficial to host repair 
and diminish host pathology due to the wound repair features of M2 macrophages 
(Shirey et al., 2010). The relevance of macrophage activation may, therefore, be 
important in regard to the macrophage interactions of PRRSV. Furthermore, 
previous literature supports the significance of macrophage activation in PRRSV, 
with the suggestion that macrophage susceptibility to PRRSV varies between 
macrophage types (Duan et al., 1997a).
1.3.5. Porcine Macrophages and PRRSV
Studies of porcine macrophages are few in comparison to those of humans 
and mice, and it is unknown whether the same macrophage sub-populations also
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exist in the pig (Ezquerra et al., 2009). Although well described in humans and 
mice, the differentiation of monocytes to macrophages using M-CSF in vitro is not 
well established for the porcine species. Studies using porcine monocytes do not 
describe the use of purified M-CSF, and instead many have used L929 conditioned 
media as a source of M-CSF (Genovesi et al., 1990; Mayer, 1983), or without any 
serum at all (McCullough et al., 1997). The differentiation of porcine monocytes to 
macrophages results in an alteration of the cell surface phenotype, including the 
induction of the porcine macrophage lineage marker SWC9 (McCullough et al., 
1999; McCullough et al., 1997).
Interestingly, differences between mouse and human activated macrophages 
have been highlighted, including the production of NO by Ml macrophages, 
observed in mouse but not human macrophages (Hibbs, 2002; Weinberg et al., 
1993). This raises questions as to whether porcine macrophages would show 
differences also in macrophage phenotypes, and given whether they would match 
with the Ml and M2 macrophages described of mouse, human, or exhibit a specific 
phenotype of their own.
The susceptibility of porcine alveolar macrophages to PRRSV is well 
described in vitro and in vivo (Gomez-Laguna et al., 2013; Haynes et al., 1997), and 
ex vivo pulmonary alveolar macrophages (PAMs) are used for the propagation of 
PRRSV. Whilst there are no reports of PRRSV infection of in vitro macrophages 
derived from monocytes using M-CSF, there is one study that shows PRRSV 
infection in macrophages derived from monocytes using L929 cell supernatant 
(Thacker et al., 1998). The replication cycle of PRRSV is reported to complete 
within 12 hours in macrophages, although this is likely to vary between virus strains 
(Costers et al., 2009).
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1.3.6. Dendritic Cells
Derived from the same myeloid precursor are the closely related dendritic 
cells (DCs), originally identified by Steinman and colleagues in the early 1970s 
(Steinman and Cohn, 1973). DCs are thought to be the most potent antigen 
processing and antigen presentation cells (APCs) that play an important role in 
innate and adaptive immunity against viral infection (Peters et al., 1996). Classical 
DCs are located in nearly all organ systems and circulate in peripheral blood 
(Banchereau and Steinman, 1998), expressing a variety of specialised pattern 
recognition receptors (PRRS), including Toll-like receptors (TLRs) for the 
recognition of pathogen associated molecule patterns (PAMPs) (Gijzen et al., 2006). 
DCs are short-lived cells, and are replaced by blood-borne precursors including 
monocytes (Liu et al., 2009; Waskow et al., 2008). Also sharing the same myeloid 
precursor are plasmacytoid DCs (pDCs), which differ from classical DCs in that they 
are relatively long lived and exist in the bone marrow and all peripheral organs 
(Geissmann et al., 2010). They are characterised by their high levels of IFN-a 
production and hence play a significant role in responding to viral infections 
(Calzada-Nova et al., 2010). Since pDCs cannot be derived from monocytes, this 
thesis will concentrate on classical DCs, which MoDC have been shown to be 
representative of (Cheong et al., 2010).
Like other myeloid cells, DCs show heterogeneity and two activation subsets 
exist in the form of immature DCs (iDCs) and mature DCs (mDCs), whereby 
maturation of DCs is necessary for initiation of immunity. In most tissues, DCs 
reside in an immature state. iDCs are unable to stimulate T-cells as they lack the 
requisite accessory signals for T-cell activation, such as CD40, CD54 and CD80/86 
and the ability to produce cytokines such as IL-12 (Banchereau et al., 2000). They
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are, however, well equipped for antigen uptake, via mechanisms such as 
phagocytosis (Svensson et al., 1997), as described in section 1.3.3 on macrophages. 
iDCs can also acquire antigen by macropinocytosis (Sallusto et al., 1995), or by 
receptor-mediated endocytosis (Jiang et al., 1995; Sallusto and Lanzavecchia, 1994). 
Upon acquisition of antigen, iDCs migrate via afferent lymphatics and high 
endothelial venules to T-cell and B-cell rich areas of lymphoid organs (Kuby, 2007). 
iDCs can readily respond to inflammatory cytokines and microbial products, and 
whilst iDCs have abundant MHCII molecules within intracellular compartments, 
relocalisation of MHCII to the surface of DCs occurs during maturation (Celia et al., 
1997).
Maturation of DCs results in modulation of chemokine receptors and DCs 
gain the ability to migrate quickly and have strong T-cell attracting and activating 
potential due to their expression of MHC-II, co-stimulatory molecules and adhesion 
molecules (Kleijmeer et al., 1995). DCs are also able to directly cross-present 
antigen to CD8+ T-cells via MHC-I, and are more renown for this than macrophages 
are (Bevan, 2006; Heath and Carbone, 2001). Mature DCs (mDCs) therefore are 
characterised by the loss of phagocytic capacity and the expression of accessory 
molecules. The effective activation of T-cells requires the expression of one or both 
of the co-stimulatory molecules B7-1 (CD80) and B7-2 (CD86) (Kleijmeer et al., 
1995). Other molecules such as intercellular adhesion molecule-1 (ICAM-1) 
(CD54), lymphocyte function associated antigen-3 (LFA-3) (CD58) and CD83 are 
thought to be involved in T-cell activation. It is thought that different TLR ligands 
may induce distinct DC responses via differences in extracellular signalling, 
resulting in different Thl/Th2 cytokine responses depending on the stimulus 
(Dabbagh and Lewis, 2003).
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mDCs are also characterised by increased levels of cytokine production 
(Banchereau and Steinman, 1998; Mellman and Steinman, 2001). DCs are a major 
source of many cytokines, such as IFN-a, IL-1, IL-6 and IL-12, all of which are 
important in the initiation of innate immune responses (Celia et al., 1996; Macatonia 
et al., 1995; Zhou and Tedder, 1995). The DC secretion of IL-12, critical for 
activation of Thl activation, is inhibited by various tumour derived factors, including 
nitric oxide (NO), prostaglandin E2 (PGE2), IL-10, IFN-a and immunosuppressive 
cytokine transforming growth factor (TGF)-p (Strobl et al., 1996; Zhou and Tedder, 
1995).
The unique ability of mDCs to stimulate naive T-cells makes them a 
promising vaccine adjuvant. Therefore, a significant amount of research is carried 
out in vitro using monocyte derived DCs (MoDCs), which can be generated from 
peripheral blood monocytes using growth factor granulocyte macrophage-colony 
stimulating factor (GM-CSF) and IL-4 (Chapuis et al., 1997). MoDCs are 
subsequently matured in vitro, using a cocktail of factors which mimic the in vivo 
infectious or inflammatory conditions and act as ‘danger signals’ to initiate DC 
maturation (Matzinger, 2002). This includes some factors which are TLR ligands, 
such as the microbial product LPS, from gram negative bacteria, and host 
inflammatory cytokines molecules that are released following tissue damage, such as 
TNF-a, IL1-P and IL-6 (Jeras et al., 2005). PGE2, which specifically up-regulates C- 
C chemokine receptor 7 (CCR7), essential for DC homing to secondary lymphoid 
organs (Jeras et al., 2005; Scandella et al., 2002). Following maturation, MoDC 
increase their expression of CD83, CD80, CD86, MHCII and C-CCR7 molecules 
(Figdor et al., 2004). More recent MoDC maturation markers have been identified as 
IL-2 receptor alpha CD25 and CD43 (Velten et al., 2007). Mature MoDCs also
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demonstrate enhanced T-cell activation, measured by T-cell proliferation assays, and 
increased cytokine production (Velten et ah, 2007).
1.3.7. Porcine dendritic cells and PRRSV
Whilst the dendritic cell research of veterinary species is few in comparison 
to that of humans and mice, the generation of MoDC has been described in various 
species, including porcine (Foss et al., 2003), feline (Mizukoshi et al., 2009), equine 
(Moyo et al., 2013) and bovine (Howard et al., 1999). In vivo, porcine DCs are 
described in the thymus (Salmon et al., 2000), skin (Bautista et al., 2002), and 
Peyer’s patches (Makala et al., 1998). Porcine MoDC generation in vitro is 
described using both bone marrow monocytes (Carrasco et al., 2001; Peng et al., 
2009) and blood monocytes, using a variety of factors for their differentiation 
(Carrasco et al., 2001; Paillot et al., 2001). Whilst recombinant IL-4 and GM-CSF 
are most commonly used, Bautista and colleagues suggested that IL-13 should 
replace IL-4 in swine MoDC differentiation because IL-4 is not a prominent cytokine 
in some breeds (Bautista et al., 2007). Interestingly, it is reported that CD163+ 
monocytes differentiate into more efficient MoDCs which express higher MHCII 
and CD80/86 (Chamorro et al., 2004).
Porcine MoDC show many similarities with human MoDC, and express the 
following molecules on their surface: CD1, CD80/86, CD 172a, major 
histocompatibility complex (MHC)-class II (Bautista et al., 2007; Carrasco et al., 
2001; Paillot et al., 2001), however, the limited availability of porcine specific 
antibodies has restricted their further characterisation.
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The interaction of PRRSV with DCs is poorly understood. Whilst there are 
many reports of PRRSV-2 infection with MoDCs (Flores-Mendoza et ah, 2008; 
Wang et ah, 2007), there are very few reports concerning PRRSV-1 infection of 
MoDCs (Silva-Campa et ah, 2010). PRRSV-2 infection of MoDCs has shown to 
increase Foxp3+CD25+ T-cells, associated with an up-regulation in TGF-|3 (Silva- 
Campa et ah, 2009). This subset of T-cells resembles the TGF-P secreting Th3 
regulatory T-cells described in humans and mice, therefore, this supports the 
hypothesis that PRRSV induces regulatory T-cells (T-regs) which could play a role 
in the delayed cellular immune responses in PRRSV infected pigs early post­
infection. In contrast, PRRSV-1 infection of MoDCs appeared not to induce T-regs 
(Silva-Campa et ah, 2010). There are reports to suggest that PRRSV infection of 
DCs impairs their function, in particular by the down-regulation of MHCI and 
MHCII and hence the impairment of antigen presentation following PRRSV-2 
infection of MoDCs (Park et ah, 2008; Wang et ah, 2007). PRRSV is also reported 
to reduce the phagocytic activity of MoDCs and induce their cell death via apoptosis 
and necrosis (Wang et ah, 2007).
1.4. Hypothesis, aims and objectives
PRRSV continues to be an economically devastating disease of swine for 
which an efficient control is urgently required. The current understanding of the 
immune response to PRRSV suggests that it is the combination of events during 
PRRSV interaction with myeloid cells that decides the fate of an immune response. 
Such immune responses, and the myeloid cells with which PRRSV interacts, 
however, are far from being fully understood. In particular, there is a lack of 
research characterising the different states of activation or maturation of which these
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porcine myeloid cells exist. Since PRRSV has shown several mechanisms of 
immunomodulation, it is likely that activation or maturation states are modulated 
during PRRSV infection. Furthermore, the susceptibility of each of these cells and 
their subtypes has not thoroughly been investigated. Studies of PRRSV-1 are limited 
in comparison to PRRSV-2, due to the lack of cell-lines available for in vitro 
propagation. The overall aim of this thesis, therefore, was to fully characterise these 
myeloid cells, in particular, monocytes, macrophages and dendritic cells, in their 
various states of activation, and to subsequently assess where PRRSV replication 
occurs and what role CD 163 and CD 169 play in the replication process. It is 
hypothesised that porcine myeloid cells exist in various distinct forms of activation 
and/or maturation, wherein PRRSV shows differences in replication. It is assumed 
that clarification of which cells PRRSV is most able to replicate in will give clues to 
how PRRSV induces delayed host immune responses.
In summary, the objectives of this thesis are as follows:
• To characterise the physiology of porcine monocytes by assessing their 
responses to known growth factors such as macrophage-colony stimulating 
factor (M-CSF) and granulocyte-macrophage colony stimulating factor (GM- 
CSF), and to investigate whether these responses result in increased 
susceptibility to PRRSV-1.
• To optimise the differentiation of monocyte derived macrophages (MoM0s) 
and establish a porcine Ml and M2 macrophage activation system, using the 
current human system as a guideline, and characterise these macrophage 
subsets by their phenotype and function.
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• To optimise the differentiation of monocyte derived dendritic cells (MoDCs) 
using GM-CSF and M-CSF respectively, and to characterise these cells via 
their phenotype and function according to their maturation states.
• To assess the role of CD 163 and CD 169 as putative key receptors involved in 
PRRSV (Van Breedam et al., 2010a), by assessing their modulation by a 
variety of pro and anti-inflammatory factors.
• To study the interaction with PRRSV-1 using strain Lena as an example of a 
more pathogenic variant detected in Eastern Europe.
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Chapter II
Materials and 
Methods
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2. MATERIALS AND METHODS
2.1. Animals used in the study
The animals used in this study were pathogen free Large White Cross 
Landrace pigs, a popular breed used in the British pork industry, bred and housed at 
the Animal Health and Veterinary Laboratories Agency (AHVLA). ASU staff 
kindly provided the collection of blood from pigs and carried out the post mortems. 
All work was carried out under license from the UK Home Office (PPL 70/7057) 
under the Animal Act 1986 and approved by an ethics committee.
2.2. Isolation and culture of porcine cells
All porcine primary cells were collected from pigs under the age of 2 years. 
Venous blood was collected from live animals for the isolation of monocytes, and 
lungs were obtained from post mortem pigs for the isolation of alveolar 
macrophages.
2.2.1. Peripheral blood monocytes
CD14+ monocytes were isolated from whole porcine blood using a standard 
magnetic cell separation method via CD 14 staining followed by positive magnetic 
sorting as described by the manufacturer (Miltenyi Biotec, Bergisch Gladbach, 
Germany).
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Blood was collected either immediately post mortem or from live animals. 
Up to 200 ml of whole blood was collected into sterile duran bottles containing 25 
I.U of heparin sodium (LEO, Ballerup, Denmark) to prevent blood coagulation. 30 
ml of this was layered onto 20 ml Biocoll separating solution, 1.077 g/ml density 
(Biochrom, Berlin, Germany) and centrifuged for 30 minutes at 1455 g and at room 
temperature with deceleration set to slow (Boyum, 1968). The peripheral blood 
mononuclear cell (PBMC) interface was removed and washed 3 times with 50 ml 
4°C Dulbecco’s PBS (PBS) (Invitrogen, Paisley, UK). PBMC were counted and 
resuspended in 10 pi anti-human CD 14 MicroBeads (Miltenyi Biotec, Gergisch 
Gladbach, Germany) per 107 cells and incubated at room temperature for 12 minutes. 
After a further two washes with PBS supplemented with 2% fetal bovine serum 
(PBS), cells were resuspended in 500 pi PBS supplemented with 2% PBS and 5 mM 
Ethylenediaminetetraacetic acid (EDTA) (Sigma, Poole, UK) (MACS buffer) per 108 
cells and this was applied to a MACS LS column placed on a magnetic quadra 
MACS unit (Miltenyi Biotec, Gergisch Gladbach, Germany). Flow through was 
collected as the CD 14 negative fraction and after washing the column with MACS 
buffer, the CD 14 positive fraction was collected by removing the column from the 
magnetic field of the quadra unit and forcing through 7 ml RPMI-1640 media 
supplemented with 10% PBS, 100 lU/ml of penicillin (Invitrogen, Paisley, UK), 100 
pg/ml of streptomycin (Invitrogen, Paisley, UK), 50 pg/ml of gentamycin 
(Invitrogen, Paisley, UK) (complete tissue culture [TC] medium) and cultured on 
ultra low bind (ULB) culture plates in an incubator at 37°C and 5% CO2 conditions.
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2.2.2. Porcine alveolar macrophages (PAMs)
PAMs were obtained from the lungs of post mortem pigs of up to 2 years of 
age. Animals were euthanized by captive bolt and the lungs removed so that 
bronchoalveolar lavage fluid (BALF) could be obtained. In a sterile environment 
and using aseptic technique, lungs were filled with PBS, the tissue massaged, and 
contents extracted into sterile falcon tubes. These were centrifuged and the pellet 
washed 3 times with PBS. Due to the large number of cells obtained from one 
animal, PAMs were usually cryopreserved and thawed when required for further use. 
PAMs were cultured in full TC medium as described in 2.2.1
2.2.3. MARC-145 cells
MARC-145 cells are a continuous cell line derived from African green 
monkey kidney cell line (MAI 04), routinely used for the propagation of North 
American genotype PRRSV-2. MARC-145 cells were obtained from frozen stocks 
the AHVLA Cell and Tissue Culture Section (CTCS) and cultured at a density of 
2.5x104/ml in full TC medium, as detailed in section 2.2.1.
2.2.4. Light microscopy
Light microscopy was used throughout the duration of cell cultures to 
monitor the viability and assess the morphology of cells, using a Leica DM IL LED 
inverted microscope, with 10X or 20X lenses and 10X binocular magnification. Cell 
cultures were photographed using the attached digital camera.
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2.3. Differentiation of monocytes into macrophages or dendritic cells
Freshly isolated monocytes, obtained as described in 2.2.1, were used for the 
in vitro differentiation of macrophages or dendritic cells.
2.3.1. Differentiation of monocyte derived macrophages (MoM0s)
For the differentiation of monocytes to monocyte derived macrophages 
(MoM0), freshly isolated monocytes were cultured as described in section 2.2.1, at a 
cell density of lx l0 6/ml (1 ml/well) in full TC medium supplemented with 50 ng/ml 
of recombinant human M-CSF (Miltenyi Biotec, Bergisch, Gladbach, Germany) for 
4 days (Table 2.3). Cell differentiation was monitored by assessment of cell 
morphology using light microscopy, as described in section 2.2.4, and subsequently 
by phenotypic and functional characterisation, described in sections 2.6.3, 2.5.3 and 
2.5.4 .
2.3.2. Differentiation of monocyte derived dendritic cells (MoDCs)
For the differentiation of monocytes to monocyte derived dendritic cells 
(MoDCs), freshly isolated monocytes were cultured at a cell density of 2xl06/ml (1 
ml/well) in full TC medium supplemented with 10 ng/ml of recombinant porcine 
GM-CSF and 10 ng/ml of recombinant porcine IL-4 (R&D Systems, Abingdon, UK) 
for 4 days (Table 2.3). Cell differentiation was monitored by assessment of cell 
morphology during the culture period using light microscopy, as described in section
2.2.4, and subsequently by phenotypic and functional characterisation, described in 
sections 2.6.3, 2.5.3 and 2.5.4.
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2.3.3. Treatment of freshly isolated monocytes, PAMs, MoM0s and MoDCs
Following isolation or differentiation, monocytes, PAMs, MoM0s and 
MoDCs were all treated with various inflammatory mediators and their responses 
characterised by light microscopy (2.2.4), phenotypic analysis (2.6.3), and functional 
analysis (2.5.3 and 2.5.4).
2.3.4. Treatment of monocytes and PAMs with M-CSF
The effects of macrophage-colony stimulating factor on the viability, 
proliferation, and susceptibility to PRRSV of monocytes and PAMs were assessed 
using recombinant human macrophage-colony stimulating factor (M-CSF) (R&D 
systems, Abingdon, UK). Freshly isolated monocytes or PAMs were obtained as 
described in sections 2.2.1 and 2.2.2 and cultured at a density of 5xl05-2xl06/ml 
(1 ml/well) for up to 6 days in complete TC medium supplemented with M-CSF at 
various concentrations (Table 2.3). As a control, monocytes were also cultured with 
complete TC medium only or complete TC medium supplemented with 10 ng/ml 
recombinant porcine granulocyte macrophage-colony stimulating factor (GM-CSF) 
(R&D systems, Abingdon, UK), listed in Table 2.3. Cells were infected as described 
in section 2.4. Cell viability was assessed (2.6.2), as was cell proliferation (2.5.1 and 
2.5.2).
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2.3.5. Treatment of freshly isolated porcine monocytes with inflammatory
factors
To assess the effect of inflammatory factors on expression of PRRSV 
receptors on monocytes, monocytes were isolated as described in section 2.2.1, and 
cultured at a density of lx l0 6/ml in full TC medium supplemented with various 
individual cytokines or dexamethasone for 2 days. The panel of cytokines included 
recombinant porcine cytokines: IFN-a, IFN-y, IL-4, IL-10, GM-CSF, recombinant 
equine cytokines: IL-1 (3, IL-6 and recombinant human M-CSF (R&D Systems, 
Abingdon, UK). Monocytes were also treated with a range of concentrations of 
water soluble dexamethasone (Sigma, UK). The concentrations which these factors 
were used are listed in Table 2.3.
2.3.6. Activation of monocyte derived macrophages (MoM0 s)
On day 4 of culture, culture medium was gently removed using a pipette and 
without disrupting the cells, and replaced with fresh TC medium prior to adding 
macrophage activating factors. For classical activation of MoMos (for M l 
macrophages), 10 ng/ml of lipopolysaccharide (LPS) (from Salmonella Minnesota, 
TLR grade) (Enzo Life Sciences, Exeter, UK) and 100 ng/ml of recombinant porcine 
IFN-y (R&D Systems, Abingdon, UK) were added to MoMos, listed in Table 2.3 . 
For alternative activation (for M2 macrophages), 10 ng/ml of recombinant porcine 
IL-4 was added to MoM0s. MoM0s were also treated with 10 pg/ml of water 
soluble dexamethasone (Sigma, Poole, UK) or 10 ng/ml of recombinant porcine IL- 
10 (R&D Systems, Abingdon, UK), listed in Table 2.3. MoM0s were then assessed
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according to their phenotype, described in section 2.6.3, their function, as described 
in sections 2.5.3 and 2.5.4, or infected with PRRSV, described in section 2.4.
2.3.7. Activation/maturation of MoDC
Following 4 days of culture, MoDCs were treated with a maturation cocktail 
for 24 hours. Wells were spiked with 100 ng/ml of LPS (Salmonella Minnesota) 
(Sigma, Poole, UK), 100 ng/ml of porcine IFN-y, 20 ng/ml of porcine TNF-a, 20 
ng/ml of equine IL-6, 10 ng/ml of equine IL-1 (3, and 1 pg/ml of prostaglandin Ez 
(PGE2) (R&D Systems, Abingdon, UK) (Table 2.3). MoDCs were then assessed 
according to their phenotype, using flow cytometry described in section 2.6.3, their 
function, described in sections 2.5.3 and 2.5.4, or infected with PRRSV, described in 
section 2.4.
2.4. PRRSV Infection
All infections were carried out using the European genotype PRRSV-1 Lena 
isolate at time-points described throughout.
2.4.1. PRRSV Virus isolation and titration
PRRSV-1 strain Lena is a particularly pathogenic subtype 1.3 strain isolated 
in Eastern Europe recently described (Kamiychuk et al., 2010) and was supplied by 
Hans Nauwynck (Ghent University) as part of the EU research consortium 
PoRRSCon. Virus was propagated on PAMs isolated and cultured as described in 
section 2.2.2. 1 ml of virus stock was added to 75 cm2 culture flasks containing 10
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ml of PAMs at a density of 2xl06/ml, at and incubated for 3 days before freeze 
thawing cells and harvesting the supernatant as new virus stock. Mock supernatant 
was obtained from PAMs cultured in the same way for 3 days without virus. Virus 
and mock stocks were stored at -80°C until required.
Virus stocks were titrated using PAMs from AHVLA CTCS on 96-well flat- 
bottom plates at a density of 2xl06/ml, using immunoperoxidase (IPX) staining and 
the Reed and Muench method to determine the tissue culture infective dose 
(TCID)5o. Briefly, 10-fold dilutions of the virus stock was added to PAMs (8 
replicate wells for each dilution), and 3 days after infection PAMs were washed with 
0.5 M NaCl (Sigma, Poole, UK) and fixed in 4% paraformaldehyde (PFA) (Sigma, 
Poole, UK) and stained with the anti-PRRSV monoclonal antibody (mAb) SDOW- 
17 (Rural Technologies Inc, Brookings, USA), using a 1/100 dilution in IPX serum- 
and-conjugate buffer. IPX serum and conjugate buffer contained 0.01M phosphate 
buffered saline (PBS) (pH 7.6), 0.5M NaCl and 0.01% Tween-80 (Sigma, Poole, 
UK). PAMs were incubated with the mAb dilution for 1 hour at 37°C and washed 3 
times with IPX wash buffer containing 0.01M PBS (pH 7.6) and 0.05% Tween 80. 
The secondary antibody, polyclonal rabbit anti-mouse horseradish peroxidase (HRP) 
(Dako, Cambridge, UK), diluted 1/150 in IPX serum-and-conjugate buffer, was 
added to cells and incubated for 1 hour at 37°C. After washing 3 times with IPX 
wash buffer, 50 pi of freshly prepared carbazole substrate buffer, containing 0.06% 3 
amino-9-ethylcarbazole (Sigma, Poole, UK), 0.01% hydrogen peroxide (H2O2) 
solution (Sigma, Poole, UK) diluted in acetic acid buffer (0.08% glacial acetic acid 
[Sigma, Poole, UK], 0.04 M anhydrous sodium acetate [Sigma, Poole, UK], de­
ionised water) was added to wells. Cells were incubated for 15 minutes until a 
colour change was observed to reddish-brown, and washed twice in IPX wash buffer.
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Mock infected PAMs were stained using the same protocol and used as a negative 
control.
Cells were viewed under an inverted light microscope, described in section 
2.2.4, and wells deemed positive for PRRSV (by staining brown) were counted for 
each virus dilution. Virus titres were calculated as the reciprocal of the dilution of 
the last well showing specific staining (Reed and Muench, 1938).
2.4.2. PRRSV infection of cells
Cells were infected with PRRSV-1 strain Lena at a multiplicity of infection 
(m.o.i) of 0.1. At described time-points post infection (p.i), cells were harvested 
using multi-pipetting, or using 1.7 cm blade cell scrapers (Starstedt, Leicester, UK) 
for the removal of adherent cells such as MoMos, and centrifuged to obtain cell 
pellets. Cell supernatant was removed for analysis of infection by quantitative 
reverse transcriptase-polymerase chain reaction (RT-PCR) analysis where required, 
described in section 2.4.3, and cell pellets were washed in PBS and analysed for 
infection using quantitative RT-PCR, described in section 2.4.3 and 2.4.4, or by 
using flow cytometry, described in 2.6.5. Cell pellets or cell supernatants were 
stored at -70°C prior to RNA extraction.
Time-zero samples were obtained where required, following 2 hours of 
incubation with virus at 4°C to achieve attachment but no internalisation o f virus. 
After 2 hours, cells were washed twice in fresh TC medium and gentle centrifugation 
at 9 g for 5 minutes. Cells were incubated at 37°C until further time-points.
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2.4.3. Analysis of PRRSV infection using a TaqMan PCR
For the isolation of viral RNA from cells or cell supernatant, RNA extraction 
was carried out manually using the QiaAmp Viral RNA Mini Kit or robotically using 
a Biorobot Universal System (both Qiagen, Manchester, UK), when the number of 
samples for analysis exceeded 12. For both methods, RNA was extracted from 140 
pi of cell supernatant or from cells resuspended in 140 pi AVL buffer (viral lysis 
buffer + carrier RNA). Briefly, this was mixed with 420 pi AVL buffer before 560 
pi of ethanol was added. This was added to a column with a QiaAmp membrane to 
which RNA is absorbed whilst other products pass through the column and are 
separated from the RNA. The column was washed with 2 different wash buffers 
supplied with the kits, and resuspended in 60 pi of elution buffer. Eluted RNA was 
stored at -20°C prior to PCR analysis. Eluted RNA was diluted 1/10 in nuclease free 
water before qPCR analysis.
For PRRSV detection by reverse transcription real time quantitative TaqMan 
reverse transcriptase PCR (qRT-PCR), 2 pi of diluted RNA was added to 23 pi of a 
PCR mastermix containing EU PRRSV forward/reverse primers and probe, and 
contents of the Quantitect RT-PCR Kit (Qiagen, Manchester, UK), detailed in Table
2.1. For RNA extracted from cells, a eukaryotic 18S rRNA endogenous control was 
added to allow normalization of RNA which is a surrogate to the number of cells 
(Applied Biosystems, Life Technologies Limited, Paisley, UK). The PCR was 
carried out using a MxSOOOP Real time PCR system (Agilent, La Jolla, California) 
using the following thermal profile:
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50°C 30 min 1 cycle (segment 1)
95°C 15 min
94°C 20 sec
>-
72°C i* 45 sec
94°C 20 sec
►
55°C 45 sec
1 cycle (segment 2)
17 cycles (segment 3- touchdown)
38 cycles (segment 4)
* ^  -  72°C plateau on the thermal profile shows this is a Touchdown PCR - 
decrease of 1°C in annealing temperature is made for each of the 17 cycles.
Endpoint data collection points were collected at the 55°C plateau in segment 4. 
Table 2.1. Contents of the RT qPCR TaqMan mastermix.
Reagent Concentration Volume for one 
reaction (pi)
Nuclease free water As supplied 7.75
Quantitect Mix As supplied 12.5
RT Enzyme As supplied 0.25
Eu-for primer (Eu-for 5’ GAT GAC 
RTC CGG CAY C 3 ’)
15 pM 0.5
Eu-rev primer (Eu-rev 5 ’ CAG TTC 
CTG CGC CTT GAT 3’)
15 pM 0.5
Eu-probe (Eu-probe 5 ’ Fam-TGC AAT 
CGA TCC AGA CGG CTT-Tamra, 
R=A+G Y=C+T)
10 pM 0.5
Eukaryotic 18S rRNA Endogenous 
control (VIC/MGB Probe)
As supplied 1.0
Final Volume (pi) 23.0
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2.4.4. Analysis of RT q-PCR data
For the analysis of PRRSV replication in cell supernatants, the threshold 
cycles (Ct) of PRRSV replication (detected by FAM fluorescence) in the cell 
supernatant obtained at 2 hours p.i (i.e. the time-zero negative control) was 
subtracted from the Ct of PRRSV detection at each time-point p.i, using the 
following equation:
ACt = (CtFAM[post-infection]) -  (CtFAM [time-zero])
Ct = Cycle threshold
FAM = detection of PRRSV primers
Alternatively, where replication was measured in cells, relative quantitation 
was used to analyse changes between the time-zero negative control and the time p.i, 
using normalisation against an endogenous control (18S rRNA) and comparing the 
PRRSV-specific Cts using the AACt method (Livak and Schmittgen, 2001). To 
determine which calculation could be used, a validation test was performed to 
determine that the efficiencies of the target gene and endogenous gene primers were 
similar. Standard curves were performed using serial dilutions of both the target 
primers (PRRSV) and the endogenous reference (18S) primers and the amplification 
efficiencies determine by calculation of the slope of the line (Figure 2.1).
To calculate AACt, the Ct of PRRSV detection (detected by FAM 
fluorescence) was compared against the Ct of endogenous 18S rRNA (detected by 
HEX fluorescence) in both relative samples and the time-zero negative control. This 
used the following equation:
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A FAM efficiency
y = -3 AS6*log(X)+:l 85
Using 0.1
y = -3 386:|:log(0.1) +2I S5 
Y = 25.2
HEX efficiencx
y = -3  188M pg(X )+19 07
Using 0 1
v — -3 188 * log(O.l) + 19.0" 
y  =22 .3
TK
Figure 2.1. Validation experiment to determine relative quantitation method. The
efficiency o f the target primers, detected on FAM (A), and the endogenous control (18S) 
primers, detected on HEX (B), were calculated using the slope o f the standard curves, 
performed in triplicate using 10-fold dilutions o f RNA extracted from untreated monocytes 
infected with PRRSV Lena.
AACt =(CtFAM -  CtHEX [post-infection]) -  (CtFAM -  CtHEX [time-zero])
Ct = Cycle threshold
FAM = detection of PRRSV primers
HEX = detection of 18S primers
Each ACt change, therefore, represents a 2-fold difference in abundance.
A detection limit of Ct>28 was used throughout.
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2.5. Assessment of cell function
The functions of porcine primary cells and differentiated cells were analysed 
where described, using the following methods.
2.5.1. Thymidine proliferation assay
M-CSF treated monocytes and PAMs were labelled with radioactive 
thymidine to assess cell proliferation. Cells were pulsed with 1 pCi/well 3H- 
thymidine (GE Healthcare, Little Chalfont, UK) and incubated for 72 hours. Cells 
were harvested onto filter mats using a Harvester 96 Mach III (TomTec Inc, 
Hamden, USA) and 3H-thymidine incorporation was measured by addition of 
25pl/well Microscint O and counting on a MicroBeta2 2450 Plate Counter (both 
Perkin Elmer, High Wycombe, UK).
2.5.2. EdU Click-iT® Proliferation Assay
For the assessment of cell proliferation over time in culture, an EdU Click- 
iT® Kit (Invitrogen, Paisley, UK) was used. Freshly isolated monocytes were 
labelled with 5 pM (5-ethynyl-2’ -deoxyuridine) and set up in culture in full TC 
medium with or without 200 ng/ml recombinant human M-CSF (R&D Systems, 
Abingdon, UK). At various time-points over 6 days, monocytes were harvested 
using cell scrapers, and stained with a LIVE/DEAD Violet or LIVE/DEAD PE stain 
as described in section 2.6.2. After washing, cells were resuspended in 100 pi of 
Click-iT® fixative for 15 minutes at RT, protected from light. Cells were washed in
54
PBS + 1% FBS and resuspended in 100 pi of IX Click-iT® saponin-based 
permeabilization and wash reagent. After 15 minutes incubation at RT, 0.5 ml of 
freshly prepared Click-iT® reaction cocktail (containing PBS, copper sulphate, 
fluorescent dye azide [Alexa Fluor® 647] and IX reaction buffer additive) was 
added to cells and incubated for 30 minutes at RT, protected from light. Cells were 
washed in IX Click-iT® saponin-based permeabilization and wash reagent before 
flow cytometric analysis, described in section 2.6.
2.5.3. Endocytosis Assay
Endocytosis was assessed using Allophycocyanin (APC ^ -labelled 
ovalbumin (Invitrogen, UK). Cells were then resuspended in cold RPMI and added 
to 96 well round bottom plates at lx l0 5/well and incubated on ice for 30 minutes. 
APC*-ovalbumin was added to cells at 20 pg/ml and incubated for 1 hour at either 
4°C (control plate) or 37°C. Some cells were without beads as a further negative 
control. Cells were washed three times with cold PBS stained for viability using 
LIVE/DEAD violet stain (section 2.6.2). Cells were resuspended in cold PBS for 
flow cytometric analysis, described in section 2.6.
2.5.4. Phagocytosis Assay
Phagocytosis was assessed using fluorescin isothiocyanate (FITC)-labelled 
FluoSpheres® sulfate microsphere particles (4 pm diameter) or FITC-labelled 
carboxylate-modified microspheres (1 pm diameter) where described (Invitrogen, 
Paisley, UK). Cells were split into two wells of a 24-well ultra low bind (ULB) plate 
to allow for a control well without particles, and supplemented with 500 pi of fresh
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RPMI resulting in a cell density of 5xl05/ml. Microspheres were added at 2xl05 
beads/ml and incubated for 3 hours at either 4°C (negative control) or 37°C. Cells 
were then harvested and washed 3 times in cold PBS and consequently stained for 
viability using LIVE/DEAD violet stain (section 2.6.2). Cells were resuspended in 
cold PBS for flow cytometric analysis.
2 5.4.1. Confocal microscopy analysis of phagocytosis
For confocal microscopy analysis of phagocytosis, cells were cultured on 8- 
well plastic Nunc Lab Tek chamber slides (Fisher Scientific, Loughborough, UK) at 
5xl05/ml and FITC-labelled carboxylate-modified microspheres (1 pm diameter) 
(Invitrogen, Paisley, UK) were added directly to wells at a ratio of 5:1 (beadsrcell) 
and incubated at 37°C for 4 hours. Cells were washed 3 times with cold PBS and 
mounted in Vectashield soft-set mounting media with propidium iodide (PI) (Vector 
Laboratories, Peterborough, UK). Slides were mounted with coverslips, sealed with 
clear nail varnish and assessed using a Zeiss LSM5.1 confocal fluorescent 
microscope, and Cy5 and Cy2 channels used to detect microspheres and PI stain 
respectively. A z-stack was performed to determine internalisation of micro spheres, 
imaging 1 pm slices of cells. Images were scanned and saved for analysis using 
LSM image browser, downloaded from:
http://microscopy.zeiss.com/microscopy/en_gb/downloads/Ism-5-series.htmI 
(Zeiss, 2013).
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2.6. Flow Cvtometrv
All flow cytometry experiments were carried out using a MACSQuant 
Analyzer flow cytometer (Miltenyi Biotec, Gergisch Gladbach, Germany). In all 
cases, antibodies were adding following the harvesting of cells from culture plates, 
and centrifugation of cells at 931 g for 5 minutes at 4°C to obtain a cell pellet, which 
was resuspended for staining with a viability dye described in section 2.6.2.
2.6.1. Zenon® conjugation of monoclonal antibodies
Where described, unconjugated antibodies were labelled using Zenon® 
Alexa Fluor® Mouse IgG Labelling Kits (Invitrogen, Paisley, UK), according to the 
antibody isotype and using the manufacturer’s protocol. This enables the parallel use 
of antibodies with different labels, avoiding a secondary labelling step with anti- 
mouse antibodies. Briefly, 1 pg of antibody was mixed with 5 pi of Zenon® mouse 
IgG labelling reagent. This was incubated at room temperature for 5 minutes, 
followed by addition of 5 pi of the Zenon® blocking reagent and a further 5 minute 
incubation at room temperature. The conjugated antibody was then diluted as 
determined by titration and used accordingly.
2.6.2. Flow cytometric analysis of cell viability
Cell viability was measured using either Via-Probe or LIVE/DEAD Violet 
Fixable dye staining before flow cytometric analysis.
Cell pellets were resuspended in 1 ml of cold PBS and incubated with 20 pi 
of 7AAD nucleic acid dye Via-Probe (BD Biosciences, Oxford, UK) for 20 minutes
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at 4°C protected from light. 7AAD is a nucleic acid dye which excludes dead cells 
by staining only those with disrupted membranes. Percentages of live cells were 
analysed using the FL3 laser of the flow cytometer.
Alternatively LIVE/DEAD Violet fixable dye (Invitrogen, Paisley, UK) was 
used for eliminating dead cells during flow cytometry and before proliferation, 
endocytosis, and phagocytosis assays. Cell pellets were resuspended in 1 ml of cold 
PBS and 1 pi of LIVE/DEAD fixable dye was added to cells and incubated at RT for 
20 minutes, protected from light. Cells were washed twice with PBS before analysis 
by Violet fluorescence using flow cytometry. LIVE/DEAD PE fixable dye 
(Invitrogen, Paisley, UK), was used in the same way as an alternative dye on 
occasion. The LIVE/DEAD stain is based on the reaction of the fluorescent reactive 
dye with cellular proteins (amines). As the dye cannot penetrate cell membranes, it 
allows the discrimination between live and dead cell populations; the staining of cell 
surface proteins on live cells results in dim fluorescence, whereas the ruptured 
membranes on dead cells enables the dye to stain both intracellular and extracellular 
amines, resulting in more intense fluorescence.
2.6.3. Flow cytometric analysis of surface molecules
For staining of surface molecules where described, cell pellets were stained 
with LIVE/DEAD Violet fixable dye, described in section 2.6.2 and following 
resuspension in PBS, added to round bottom 96-well plates (~5xl05/well) and 
stained with antibodies listed in Table 2.2. Cells were incubated at 4°C for 30 
minutes before washing twice in PBS supplemented with 1% FBS and 0.09% 
sodium azide (FACS buffer). Where double staining of cells was performed where 
described, the second antibody was added following washing of the first antibody
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and incubated at 4°C for a further 30 minutes. Single colour antibody stains were 
performed to allow compensation of spill-over of fluorescence. Individual samples 
were also stained with isotype negative controls of matching concentration to the 
relative antibody where described, also listed in Table 2.2. As an additional control, 
cells were left unstained and analysed for background fluorescence. After the final 
antibody wash, cells were resuspended in either 200 pi of IX CellFix (BD 
Biosciences, Loughborough, UK).
2.6.4. Analysis of flow cytometry data: Gating strategies
Flow cytometry data was analysed using the MACSQuantify software 
version 2.4. The gating strategy involved identifying the cells of interest according 
to their size and granularity in FSC/SSC, and assessing this population for Violet 
fluorescence. Cells negative for Violet fluorescence were gated as the live 
population and it was these cells analysed for antibody expression. Cells stained 
with the relative isotype control were used to determine the location of background 
fluorescence (Figure 2.2). Fluorescence was measured according to mean 
fluorescence intensity (MFI), and by percentage of the live population. Cells were 
analysed in duplicate and biological repeats carried out at least 3 times to obtain 
mean values.
2.6.5. Flow cytometric analysis of infection
Cell pellets were first stained with a LIVE/DEAD Violet Viability stain 
described in section 2.6.2. Cells were washed with FACS buffer and resuspended in 
PBS. Cells were added to round bottom 96-well plates (~5xl05/well) before being
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fixed and permeabilised with CytoFix/CytoPerm kit according to the manufacturer’s 
protocol (BD Biosciences, Oxford, UK). Briefly, 100 pi of cold CytoFix/CytoPerm 
Ix solution was added to wells and incubated at 4°C for 20 minutes. Cells were 
washed twice in a IX solution of supplied PermWash and resuspended in 50 pi of 
the same solution to maintain permeability. The PRRSV specific monoclonal 
antibody (mAb) SDOW-17 (Rural Technologies Inc, Brookings, USA) was diluted 
1/20 in PermWash and 5 pi was added to cells and incubated for 30 minutes at 4°C. 
An anti-mouse IgGl isotype control was also used dilution to stain cells to assess for 
non-specific binding. Cells were washed twice with cold PermWash and stained 
with 5 pi of a 1/10 dilution (also diluted in PermWash) of anti-mouse IgGl-APC* 
conjugated secondary reagent (BD Biosciences, Oxford, UK) to allow 
immunofluorescence detection. As a further negative control, unstained cells were 
stained with secondary antibody only. Cells were incubated for 30 minutes at 4°C 
and washed twice in cold PermWash. Cells were resuspended in 200 pi of cold PBS 
and analysed on the MACSQuant flow cytometer for APC* fluorescence. 
Antibodies used are listed in Table 2.2.
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Figure 2.2. Gating strategy for flow cytometric analysis. The relevant population o f cells 
were gated according to FSC/SSC (A). This population was then analysed for Violet 
fluorescence to eliminate dead cells (B). The live population, i.e. violet-negative cells, was 
then analysed for the relevant fluorescence according to the antibody conjugate or secondary 
antibody used. Cells stained with the relative isotype control were used to determine the 
location o f the gate in which cells were deemed positive (C), this gate was carried over onto 
antibody stained cells to determine positive fluorescence (D).
2.6.6. Statistical analysis
Data was analysed and statistical tests were performed using GraphPad Prism 
Software, version 6.01. All experiments were performed at least 3 times using cells 
isolated from 3 different pigs. Statistical tests such as One-way or Two-way analysis 
of variance (ANOVA) and student t-tests were performed as detailed in the results 
section.
Table 2.2. Table o f primary and secondary antibodies used throughout the study, *nd = not determined
Antibody Host Species Target
Species
Clone Isotype Concentration
(mg/ml)
pg/test Conjugate Supplier
1° 
A
N
T
IB
O
D
IE
S
SLA Class II DR Mouse Pig 2E9/13 IgGl 0.1 0.50 FITC AbD Serotec, Kidlington, UK
CD14 Mouse Pig MIL-2 IgG2b 0.1 0.50 FITC AbO Serotec, Kidlington, UK
CD163 Mouse Pig 2A10/11 IgGl 0.1 0.50 FITC AbD Serotec, Kidlington, UK
CD169 Mouse Pig 3B/11/11 IgGl 0.1 0.05 Unconjugated AbD Serotec, Kidlington, UK
CD152-muIg (CTLA4) Mouse Human IgG2a 0.5 1.25 Unconjugated Enzo Life Sciences, Exeter, UK
CD25 Mouse Pig K231.3B2 IgGl nd nd Unconjugated AbD Serotec, Kidlington, UK
CD206 (ct-MMR) Goat Human Polyclonal 0.2 1.00 Biotinylated R&D Systems, Abingdon, UK
CD209 (DC-SIGN) Sheep Human Polyclonal 0.2 1.00 Unconjugated R&D Systems, Abingdon, UK
CD83 Sheep Human Polyclonal 0.2 1.00 Biotinylated R&D Systems, Abingdon, UK
SWC9 Mouse Pig PM 18-7 IgGl 1 0.50 Unconjugated Abeam, Cambridge, UK
SDOW-17 Ascites Mouse Pig IgGl nd nd Unconjugated Rural Technologies, Inc
I
Gl-APC* Rat Mouse X56 0.2 0.10 APC* BD Biosciences, Oxford, UK
Donkey anti-goat IgG Donkey Goat 2 1.00 APC* Invitrogen, Paisley, UK
%
Donkey anti-sheep IgG Donkey Sheep 2 1.00 APC* Invitrogen, Paisley, UK
s Streptavidin-PE-Cy7
■
0.2 0.05 PE-Cy-7 eBiosciences, Hatfield, UK
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Table 2.3. Table o f  cytokines. Cytokines and factors used throughout the study for the stimulation o f  porcine immune cells are detailed. *n/a= not applicable 
*EU endotoxin unit
Cytokine/factor Target Species Concentration used 
(ng/ml)
Source Endotoxin Level (EU per 1 
pg of the protein)
Supplier
Recombinant M-CSF Human 3.10-200 E. Coli-derived <1.0 R&D Systems, Abindgdon, UK
Recombinant M-CSF Human 50 E. Coli-derived <1.0 Miltenyi Biotec, Gladbach, Germany
Recombinant IFN-y Porcine IxlO6 units/ml Mammalian cells <1.0 R&D Systems, Abindgdon, UK
Recombinant IL-10 Porcine 10 E. Coli-derived <0.01 R&D Systems, Abindgdon, UK
Recombinant GM-CSF Porcine 10 E. Coli-derived <0.1 R&D Systems, Abindgdon, UK
Recombinant IL-4 Porcine 10 E. Coli-derived <1.0 R&D Systems, Abindgdon, UK
Recombinant IL-ip Equine 10 E. Coli-derived <1.0 R&D Systems, Abindgdon, UK
Recombinant TNF-a Porcine 20 E. Coli-derived <0.01 R&D Systems, Abindgdon, UK
Recombinant IL-6 Equine 20 E. Coli-derived <1.0 R&D Systems, Abindgdon, UK
Recombinant IFN-y Porcine 100 E. Coli-derived <1.0 R&D Systems, Abindgdon, UK
Lipopolysaccharide (LPS) n/a 10 Salmonella Minnesota n/a Enzo Life Sciences, Exeter, UK
Prostaglandin Ez (PGE2) n/a 1000 Rabbit n/a Enzo Life Sciences, Exeter, UK
Dexamethasone (water soluble) n/a 0-10 n/a n/a Sigma, Poole, UK
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3. THE ROLE OF MONOCYTES IN PRRSV
3.1. Rationale and aims
It is well-known that PRRSV has cell tropism for porcine myeloid cells, and 
the primary cell target for PRRSV replication is the pulmonary alveolar macrophage 
(PAM) (Haynes et ah, 1997). Whilst a cell line is available for the propagation of 
PRRSV type 2 (PRRSV-2) (green African monkey kidney cell line [MARC-145]), 
there is currently no cell line capable of growing PRRSV type 1 (PRRSV-1). 
Therefore, it is routinely propagated using freshly isolated PAMs, which are less 
than ideal given that they are not always equal in their susceptibility to PRRSV 
infection and are limited in their availability.
In contrast to macrophages, little is known about how monocytes interact 
with PRRSV, and it has been previously reported that monocytes are refractory to 
PRRSV infection in vitro (Duan et ah, 1997a). Since monocytes are a transient 
heterogenous population, displaying a variety of functions over intermediate stages 
of differentiation, it is likely that the susceptibility of monocytes to viral infection 
also varies over time and changes under different cell conditions. The heterogeneity 
of monocytes, however, means that they are poorly understood.
The first aim of this chapter, therefore, was to investigate the physiology of 
porcine monocytes. Their responses to known growth factors such as macrophage- 
colony stimulating factor (M-CSF) and granulocyte-macrophage colony stimulating 
factor (GM-CSF) were of interest, given these factors might increase cell viability 
and proliferation. Following treatment of monocytes with growth factors, monocytes
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were infected with PRRSV-1 to investigate the hypothesis that changes in monocyte 
viability and proliferation would result in increased susceptibility to PRRSV.
The next focus of this chapter involved further assessing the interaction of 
PRRSV with monocytes, following the recent identification of CD 163 and CD 169 as 
putative key receptors involved in PRRSV entry (Van Breedam et al., 2010a). The 
first approach was to try to modulate CD 163 and CD 169 expression on monocytes in 
vitro, using a variety of pro and anti-inflammatory cytokines and other activating 
factors. Secondly, following treatment with such cytokines and activating factors, 
monocytes were infected with PRRSV in order to investigate the hypothesis that up- 
regulation of CD 163 and CD 169 on monocytes correlates with enhanced monocyte 
susceptibility to PRRSV.
In summary, this chapter characterises porcine monocyte physiology in 
response to various cytokines and factors, and assesses the potential role of 
monocytes as a more reliable method of propagating PRRSV in vitro.
3.2. The susceptibility of PAMs to PRRSV
Observations from routine PRRSV culture at the AHVLA had demonstrated 
that some batches of PAMs were better than others at propagating PRRSV. The first 
approach was therefore to evaluate the reliability of using PAMs as a reference for 
PRRSV replication. The variability of PAMs was analysed using PAMs from 3 
different pigs to measure PRRSV replication over 5 days, using a PRRSV TaqMan 
qPCR as described in Chapter 2 section 2.4.3. For this experiment, qPCR was used
66
to measure virus replication by calculating the difference in Ct (ACt), representing 
the amount of viral RNA detected in cell culture supernatant.
Data showed variable levels of replication at different time points using three 
batches of PAMs from three different animals (Figure. 3.1). PAMs from one animal 
showed equal levels of PRRSV replication over 5 days (Figure 3.1 A), PAMs from 
another showed increasing PRRSV replication over 5 days (Figure 3.1 B), whilst 
PAMs from a third animal showed decreasing PRRSV replication over 5 days of in 
vitro culture (Figure 3.1 C).
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Figure 3.1. The variability o f PRRSV replication in PAMs. PAMs were isolated by 
bronchoalveolar lavage (BAL) collection from pigs post mortem and infected with PRRSV- 
1 strain Lena (m.o.i = 0.1) either immediately after isolation (day 0), or following 2 or 5 
days o f culture in full tissue culture medium. At 48 hours post-infection (p.i), viral RNA 
was extracted from PAM supernatant and quantified by qPCR. ACt, representing PRRSV 
replication, was measured by calculating the difference between the Ct value o f cell 
supernatant 2 hours p.i and the Ct value o f RNA in cell supernatant 48 hours p.i. Bars show 
the mean ACt +SD of 3 replicate experiments using PAMs from different animals, A, B, and 
C represent each individual animal.
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3.3. Modulating Monocyte Biology with M-CSF
Having confirmed that PAMs were variable in their susceptibility to PRRSV 
infection, subsequent studies focussed on porcine monocytes and how they could be 
driven to a state susceptible to PRRSV. Firstly the effects of macrophage-colony 
stimulating factor (M-CSF) and granulocyte-macrophage colony stimulating factor 
(GM-CSF) were assessed on monocytes. As both factors are known to modulate the 
survival and differentiation of mononuclear phagocytes (Pixley and Stanley, 2004), 
the hypothesis was that through using these factors to modulate monocyte 
physiology, enhance viability and drive macrophage differentiation, their 
susceptibility to PRRSV would also increase. Monocytes were assessed alongside 
PAMs in their morphology, cell viability, and subsequent to initial observations by 
light microscopy, their ability to proliferate in response to M-CSF or GM-CSF.
3.3.1. The effects of M-CSF on morphologies of monocytes and PAMs
Freshly isolated monocytes or PAMs were cultured for 7 days either in media 
alone or supplemented with various concentrations of M-CSF or GM-CSF. Light 
microscopy showed that M-CSF altered normal monocyte morphology towards a 
macrophage-like structure. In detail, monocytes treated with 50 ng/ml of M-CSF 
appeared to be more adherent, and many of the cells had clustered (Figure 3.2 B). 
Furthermore, some monocytes showed cellular elongations when treated with 50 
ng/ml of M-CSF. Increasing M-CSF concentration to 100 ng/ml appeared to induce 
more densely formed cell clusters and suggested an increase in cell number (Figure
3.2 C). With regard to PAMs, little effect of M-CSF on morphology was observed 
when treated with 50 ng/ml of M-CSF (Figure 3.2 E), although 100 ng/ml of M-CSF
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did adjust PAM morphology, with the appearance of larger cell clusters and some 
PAMs expressing long projections from their surface (Figure 3.2 F).
GM-CSF treatment of monocytes also resulted in the appearance of small cell 
clusters, but showed no difference in cell size or density, and images suggested there 
were fewer cells in GM-CSF treated monocytes than in untreated and M-CSF treated 
cultures (Figure 3.2 G). In contrast, PAMs treated with GM-CSF formed large cell 
clusters which had joined together to suggest a polyploid-like cell structure (Figure
3.2 H).
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Figure 3.2. The effect of M-CSF on the morphology of monocytes and PAMs. PAMs 
and monocytes were cultured in medium alone or supplemented with 10 ng/ml GM-CSF, 50 
ng/ml or 100 ng/ml o f M-CSF for 5 days. Representative light microscope images show 
morphology o f monocytes (A, B, C) and PAMs (D, E, F) in medium only (A, D), with 50 
ng/ml M-CSF (B, E) 100 ng/ml M-CSF (C, F), or 10 ng/ml GM-CSF (G, H). Magnification 
is 20X.
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3.3.2. M-CSF effect on monocyte viability
In order to investigate the effects of M-CSF on monocyte viability further, 
the percentage of live monocytes was determined by flow cytometry. After 7 days 
of culture in medium alone or medium supplemented with M-CSF or GM-CSF, 
monocytes and PAMs were stained with ViaProbe, a nucleic acid dye which 
excludes dead cells by staining only those with disrupted membranes, and analysed 
by flow cytometry as described in section 2.6.2.
Flow cytometry analysis showed that while GM-CSF treatment reduced the 
viability of monocytes and PAMs, M-CSF treatment increased viability (Figure 3.3 
A, B). The viability of monocytes without M-CSF treatment was already very high 
(95.3%), and increased with increasing M-CSF concentration, reaching almost 100% 
viability with 200 ng/ml of M-CSF. The differences in viability induced by M-CSF, 
however, did not reach statistical significance, due to the high percentage of viability 
in the untreated monocytes (Figure. 3.3 B). Viability of M-CSF treated monocytes 
however was always significantly higher than GM-CSF treated monocytes (pO.Ol 
with 200 ng/ml M-CSF) (Figure 3.3 A, B).
In untreated cultures, the viability of monocytes was significantly higher than 
PAMs (pO.001), but with high concentrations of M-CSF treatment (>60 ng/ml) 
there were no significant differences between the viability of PAMs and monocytes 
(Figure 3.3 B). PAMs treated with 60 ng/ml M-CSF were also significantly more 
viable than when treated with GM-CSF (pO.Ol), which had the lowest viability of 
all cultures and significantly lower than GM-CSF treated monocytes (p <0.001). 
Treatment with 200 ng/ml of M-CSF caused a significant increase in viability from
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untreated PAMs (p<0.5) and a highly significant increase in viability from GM-CSF 
treated PAMs (pO.OOl) (Figure 3.3 A, B).
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Figure 3.3. The effect of M-CSF on viability o f PAMs. Monocytes (heavy blue) and 
PAMs (heavy red) were cultured for 7 days in medium alone or supplemented with 10 
ng/ml GM-CSF (A), or with 20, 60 or 200 ng/ml o f M-CSF (B) for 5 days. Cells were 
stained with Via-Probe (7AAD nucleic acid dye) and analysed by flow cytometry to 
determine percentage o f viable cells. Dots show mean percentage viability in 3 replicate 
experiments ±SD. One-way ANOVA was used to assess significance between treatments 
and Two-way ANOVA to assess significance between PAMs and monocytes, both followed 
by Bonferroni’s multiple comparison tests, ***p<0.001, **p<0.01, *p<0.05.
3.3.3. Thymidine incorporation by M-CSF treated monocytes
To determine whether M-CSF treatment resulted in any proliferation of 
monocytes or PAMs, thymidine incorporation assays were employed, as described in
2.5.1. M-CSF treatment increased the incorporation of thymidine, representative of 
proliferation, in both monocytes and PAMs in a dose dependent manner (Figure 3.4). 
Whilst only 12.5 ng/ml of M-CSF was needed to induce a significant increase in 
proliferation of monocytes (pO .O l), PAMs did not proliferate significantly until 
treated with 100 ng/ml M-CSF (pO.OOl). The effect of M-CSF on PAMs was
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always significantly lower than that observed on monocytes, indicating that 
monocytes were more receptive to the effect o f M-CSF than PAMs were (monocytes 
proliferated at a 4X greater rate than PAMs with 200 ng/ml M-CSF treatment 
(pO.OOl). Without M-CSF treatment, neither monocytes nor PAMs proliferated 
(Figure 3.4).
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Figure 3.4. M-CSF induced proliferation in monocytes. Monocytes (heavy blue) and 
PAMs (heavy red) were cultured in medium alone or medium supplemented with serial 
dilutions o f M-CSF ranging from 3.10-200 ng/ml for 3 days before a thymidine 
incorporation assay was used to measure cell proliferation. Dots represent means o f  3 
replicates ±SD. One-way ANOVA was used to compare significance between M-CSF 
concentration, or two-way ANOVA was used to assess significance between monocytes and 
PAMS, both followed by Bonferroni’s multiple comparison test, ***p<0.001, **p<0.01.
3.3.4. EdU incorporation by M-CSF treated monocytes
Having confirmed that M-CSF induced monocyte proliferation, the next aim 
was to measure this more quantitatively using an alternative method. Monocytes 
were assessed in response to M-CSF using a 5-ethynyl-2-deoxyuridine (EdU)
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incorporation kit, which is analysed using flow cytometry, as described in 2.5.2. 
EdU is incorporated into DNA during active synthesis and can then be detected 
using a click reaction, which is a copper (I) catalyzed reaction between an azide and 
an alkyne. The EdU contains the alkyne which can be reacted with an azide- 
containing detection reagent to form a stable, triazole ring. For this assay, an azide- 
modified dye, allophycoerythin (APC*) was used for detection of DNA synthesis by 
flow cytometry.
Freshly isolated monocytes were isolated and cultured as before, with or 
without 200 ng/ml M-CSF, with the addition of 5 pM EdU to all cells. Monocyte 
proliferation was measured over 5 days of culture. No differences were observed 
between incorporation of EdU in untreated and treated monocytes after day one of 
culture, although differences were observed between days 3 and 5 of culture (Figure 
3.5 and Figure 3.6). M-CSF treated monocytes showed increased percentage of cells 
with detectable APC* (Figure 3.7) in comparison to untreated monocytes. On day 3, 
the mean percentage of M-CSF treated monocytes expressing APC* was 3.43%, 
significantly higher than untreated monocytes which had 0.72% (p<0.5) (Figure 3.6).
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Figure 3.5. EdU Staining for flow cytometric quantification of M-CSF induced proliferation o f  monocytes. Freshly isolated porcine monocytes were 
treated with 5 pM  5-ethynyl-2-deoxyuridine (EdU) and cultured in medium alone or medium supplemented with 200 ng/ml recombinant human M -CSF for 5 
days. Cells were harvested on days 1, 3, 4 and 5 and stained with the Click-It® reaction cocktail before flow cytometric analysis. M onocytes were gated on 
FSC and SSC (A) and dead cells eliminated using a LIVE/DEAD PE stain (B). Unstained M-CSF treated monocytes were also analysed at the same time- 
points to assess for auto-fluorescence (C). Live monocytes are shown in subsequent plots, where APC* fluorescence represents EdU incorporation, shown 
within pink boxes in cells without M-CSF (D-G) and cells with M-CSF (H-K), measured on day 1 (D,H), day 3 (E,I), day 4 (F,J) and day 5 (G ,K) Data are 
representative o f 3 replicate experiment.
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Figure 3.6. M-CSF treatment induces proliferation of monocytes. Freshly isolated 
porcine monocytes were treated with 5 pM EdU and cultured with medium alone (black  
bars) or medium supplemented with 200 ng/ml recombinant human M-CSF (grey bars). 
Cells were harvested on days 3, 4 and 5 o f culture and stained with the Click-It® reaction 
cocktail before flow cytometric analysis o f APC* fluorescence, where bars represent mean 
percentage o f cells fluorescing APC* +SD in 4 replicate experiments. Paired t-tests were 
used to assess significance between untreated and M-CSF treated monocytes, *p<0.05.
In addition to measuring the percentage of cells expressing APC*, the total 
numbers of monocytes in untreated and M-CSF treated cultures were also taken from 
the flow cytometric analysis in order to support the theory that these cells were 
proliferating. On day 4 of culture, M-CSF treated monocytes had a mean cell count 
of 3.4x104, which was significantly higher than untreated monocytes which had a 
mean cell count of 2.6x104 (p<0.5) (Figure 3.7).
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Figure 3.7. Effect of M-CSF treatment on monocyte counts. Freshly isolated porcine 
monocytes were treated with 5 pM EdU and cultured with medium alone (black bars) or 
medium supplemented with 200 ng/ml recombinant human M-CSF (grey bars). Cells were 
harvested on days 3, 4 and 5 o f culture and flow cytometry used to count total number o f 
cells within the FSC/SSC monocyte gate. Bars represent mean counts o f cells +SD in 4 
replicate experiments. Paired t-tests were used to compare untreated and M-CSF treated 
monocytes in 4 replicate experiments, *p<0.05.
3.4. The effect of M-CSF on PRRSV replication by monocytes and PAMs
Confirmation of the positive effects of M-CSF on monocyte viability and 
proliferation led to the hypothesis that M-CSF might also enhance monocyte 
susceptibility to PRRSV infection. Two different strains of PRRSV-1 were used to 
infect untreated or M-CSF treated monocytes and PAMs. These included a field 
strain, Lena, and the strain used in the Porcilis Vaccine, DV, which is adapted to 
grow on a green African monkey kidney cell line (MARC-145). Monocytes and 
PAMs were infected at various time points for 48 hours and the production o f viral 
proteins in monocytes and PAMs, representing virus infection, was assessed by 
intracellular staining with anti-PRRSV monoclonal antibody (mAb) SDOW-17, 
detected by flow cytometry as described in section 2.6.5. The production of virus
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was measured by qPCR analysis of viral RNA extracted from cell supernatant, as 
described in section 2.4.3.
3.4.1. Flow cytometric analysis of PRRSV in M-CSF treated monocytes and
PRRSV
Monocytes and PAMs were infected either immediately following cell 
isolation (with or without addition of M-CSF), or following 2 or 5 days of culture 
with M-CSF or medium alone. At 48 hours post-infection (p.i), cells were harvested 
and analysed for the presence of PRRSV protein using flow cytometry analysis, 
gated as before.
There were no differences observed between the infection of PRRSV Lena 
infection in untreated and M-CSF treated monocytes or PAMs (Figure 3.8 F, L and 
Figure 3.9 F, L). However, when infected with the vaccine strain, DV, monocytes 
and PAMs treated with M-CSF both showed significantly increased expression of 
PRRSV viral protein compared to untreated monocytes and PAMs (p<0.05) (Figure 
3.10 F, L and Figure 3.11 F, L). These data are summarised in Figure 3.12.
78
A B
y  \ -
?
SO 500 750 1000
: 52T c
..5
D
Ï
0 550 SCO 750 1
-
QW** J
ü Ü ^
, m m ' ,
'*°
S
K
FSC SSC LIVE DEAD Violet Cnstained G I APC 2° Ig G l Isotype G1APC SDOW-17 G1APC
Figure 3.8. M-CSF effect on PRRSV Lena infection o f monocytes. M onocytes were cultured in medium alone (A-F) or supplemented with 50 ng/ml M- 
CSF (G-L) for 2 days before infection with PRRSV Lena isolate. At 48 hours post infection (p.i) cells were harvested and stained intracellularly with anti- 
PRRSV mAh SDOW -17 and secondary mAh G l-A PC* for detection o f PRRSV by flow cytometry. M onocytes were gated on according to FSC/SSC (A, 
G), and dead cells eliminated using LIVE/DEAD Violet stain (B ,H ) For controls, monocytes were unstained (C,I), stained with secondary antibody G l-  
APC* alone (D,J), stained with anti-mouse IgG l isotype control and secondary G l-A PC * (E,K), or stained with SDOW-17 and secondary G l-A PC * (F,L). 
Data are representative o f  three replicate experiments.
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Figure 3.9. M -CSF effect on PRRSV Lena infection o f PAMs. PAMs were cultured in medium alone (A-F) or supplemented with 50 ng/ml M -CSF (G- 
L) for 2 days before infection with PRRSV Lena isolate. At 48 hours post infection (p.i) cells were harvested and stained intracellularly with anti-PRRSV 
mAb SDOW-17 and secondary mAb G l-A PC * for detection o f PRRSV by flow cytometry. PAMs were gated on according to FSC/SSC (A ,G ) and dead 
cells eliminated using LIVE/DEAD Violet stain (B,H). For controls, PAMs were unstained (C,I), stained with secondary antibody G l-A PC * alone (D,J), 
stained with anti-mouse IgGl isotype control and secondary G l-A PC * (E,K), or stained with SDOW-7 and secondary G l-A PC * (F,L). Data are 
representative o f three replicate experiments.
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Figure 3.10. M -CSF effect on PRRSV DV infection o f monocytes. Monocytes were cultured in medium alone (A-F) or supplemented with 50 ng/ml M- 
CSF (G-L) for 2 days before infection with PRRSV DV isolate. At 48 hours post infection (p.i) cells were harvested and stained intracellularly with anti- 
PRRSV mAb SDOW-17 and secondary mAb G l-A PC* for detection o f PRRSV by flow cytometry. Monocytes were gated on according to FSC/SSC (A, 
G) and dead cells eliminated using LIVE/DEAD Violet stain (B,H). For controls, monocytes were unstained (C,I), stained with secondary antibody G l-  
APC* alone (D,J), stained with anti-mouse IgGl isotype control and secondary G l-A PC * (E,K), or stained with SDOW -7 and secondary G l-A PC * (F,L) 
Data are representative o f three replicate experiments.
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Figure 3.11. M -CSF effect on PRRSV DV infection o f PAMs. PAMs were cultured in medium alone (A-F) or supplemented with 50 ng/ml M -CSF (G-L) 
for 2 days before infection with PRRSV DV isolate. At 48 hours post infection (p.i) cells were harvested and stained intracellularly with anti-PRRSV mAb 
SDOW-17 and secondary mAb G l-A PC* for detection o f PRRSV by flow cytometry. PAMs were gated on according to FSC/SSC (A ,G ) and dead cells 
eliminated using LIVE/DEAD Violet stain (B,H). For controls, PAMs were unstained (C,I), stained with secondary antibody G l-A PC * alone (D,J), stained 
with anti-mouse IgGl isotype control and secondary G l-A PC * (E,K), or stained with SDOW -17 and secondary G l-A PC * (F,L). Data are representative o f 
three replicate experiments.
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Figure 3.12. The effect o f M-CSF treatment on PRRSV Lena/DV infection of 
monocytes. Monocytes were cultured in media alone (unfilled bars) or treated with 50 
ng/ml M-CSF (filled bars) for 2 days before infection with PRRSV Lena or DV isolates. At 
48 hours post infection (p.i), cells were harvested and stained intracellularly with anti- 
PRRSV mAb SDOW-17 and secondary mAb Gl-APC* for detection o f PRRSV by flow 
cytometry. Bars represent mean percentage o f cells infected with PRRSV Lena (A) or 
PRRSV DV (B) +SD o f 3 replicate experiments. Two-way ANOVA was used to assess 
significance followed by Bonferroni’s multiple comparison test, *p<0.05.
3.4.2. PRRSV infection in M-CSF treated monocytes and PAMs using RT 
qPCR
Untreated and M-CSF treated monocytes and PAMs were infected with 
PRRSV Lena or PRRSV DV, as described in section 2.4. RT qPCR was used to 
measure Ct values of PRRSV RNA in the cell supernatants, both at time zero (2 
hours p.i at 4°C) and at 48 hours p.i, in order to obtain a ACt value which was 
representative of PRRSV replication.
No significant differences were observed between the ACt of untreated and 
M-CSF treated monocytes infected with Lena, at day 0 or at day 2 o f in vitro culture 
(Figure 3.13 A, B). However, M-CSF treatment for 5 days prior to infection enabled 
monocytes to maintain significantly higher levels of virus replication (pO.Ol), 
whereas untreated monocytes had decreased their virus replication by this time-point
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of infection (Figure 3.13 A). Interestingly, levels of ACt of monocytes infected at 
day 2 (with and without M-CSF) and day 5 (with M-CSF treatment) were 
comparable to ACt levels of PAMs. PAMs infected with Lena showed no change in 
replication over 5 days, and no differences were observed between PRRSV 
replication in untreated and M-CSF treated PAMs (Figure 3.13 B).
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Figure 3.13. M-CSF effect on viral replication of DV in monocytes and PAMs.
Monocytes and PAMs were infected with Lena (A,B) or DV isolates (C,D) when freshly 
isolated (day 0), or following 2 or 5 days o f culture, with 50 pg/ml M-CSF (filled bars) or 
without (unfilled bars). At 48 hours p.i viral RNA was extracted from cell supernatant and 
assessed for virus replication using qPCR. ACt represents difference between Ct values 
from supernatant harvested 2 hours p.i and 48 hours PI. Data shows mean ACt +SD in 4 
replicate experiments. Two-way ANOVA was used to assess significance followed by 
Bonferroni’s multiple comparison test, ** p < 0.01.
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Consistent with the flow cytometry analysis of viral protein expression, viral 
replication of PRRSV DV strain was significantly enhanced with M-CSF treatment 
of monocytes for 2 days (pO.Ol) (Figure 3.13 C). DV replication in PAMs was 
similar to that in monocytes, with similar ACt levels and the same effect of M-CSF 
significantly increasing replication was also observed on day 2 infection of PAMs 
with PRRSV DV (p<0.01) (Figure 3.13 D). M-CSF had no significant effect on DV 
strain replication at day 0 or day 5 infection, neither in monocytes or PAMs, where 
ACt levels were lower (Figure 3.13 C).
3.4.3. PRRSV DV strain propagation on M-CSF treated of monocytes
Previous work in the AHVLA laboratory showed that PAMs had low 
susceptibility to PRRSV DV strain, which was only successfully propagated on the 
MARC-145 cell line. However, since M-CSF had a significant effect on PRRSV 
DV replication on monocytes, it was investigated whether monocytes treated with 
M-CSF could be used to propagate the PRRSV DV strain. DV strain was added to 
freshly isolated monocytes treated with 50 ng/ml M-CSF using an m.o.i of 0.1 for 2 
days, after which cell culture supernatant was then passaged onto a 10X greater 
volume of 2 day old M-CSF treated monocytes. After a further 2 days, cell 
supernatant was harvested and added to PAMs for 3 days, followed by detection of 
PRRSV using SDOW-17 and immunoperoxidase (IPX) staining as described in 
section 2.4.1. Despite previously showing resistance to infection with DV strain, 
PAMs could be infected with DV strain that had been propagated on monocytes 
treated with M-CSF (Figure 3.14).
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Figure 3.14. MARC-145 adapted DV PRRSV strain infection of PAMs. PRRSV DV 
isolate was used to inoculate monocytes treated with M-CSF for 48 hours. Monocyte 
supernatant was then passaged onto a 10X greater volume o f M-CSF treated monocytes and 
cultured for a further 48 hours. Monocyte supernatant was harvested as virus stock and 
added to PAMs for 3 days before immunoperoxidase staining using SDOW-17 mAh. The 
left hand side panel shows mock infected PAMs and the right hand panel shows PAMs 
infected with DV PRRSV strain grown on monocytes.
3.5. Analysis of CD163 and CD169 Expression on Monocytes
Having shown that porcine monocytes could be infected in vitro with 
PRRSV, and in the case of Lena, independently of M-CSF treatment, the next aim 
was to examine whether other factors could increase monocyte susceptibility to 
PRRSV. Since CD 163 and CD 169 have been identified as putative PRRSV 
receptors, studies focussed on identifying factors, or cytokines, which could 
modulate these molecules. Investigations assessed whether the expression o f these 
molecules on monocytes directly correlated with their susceptibility to PRRSV 
through enhanced viral replication.
3.5.1. Porcine monocyte expression of CD163 and CD169
Before addressing how the modulation of PRRSV receptors could be 
targeted, it was necessary to determine the distribution of CD 163 and CD 169
expression on monocytes, and to identify at what time-point of culture the receptors 
were expressed. In order to do this, CD 163 and CD 169 expression was measured on 
monocytes and PAMs over 5 days of culture using flow cytometry analysis. Surface 
and intracellular staining was carried out on the same cells, using anti-CD 163 or 
anti-CD 169 mAbs that were each conjugated with two different fluorescent labels in 
order to distinguish surface and intracellular expression of the receptors.
The percentage of porcine monocytes expressing both CD 163 and CD 169 on 
the surface was higher on than the percentage of cells expressing both molecules 
intracellularly. The highest percentage of monocytes expressing CD 163 was 
48.58%, measured extracellularly after 1 day of culture. This was significantly 
higher than percentages of cells expressing CD 163 on day 2 (23.54%) and day 5 
(19.8%) (mean values) (p<0.001). Surface expression of CD 163 on monocytes was 
detected on significantly more cells than intracellular expression was at days 1 and 
day 2 of culture, (p<0.001), but on day 5 of culture, there was no difference between 
surface and intracellular expression of CD 163 (Figure 3.15 A).
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Figure 3.15. Porcine monocyte expression of CD163 and CD169. Monocytes were 
cultured for either 1, 2, or 5 days and stained for flow cytometric analysis of PRRSV 
receptors. Anti-porcine mAbs were used for detecting the percentage of cells expressing 
CD 163 (A) and CD 169 (B) both on their cell surface (unfilled bars) and intracellularly 
(filled bars). Data shows mean of 4 replicate experiments +SD. Two-way ANOVA was 
used to assess significance between extracellular and intracellular expression and one-way 
ANOVA was used to assess significance between days, both followed by Bonferroni’s 
multiple comparison test, ***p<0.001.
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CD 169 was expressed on generally fewer monocytes than CD 163, as <30% 
of monocytes expressed CD 169 at all time-points. The highest percentage of cells 
expressing CD 169 was 28.96%, measured extracellularly after 2 days of culture, 
significantly higher than cells expressing CD 169 on days 1 (15.59%) and 5 
(21.48%) (mean values) (pO.OOl). Like CD 163, extracellular expression of CD 169 
was found to be expressed on significantly more cells than intracellular expression, 
which was significant at all time-points of culture (pO.OOl) (Figure 3.15 B). 
Extracellular CD 163 and CD 169 expression on monocytes was, however, detected 
on a much lower percentage of cells in comparison to the expression of these 
markers on PAMs (data not shown).
3.5.2. Cytokine modulation of CD163 and CD169 expression
Having confirmed extracellular expression of CD 163 and CD 169 on 
monocytes, the next aim was to assess if these molecules could be modulated, using 
M-CSF and a selection of other cytokines, some of which were known to be 
monocyte activating. Monocytes were cultured with cytokines for two days, and 
stained with anti-CD 163 and CD 169 mAbs for flow cytometric analysis of their 
surface expression.
As shown in Figure 3.16 and Figure 3.17, monocyte expression of CD 163 
was significantly increased by treatment with individual cytokines M-CSF, IL-10 
and IL-ip for 2 days (p<0.0001 in all cases). IL-10 treated monocytes showed the 
highest percentage of CD 163 positive cells (mean 94.96%) and the highest mean 
fluorescence intensity (MFI), 62.30 (Figure 3.16 K and Figure 3.17). IL-4 treatment 
appeared to have a negative effect on the percentage of cells expressing CD 163,
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however this was not a significant difference. Other cytokines, namely IFN-a, IL-6 
and GM-CSF, had no significant effect on CD 163 expression (Figure 3.17).
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Figure 3.16. Monocyte CD163 expression up-regulation by M-CSF, IL l-p  and IL-10 and down-regulation by IL-4. Freshly isolated monocytes were 
cultured for 2 days in medium alone, or supplemented with human M-CSF, porcine IL-4, equine IL -ip  or porcine IL-10, before flow cytometric analysis o f  
CD 163 expression using a mouse anti-porcine CD 163 FITC conjugated mAh. M onocytes were gated according to FSC and SSC (A ,) and dead cells were 
eliminated according to a LIVE/DEAD Violet stain (B). For negative controls, unstained monocytes were analysed (C), and an anti-mouse IgGl FITC 
isotype control was used (D), which remained unchanged between all cytokine treatments. Because monocytes were stained in parallel for CD 169 PE 
expression, single FITC stains are shown before compensation (E ) and after compensation which was applied to subsequent samples (F). Live monocytes 
positively expressing CD 163 are shown within pink squares, with the percentage o f  cells expressing CD 163 shown in pink text and mean fluorescence 
intensity (M FI) shown in red text, in monocytes untreated (G), or supplemented with M -CSF (H), IL-4 (I), IL -ip  (J) or IL-10 (K). Data are representative o f  
3 replicate experiments.
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Figure 3.17. Up-regulation of CD163 expression by monocytes treated with M-CSF, 
IL-10 and IL-lp. Monocytes were cultured for 2 days in medium alone (unstimulated) or 
supplemented with a selection of human (hu), porcine (po) or equine (eq) cytokines. 
Monocytes were surface stained with anti-porcine CD 163 mAh and analysed by flow 
cytometry to determine percentage of cells expressing these markers. Bars represent mean 
percentage of cells expressing CD 163 +SD in three replicate experiments. One-way 
ANOVA was used to assess significance followed by Bonferroni’s multiple comparison test
****p< 0.0001.
The percentage of monocytes expressing CD 169 was also increased 
significantly with M-CSF treatment (pO.Ol). A highly significant effect on CD 169 
expression was also observed with IFN-a (pO.OOOl) and IFN-y treatment 
(pO.OOOl), with IFN-a stimulated monocytes showing the highest percentage of 
CD 169 positive cells (83.81%) and the highest MFI of 40.65 (mean values) (Figure 
3.18 K and Figure 3.19). No significant effects of IL-10, IL-4, IL-lp, IL-6 or GM- 
CSF treatment on expression of CD 169 were observed (Figure 3.19).
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Figure 3.18. Up-regulation o f CD169 expression on porcine monocytes by by IFN-a. Freshly isolated monocytes were cultured for 2 days in medium 
alone, or supplemented with human M-CSF, porcine IL-4, equine IL -ip  or porcine IFN-a, before flow cytometric analysis o f CD169 expression using a 
mouse anti-porcine CD169 mAh conjugated with an Alexa Fluor PE. Monocytes were gated according to FSC and SSC (A ) and dead cells were eliminated 
according to a LIVE/DEAD Violet stain (B). For negative controls, unstained monocytes were analysed (C), and an anti-mouse IgGl PE isotype control was 
used (D), which remained unchanged between all cytokine treatments. Because monocytes were stained in parallel for CD163 FITC expression, single FITC 
stains are shown before compensation (E) and after compensation which was applied to subsequent samples (F). Live monocytes positively expressing 
CD 169 are shown within pink squares, with the percentage o f cells expressing CD169 shown in pink text and mean fluorescence intensity (M FI) shown in red 
text, in monocytes untreated (G), or supplemented with M-CSF (H), IL-4 (I), IL -lp  (J) or IFN-a (K). Data are representative o f  3 replicate experiments.
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Figure 3.19. Up-regulation of CD169 expression by monocytes treated with M-CSF, 
IFN-a, and IFN-y. Monocytes were cultured for 2 days in medium alone (unstimulated) or 
supplemented with a selection of human (hu), porcine (po) or equine (eq) cytokines. 
Monocytes were surface stained with anti-porcine CD 169 mAh and analysed by flow 
cytometry to determine percentage of cells expressing these markers. Bars represent mean 
percentage of cells expressing CD 169 +SD in three replicate experiments One-way ANOVA 
was used to assess significance followed by Bonferroni’s multiple comparison test ****p <
0.0001, **p<0.01.
3.5.3. The effect of dexamethasone on monocyte CD163 and CD169 expression
Further to investigating the effects of cytokines on monocytes, the effect of 
dexamethasone, a glucocorticosteroid known to increase CD 163 expression on 
human monocytes, and with a known role in virus reactivation, was also assessed. 
Monocytes were treated with 40 ng/ml of dexamethasone for two days, which 
resulted in a significant 3-fold increase in monocyte numbers expressing CD163, 
causing 89.07% of monocytes to be positive for CD 163 expression compared to 
untreated monocytes (16.16%) (pO.OOOl) (mean values). Dexamethasone had a 
highly significant effect on monocyte CD 169 expression also, increasing the amount 
of CD 169 positive monocytes to 72.42% from 15.70% (pO.OOOl) (mean values) 
(Figure 3.20 and Figure 3.21).
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Figure 3.20. The effects o f dexamethasone on CD163 and CD169 expression by porcine monocytes. Freshly isolated monocytes were cultured for 2 
days in medium alone (unstimulated), or supplemented with 40 ng/ml dexamethasone before analysis o f  surface CD163 and CD 169 expression. M onocytes 
were gated according to FSC and SSC (A) and dead cells were eliminated according to a LIVE/DEAD Violet stain (B). Unstained cells were analysed for 
FITC autofluorescence (C) and PE fluorescence (D). M onocytes were stained with mouse IgGl FITC isotype control (E) or IgGl PE isotype control (J) to 
assess for non-specific binding. Single colour CD 163 FITC and CD169 PE staining are shown before compensation (F, K) and after compensation (G, L). 
Anti-porcine CD163 FITC conjugated mAb was used to determine percentage o f cells expressing CD 163 cells in untreated (H ) or dexamethasone treated (I) 
monocytes. CD 169 PE conjugated mAb was used to determine CD 169+ cells in untreated (M ) and dexamethasone treated (N) monocytes. M onocytes 
expressing CD 163 or CD169 are shown within pink squares, with percentage expression o f total number shown in pink text and M FI shown in red text. Data 
representative o f 3 replicate experiments.
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Figure 3.21. The effect o f dexamethasone on the expression o f CD163 and CD169 by 
porcine monocytes. Freshly isolated monocytes were cultured for 2 days in medium alone 
(unstimulated), or supplemented with 40 ng/ml dexamethasone before flow cytometric 
analysis o f surface CD 163 and CD 169 expression. Bars represent the mean percentage o f  
cells expressing CD163(A) or CD169 (B) in 3 replicate experiments +SD. One-way 
ANOVA was used to assess significance followed by Bonferroni’s multiple comparison test, 
****p< 0.0001.
3.5.4. The effect of cytokines on PRRSV replication in monocytes
Having shown than CD 163 and CD 169 expression on monocytes could be 
significantly up-regulated by a variety of cytokines and dexamethasone, along with 
the proposal that these are the key receptors involved in PRRSV replication, 
monocytes were treated with the same factors again to investigate whether they 
could also enhance PRRSV replication. Monocytes were treated with cytokines or 
dexamethasone for 2 days before infection with PRRSV Lena isolate. At 16 hours 
post infection (p.i), viral RNA was extracted from monocytes and qPCR carried out 
to assess PRRSV replication.
Dexamethasone treatment of monocytes had the most considerable effect on 
PRRSV replication, showing an increase in mean AACt to 15.7, significantly higher
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than that of untreated monocytes, which had a mean AACt value o f 5.9 (pO.OOOl) 
(Figure 3.22). IL-10 treatment, which enhanced CD 163 but not CD 169 expression 
on monocytes, also significantly enhanced PRRSV Lena replication in monocytes, 
shown by a significant increase in AACt (pO .05) (Figure 3.22). Despite this 
significant effect of IL-10, the AACt of dexamethasone treated monocytes was still 
significantly higher than that o f IL-10 treated monocytes (pO.OOl). Conversely, a 
significant down-regulation of AACt was seen in monocytes treated with GM-CSF 
(pO .O l) and IL-6 (pO .05) compared with untreated monocytes (Figure 3.22). A 
down-regulation of AACt was also observed in IL-4 treated monocytes, although this 
was not a significant difference.
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Figure 3.22. The effect of dexamethasone and IL-10 treatment on PRRSV  
replication by monocytes. Monocytes were cultured for 2 days with various factors and 
infected with PRRSV-1 Lena (m.o.i = 0.1) for 16 hours. Viral RNA was extracted from 
monocytes and qPCR used to assess viral replication. AACt represents difference between 
Ct at 16 hours p.i and 2 hours p.i, represented by bars +SD in three replicate experiments. 
One-way ANOVA was used to assess significance followed by Bonferroni’s multiple 
comparison test, ****p<0.0001, **p<0.01, *p<0.05.
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3.5.5. The effects of low concentrations of dexamethasone
Since dexamethasone had the most significant effect on both CD 163 and 
CD 169 expression and on PRRSV replication in monocytes, further experiments 
were carried out to determine how much dexamethasone was required to up-regulate 
the percentage of monocytes expressing both CD 163 and CD 169. The concentration 
of dexamethasone added to monocyte cultures was reduced by serial 10-fold 
dilutions until no effect was observed. Dexamethasone had a highly significant 
effect on the percentage of cells expressing CD 163 at 10, 1 and 0.1 pg/ml 
(pO.OOOl) and still had a significant effect at 0.01 pg/ml (pO.OOl) (Figure 3.23 and 
Figure 3.24 A). Although the expression of CD 169 followed a similar trend as 
CD 163 in response to low concentrations of dexamethasone, this up-regulation was 
not a significant difference. In addition, the MFI of both CD 163 and CD 169 was 
also increased by dexamethasone treatment at low concentrations, however, these 
results were more variable between experiments and therefore no significant 
differences were observed (Figure 3.24 C, D).
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Figure 3.23. The effects o f low concentrations o f  dexamethasone on the expression o f CD163 and CD169 by porcine monocytes. M onocytes were 
cultured in media (E, K) or media supplemented with 10 (F, L), 1 (G, M), 0.1 (H, N), 0.01 (I, O) or 0.001 (J, P) pg/ml dexamethasone for 2 days before 
staining with anti-porcine CD 163 FITC and CD 169 PE conjugated mAb and expression analysed by flow cytometry. Monocytes were gated according to 
FSC and SSC (A) and dead cells were eliminated according to a LIVE/DEAD Violet stain (B). Live cells positively expressing CD163or CD 169 are shown 
within pink squares, with percentage expression o f  total number shown also. Monocytes were stained with IgG l FITC (C ) and IgG l PE (D) negative controls 
to assess non-specific binding. Data are representative o f 3 replicate experiments.
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F ig u re  3.24. S u m m a ry  d a ta  o f  th e  effec ts o f  low  c o n c e n tra tio n s  o f  d e x a m e th a so n e  on 
th e  ex p re ss io n  o f  C D 163  a n d  C D 169 by  p o rc in e  m o n o c y te s . Monocytes were cultured in 
media or media supplemented with 0.001 -  10 pg/ml of dexamethasone for 2 days before 
staining with anti-porcine CD 163 FITC (A , C ) and CD 169 PE (B , D ) and the expression of 
these molecules was analysed by flow cytometry. Dots represent percentage of cells 
fluorescing CD 163 (A ) and CD 169 (B), or the mean fluorescence intensity (MFI) of CD 163 
(C ) and CD 169 (D ) of 3-5 replicate experiments. Horizontal lines represent mean values 
±SEM. One-way ANOVA was used to assess significance followed by Bonferroni’s 
multiple comparison test, **** p < 0.0001, **p < 0.01.
As dexamethasone had significantly increased CD 163 and CD 169 expression 
on monocytes at low concentrations, it was then assessed whether similarly low 
doses of dexamethasone could significantly enhance PRRSV replication. Whilst the 
most significant effect of dexamethasone on PRRSV replication was seen at 10
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Hg/ml (pO.OOOl), a significant effect was also seen with as little as 0.1 pg/ml of 
dexamethasone (pO.Ol) (Figure 3.25).
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Figure 3.25. The effect o f low concentrations o f dexamethasone on PRRSV replication 
by monocytes. Fresh monocytes were cultured with medium alone or supplemented with 
various concentrations o f dexamethasone for 2 days before infection with PRRSV-1 Lena 
(m.o.i 0.1) for 16 hours. Viral RNA was extracted from monocytes and qPCR used to assess 
viral replication. AACt represents difference between Ct at 16 hours p.i and 2 hours p.i, 
shown by bars +SD in 3 replicate experiments. One-way ANOVA was used to assess 
significance followed by Bonferroni’s multiple comparison test, **** pO.OOOl, **pO.01.
To confirm a correlation between monocyte CD 163 and CD 169 expression 
and their susceptibility to PRRSV, monocytes were treated with dexamethasone for 
two days and infected with PRRSV Lena as before. At 16 hours p.i, a triple stain 
was carried out on mock and PRRSV infected monocytes to analyse expression of 
CD 163, CD 169 and SDOW-17 on the same cells. Flow cytometric analysis showed 
that cells which were gated as negative for both CD 163 and CD 169 had low levels of 
SDOW-17 positive monocytes (mean 26.18%), similar to the levels of SDOW-17 
positive cells in the CD163VCD169+ (mean 25.89%) (Figure 3.26 Q and S). Whilst
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a higher percentage of monocytes were SDOW-17 positive in CD163+/CD169", the 
highest percentage of SDOW-17 positive cells (mean 99.96%) along with the highest 
MFI (51.58) were seen in monocytes expressing both CD 163 and CD 169 (Figure 
3.26 P and T).
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Figure 3.26. M onocyte expression o f CD163 and CD169 correlation with PRRSV infection in dexamethasone treated cells. Freshly isolated monocytes 
were treated with dexa for 2 days before infection with PRRSV Lena (m.o.i 0.1) for 16 hours. Cells were harvested and stained for surface CD163 and 
CD169 and intracellularly stained for PRRSV infection using anti PRRSV mAh SDOW -17 and secondary G l-A PC. Monocytes were gated according 
FSC/SSC (A), and dead cells eliminated using a LIVE/DEAD Violet stain (B). Cells were stained with isotype controls; IgGl FITC (C), IgG l PE (G) and 
IgGl G l-A PC  (J) and single stains were carried out for CD 163 FITC (D-E) which was compensated against PE (F), and for CD 169 PE (H-I), and SDOW - 
17-G1APC (K-L). SDOW-17 APC expression is shown in mock infected monocytes (M ) and dexa treated monocytes (N), and the expression o f  CD163 
FITC and CD 169 PE was measured on the same cells (O). SDOW-17 APC expression is shown in the upper right quadrant population o f  O 
(CD 163 /CD 169 ) (P), the lower left quadrant (Q), upper left quadrant (R) and the lower right quadrant (S). The MFIs o f  CD 163 FITC (green text), CD169 
PE (red text) and SDOW-17 APC (orange text) are summarised for each quadrant according to the CD163 FITC/CD169 PE plot (T).
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3.6. Discussion
The focus of this chapter was to characterise porcine monocyte responses to 
various biologically active stimuli in vitro with respect to their susceptibility to 
PRRSV. Contrary to the previous reports that monocytes are resistant to PRRSV 
infection, these data strongly confirm that they can be infected in vitro. The 
significance of the expression of the putative PRRSV receptors CD 163 and CD 169 
by monocytes in PRRSV susceptibility has also been underlined.
3.6.1. M-CSF induced proliferation of monocytes and PAMs
Although recognised as the ‘gold standard’ for in vitro PRRSV-1 
propagation, the first finding of this study confirmed that PAMs were not always 
consistent in their susceptibility to PRRSV infection. PAMs are considered the 
predominantly and most consistently infected cell type in PRRSV infected pigs 
(Duan et al., 1997b), so it was surprising to see low levels of replication in some 
instances. This unreliability is not surprising, however, when the heterogeneity of 
macrophages is considered. As with other species, porcine macrophage populations 
exhibit a variety of changing phenotypes throughout different stages of their 
differentiation, and one characteristic noted to regularly change is susceptibility to 
viral infections (McCullough et al., 1999). The inconsistency of PAM susceptibility 
could also more simply be due to biological variation of the individual pigs with 
particular regard to their ages and genotypes. Although PAMs were obtained from 
individual pigs of the same breed (which were likely to be closely related), they were 
not genetically identical. The method of obtaining bronchoalveolar lavage (BAL) 
for isolation of PAMs is a well-established and routinely used method, but it does
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pose the risk of isolating other cells which also reside in the lung, such as epithelial 
cells and plasmacytoid dendritic cells (pDC). As widely accepted producers of IFNs 
(type I and type II) in response to viral infection (Colonna et al., 2004), pDCs in 
particular are likely to interfere with viral replication in the PAM population.
The observed heterogeneity of PAMs suggested that porcine monocytes 
might also be interesting to study, if it were possible to control the continuously 
changing population. Their existence as progenitor cells furthermore suggested that 
their susceptibility to PRRSV could be modulated in vitro. To this end, monocyte 
responses to treatment with the growth factors, M-CSF and GM-CSF were 
investigated. As expected, treated monocytes displayed altered cell morphology 
such as increased adhesion of cells, cell density, and the formation of cell clusters 
when incubated with M-CSF, which were all typical of a macrophage-like 
morphology. GM-CSF treatment, however, induced cell morphology similar to that 
seen during dendritic cell differentiation from monocytes using GM-CSF and IL-4, 
showing a dominant presence of cell clusters and cellular projections. This 
suggested that M-CSF would be more suitable than GM-CSF for the differentiation 
of macrophages from monocytes, despite some suggestion by others (Fleetwood et 
al., 2009).
Flow cytometry was used to assess the viability of monocytes, in order to
evaluate the effects of M-CSF or GM-CSF further. As monocytes are short lived
cells in vivo and survive in the periphery only for several days before macrophage
differentiation (Haynes et al., 1997), the effect of M-CSF must have played a
significant role in the surprisingly high viability observed after several days in
culture. Moreover, increasing M-CSF significantly increased the viability of
monocytes above that of PAMs, which is also in line with the understanding that in
106
vivo M-CSF is essential for monocyte survival (Brugger et al., 1991; Williams et al., 
1990), thought to be due to activation of NF-Kp phosphorylation (Wang et al., 2011). 
In contrast to M-CSF, GM-CSF reduced the viability of cultured monocytes. This 
was not expected, since it is well known that survival during monocyte derived 
dendritic cell (MoDC) differentiation is dependent on GM-CSF (Palucka et al., 1998; 
Sallusto and Lanzavecchia, 1994). The role of GM-CSF in cell survival is linked 
with mechanisms which inhibit apoptosis (Williams et al., 1990), but this effect is 
likely to be dose dependent, which may explain why no increase in viability was 
observed in this study as only one, rather than a range of concentrations, was 
assessed, which may have been too much or too little to observe an effect.
A central finding of this chapter was that M-CSF induced proliferation of 
monocytes and PAMs (although to a lower degree). This was confirmed firstly by 
significantly increased thymidine incorporation after 3 days of M-CSF treatment and 
secondly, using an EdU incorporation assay. The cell counts of M-CSF treated 
monocytes were also assessed to see whether the effect on proliferation was great 
enough to increase cell numbers. A significant increase in cell number was observed 
in M-CSF treated monocytes at day 4 rather than day 3. This may suggest that the 
rate of cell death is greater than the rate of cell proliferation at day 3, therefore 
masking any effect on cell number, although could also highlight the effect of M- 
CSF on increased monocyte viability over time.
Interestingly, the EdU incorporation assay showed that untreated monocytes
were also proliferating to some extent. There is some debate as to whether
monocytes are able to proliferate at all, whilst the proliferation of local macrophages
is well reported during inflammation rather than recruitment of leukocytes from the
blood in Th2 inflammation (Jenkins et al., 2011). The present study also observed
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some proliferation of macrophages, but it is not surprising that levels were much 
lower than monocytes given that they are considered a fully differentiated cell and 
therefore would not be expected to have the capacity to proliferate at all, especially 
in vitro.
Despite the original report that human peripheral monocytes are non­
proliferating (van Furth et al., 1979), others have identified a small subpopulation of 
human monocytes that can proliferate in vitro when stimulated with M-CSF 
(Erickson-Miller et al., 1990; Finnin et al., 1999). Highlighting the heterogeneity of 
monocytes, it was reported that 1 -5% of cells in a monocyte population are able to 
proliferate, and only do so following stimulation with high concentrations of 
cytokines (Gendelman et al., 1988). The data in the present study would suggest a 
larger proportion of cells are in fact proliferating. It is important to acknowledge 
however, that earlier studies on M-CSF would not have used recombinant M-CSF 
like in this study, but instead used M-CSF conditioned serum, which would contain 
various other factors as well as M-CSF, and thus these data may not be most reliable. 
There are two other reports of porcine monocyte proliferation in response to growth 
factors, but these both use M-CSF conditioned medium from murine L929 
fibroblasts rather than recombinant M-CSF and are not, therefore, fully comparable 
(Genovesi et al., 1989; Stanley and Heard, 1977). There are also likely to be 
endotoxins present in some batches of recombinant M-CSF, or danger associated 
molecular patterns in cell culture derived M-CSF, which may account for differences 
in their activities.
GM-CSF has also been shown to induce proliferation of murine and human
monocytes in vitro (Chen et al., 1988; Elliott et al., 1989; Finnin et al., 1999; Mock
et al., 2012); however the results of this study do not support this. It was reviewed
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by Barreda et al that the GM-CSF mediated increase in monocyte viability occurs at 
significantly lower concentrations than those required for cell proliferation (Barreda 
et ah, 2004). This may might explain the discrepancies seen with our results of GM- 
CSF effect on viability and proliferation, as the concentration may not have been 
sufficient to induce any changes in porcine monocytes for viability and hence neither 
for proliferation. In addition, porcine monocytes may also behave differently to 
human and mouse monocytes in response to GM-CSF treatment, which could be due 
to the reported differences in receptor structure and function (Elliott et ah, 1989). In 
human and mouse models, M-CSF and GM-CSF share many overlapping functions, 
however, there are also many significant differences in their effects because of the 
structural heterogeneity of their receptors (Hamilton, 2008).
The effects of enhanced proliferation along with enhanced viability induced 
by M-CSF are consistent with what is expected of M-CSF as observed in mouse and 
human models, but the effects on the proliferation of porcine monocytes exceeded 
such expectations. Since proliferation and viability are features that are likely to 
contribute to virus survival, this strengthened the hypothesis that M-CSF treatment 
would increase PRRSV replication in monocytes and PAMs in vitro.
3.6.2. M-CSF enhanced replication of PRRSV DV strain but not a field isolate
Despite previous claims that monocytes could not be infected with PRRSV in 
vitro, this study has shown not only that they can be infected at various time-points 
of culture, but also that they are capable of replicating PRRSV to a level comparable 
to that observed in PAMs. The highest levels of replication were measured when 
monocytes were infected after 2 days in culture, however, levels decreased when
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infected after 5 days. The change in susceptibility over time, as was observed in 
PAMs also, is likely to be linked to monocyte differentiation and the range of 
existing monocyte sub-populations including regulation of virus receptor expression 
or modulation of transcription factors (Auffray et al., 2009). There are a limited 
number of other studies describing PRRSV infection of monocytes in vitro, however, 
one report which shows successful replication in monocytes showed susceptibility 
only after 1 day of culture, and measured just 5% of virus antigen positive cells 
(Duan et al., 1997a). This is much lower than the 40% infected monocytes observed 
using Lena isolate as shown in this study, a difference which may be attributable to 
PRRSV isolates and lower multiplicity of infection (m.o.i) used by Duan et al 
(1997).
The positive effects of M-CSF observed on porcine cell viability and 
proliferation suggested that M-CSF might also increase cell susceptibility to PRRSV. 
Surprisingly, whilst M-CSF did not affect the replication of the field isolate Lena, it 
did significantly increase the replication of the MARC-145 cell-line adapted vaccine 
strain DV, and enabled propagation of DV isolate on monocytes and the consequent 
successful infection of PAMs. Since MARC-145 cells are not of porcine origin, not 
of a monocyte-macrophage lineage and lack CD169, PRRSV strains which infect 
this cell-line are presumed to have unique modifications in their structure by which 
they are adapted to MARC-145 infection. It is possible, therefore, that the effect of 
M-CSF is associated with such cell-line adapted properties. Assessing the effect of 
M-CSF with other PRRSV strains which are more representative of PRRSV-1 
infection in vivo would help determine this.
Whilst the effect of M-CSF on PRRSV infection of monocytes has not been 
investigated previously, it has been shown that M-CSF enhances the susceptibility of
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cells of the monocytes/macrophage lineage to African Swine Fever Virus (ASFV) 
(Genovesi et al., 1990). Similarly to PRRSV, ASFV is also reported to infect using 
CD 163 mediated entry (Sanchez-Torres et al., 2003). Although this might suggest 
some similarities with PRRSV regarding mechanisms of infection, the M-CSF used 
to show up-regulation of susceptibility in their study was also obtained from L929 
supernatant.
3.6.3. CD163 and CD169 expression is modulated by pro and anti­
inflammatory cytokines
Since M-CSF treatment conferred no enhancement of replication of PRRSV 
in monocytes other than in the MARC-145 adapted isolate DV, the next aim was to 
identify other factors which might modulate PRRSV susceptibility. Claims that 
monocytes cannot be infected in vitro are usually associated with a reported absence 
of the recently identified PRRSV receptors, CD 163 and sialoadhesin (CD 169) 
(Delputte et al., 2007). As few studies have focussed on the expression of these 
receptors on monocytes, and since they are both considered macrophage specific, the 
first aim was to assess their surface and intracellular expression by monocytes.
Both CD 163 and CD 169 were expressed by the monocytes isolated in this 
study over a 5 day time course. In most instances, CD 163 was identified 
predominantly on the surface, until day 5 when intracellular expression equalled 
extracellular expression. Percentages of cells expressing CD 169 extracellularly were 
similar to those expressing CD 163 extracellularly, but monocytes were not stained 
positive for intracellular expression of CD 169 at any time-point sampled. The 
current literature suggests that expression of CD 163 is a requirement for PRRSV
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entry into macrophages and for viral genome release (Calvert et al., 2007), which 
would suggest CD 163 would be expressed intracellularly, or that it is co-intemalised. 
Given that their model is based on the macrophage, this could suggest that the 
monocytes in our study had differentiated to a macrophage-like stage after 5 days in 
culture; a process with which up-regulation of CD 163 has been associated (Tippett et 
al., 2011). CD 169 is implicated in the attachment of PRRSV to myeloid cells 
(Delputte et al., 2005; Vanderheijden et al., 2003), which is in agreement with the 
extracellular expression detected on monocytes in this study. It has also been 
proposed, however, that PRRSV co-localises with both CD 169 on the surface and 
CD 169 beneath the plasma membrane to initiate internalisation of the virus into early 
endosomes (Van Gorp et al., 2010). No intracellular CD 169 was detected in 
monocytes in this study, although replication of PRRSV within monocytes might 
not necessarily be the same as within macrophages, and PRRSV is likely to employ 
alternative entry pathways which may be independent or overlapping of the model 
described in macrophages (Van Breedam et al., 2010a).
Having established the expression of CD 163 and CD 169 on monocytes, the 
effect of pro and anti-inflammatory cytokines on this expression and subsequent 
PRRSV replication were assessed to determine any correlation between expression 
of PRRSV receptors and PRRSV replication in monocytes. Whilst some results 
showed parallels between changes in CD 163 and CD 169 and PRRSV replication, not 
all results supported a direct correlation. M-CSF, for example, up-regulated the 
numbers of monocytes expressing both CD 163 and CD 169 but did not affect PRRSV 
replication in these cells, as was also shown earlier on in this chapter. It could be 
proposed that a threshold level of receptor expression needs to be achieved in order 
to increase PRRSV replication, and thus any cytokine needs to have a highly
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significant effect to drive expression to such a level. IL-10 for instance, had a much 
greater effect on CD163 than M-CSF did, and resulted in increased PRRSV 
replication. Yet although IL-10 increased CD 169 expression, the effect was not 
significant, which queries whether a high expression of both receptors is vital for 
replication. IL-10 has been shown to enhance CD 163 expression in human 
monocytes (Ambarus et al., 2012), macrophages (Buechler et al., 2000) and in 
porcine alveolar macrophages and monocyte derived macrophages (MoM0s), and 
combined with an increase in PRRSV replication (Patton et al., 2009). It is possible 
that IL-10 affects PRRSV replication by other mechanisms and not directly via 
expression of PRRSV receptors, although my results suggest it is to some extent 
related with CD 163 expression. The effect of IL-10 is interesting considering the 
many suggested links between IL-10 and PRRSV; some PRRSV strains induce IL- 
10, which is thought to be a virus survival mechanism via the induction of 
immunosuppression, by mechanisms including the impairment of T-cell activation 
(Flores-Mendoza et al., 2008; Suradhat et al., 2003). The effect of IL-10 up- 
regulation of expression of CD 163 may be an additional technique employed by 
PRRSV, and it should be remembered that many reports in the literature suggest a 
pro-inflammatory role for IL-10 as well as anti-inflammatory (Ouyang et al., 2011), 
thus the induction by PRRSV may not be a straight-forward one. The same study 
by Buechler et al (2000) reported that IL-6 also stimulated CD 163 expression in 
human monocytes (Buechler et al., 2000). This is in contrast with the results 
presented in this study which showed no effect of IL-6 on CD 163 or CD 169 
expression by porcine monocytes, therefore, the effects of IL-6 on CD 163 may be 
species specific. IL-6 is also considered a pro-inflammatory cytokine, although does 
have some anti-inflammatory roles (Scheller et al., 2011). The findings of the
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present study are comparable to Buechler et al with regard to the effects of IL-4, 
which down-regulated the percentage of cells expressing CD 163. In a separate study 
on PAMs, however, it was observed that IL-4 increased PRRSV permissiveness 
(Gaudreault et al., 2009), which may contradict the reported correlation between 
CD 163 and PRRSV susceptibility. If the findings of Gaudrealult et al are true, 
however, it could suggest that PRRSV infects macrophages that are alternatively 
activated, given that IL-4 drives such activation (Gordon, 2003). Furthermore, 
alternatively activated macrophages are characterised by a CD163+ phenotype, 
which may increase infection further (Martinez et al., 2008).
Treatment of monocytes with IFN-y and IFN-a had no effect on CD 163 
expression, which is in agreement with previous studies showing that IFN-y induced 
macrophages are CD 163 negative (Kodelja and Goerdt, 1994; Zwadlo et al., 1987). 
Surprisingly, both IFNs significantly increased the percentages of cells expressing 
CD 169 to high levels, but neither affected PRRSV replication, which may suggest 
that CD 163 expression is more significant in monocyte susceptibility to PRRSV than 
CD 169 expression. Equally, it could also be suggested that the anti-viral effects of 
IFN-a may have hindered any resulting increase in PRRSV replication following 
CD 169 up-regulation. In contrast to the present study, however, it has been shown 
that IFN-a treatment of porcine monocytes for 2-3 days increased PRRSV infection 
of monocytes by 20 fold (Delputte et al., 2007).
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3.6.4. Dexamethasone enhances CD163 and CD169 expression on monocytes
and increases PRRSV infection
Remarkably, treatment of monocyte cultures with dexamethasone resulted in 
almost 100% of the monocytes expressing CD 163, and 90% expressing CD 169. In 
addition to having the most significant effect on PRRSV receptor expression, 
dexamethasone also tripled PRRSV replication in monocytes. Dexamethasone has 
been shown to increase CD 163 expression in human monocytes, both in vitro 
(Ambarus et al., 2012; Buechler et al., 2000; Wenzel et al., 1996), and in vivo 
(Zwadlo-Klarwasser et al., 1990) and also in macrophages (Schaer et al., 2002). The 
effects of dexamethasone, however, on CD 169 have not previously been 
investigated. Although the finding that dexamethasone increased monocyte 
expression of both putative PRRSV receptors suggests a direct correlation between 
PRRSV receptors and PRRSV replication, it should be considered that as an anti­
inflammatory glucocorticoid, dexamethasone is likely to have a vast range of effects 
on monocytes. Not all of these have been measured in this study and therefore the 
effect of dexamethasone on PRRSV replication may not be directly linked to CD 163 
and CD 169.
Subsequent experiments determined that minute quantities (0.01 jug/ml) of
dexamethasone were sufficient to increase the percentage of CD 163 positive cells
and the amount of CD 163 expressed by individual cells (as represented by MFI).
Although similar increases were seen with CD 169 expression and MFI, the
difference was not great enough to be significant. Despite this, PRRSV replication
was also up-regulated with only 0.01 pg/ml of dexamethasone treatment, which adds
support for the theory that the role of CD 169 in PRRSV infection is not as
predominant as CD 163. Furthermore, a triple stain of dexamethasone treated
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monocytes showed that highest expression of PRRSV viral protein was in those 
expressing both CD 163 and CD 169. This shows a direct correlation between 
expression of both of these molecules and PRRSV susceptibility in dexamethasone 
treated monocytes. In addition, a higher proportion of cells were infected in those 
that were CD163+/CD169- than those that were CD 163-/CD 169+, once again 
highlighting s the significance of expression by monocytes of CD 163 to be greater 
than that of CD 169.
The ability of dexamethasone to exhibit such a significant effect at such low 
concentrations was striking in that the concentration of dexamethasone used was 
similar to cortisol levels considered markers of stress in vivo (Breinekova et al., 
2007; Buttgereit et al., 2004). Although further investigations will be required, this 
result suggests a link between PRRSV susceptibility and stress. The effect of 
dexamethasone and the importance of CD 163 and CD 169 highlighted in this chapter 
raised the question if the same concepts applied to other myeloid cells important in 
PRRSV infection. Therefore dexamethasone treatment and analysis of CD 163 and 
CD 169 was carried forward and assessed on porcine macrophages in the subsequent 
chapter.
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4. CHARACTERISATION OF PORCINE MACROPHAGES AND 
THEIR SUSCEPTIBILITY TO PRRSV
4.1. Rationale and aims
Porcine macrophages are thought to be the primary cell target of PRRSV in 
vivo, and infection of alveolar macrophages is reportedly more abundant than that of 
monocytes (Duan et a l, 1997b; Teifke et a l, 2001). However, a tropism for 
macrophages could be considered an overly generalised principle, given the high 
degree of heterogeneity displayed by macrophages regarding their function and 
morphology. In response to factors in the surrounding environment, a number of 
macrophage sub-populations can be generated via macrophage differentiation or 
activation, processes which are well explored in human and mouse models (Gordon, 
2003; Gordon and Taylor, 2005). Typically, two distinct methods of macrophage 
activation are described, known as classical activation (using IFN-y and 
lipopolysaccharide [LPS]), or alternative activation (using IL-4 or IL-13), which 
result in M l or M2 macrophage sub-populations respectively (Dalton et al., 1993; 
Gordon, 2003; Stein et al., 1992). The original description of alternative 
macrophage activation, however, holds a greater degree of discrepancy than classical 
activation, and the nomenclature applied to alternative activation is often 
inconsistent. ‘M2’ is often used as a generalised term to describe macrophages 
activated not only using the typical factors IL-4/IL-13, but also using IL-10, TGF-P, 
or glucocorticoids (Goerdt et al., 1999; Mantovani et al., 2004; Martinez et al., 
2008). While glucocorticoids and IL-10 are not always in agreement with the
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original description of alternative activation, it is clear that both factors modulate 
macrophages (Areschoug and Gordon, 2009), albeit by deactivating them (Calzada- 
Nova et ah, 2011 ; Gordon and Martinez, 2010; Thomas et ah, 2011).
Studies of porcine macrophages are few in comparison to those of humans 
and mice, and it is unknown whether the same macrophage sub-populations also 
exist in the pig (Ezquerra et ah, 2009). An in depth knowledge of macrophage 
activation systems and of the characteristics of resulting macrophage sub­
populations may be of great advantage in the understanding host-pathogen 
interactions of many important pathogens, including PRRSV. Furthermore, previous 
literature suggests that macrophage susceptibility to PRRSV varies between 
macrophage types, which may also explain the variability observed across PAMs in 
their susceptibility to PRRSV (Duan et ah, 1997a).
Therefore, in this chapter, porcine macrophages in various activation states 
are described, and their susceptibility to PRRSV is investigated. In addition to 
investigating macrophage activation by typical classical and alternative stimuli, the 
effects of dexamethasone (dexa) and IL-10 on porcine macrophages were also of 
interest in this study. This was not only because of the need to clarify the 
inconsistent literature regarding their role in macrophage activation, but also because 
such investigations would follow the interesting effects of dexa and IL-10 observed 
on monocytes in Chapter 3. The aims of this chapter, therefore, were:
• To optimise the differentiation of porcine macrophages from monocytes in 
vitro.
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• To establish a porcine Ml and M2 activation system, using the current 
human system as a guideline and subsequently characterise Ml and M2 
porcine macrophages by their phenotype and function.
• To further investigate alternative stimulation of porcine macrophages 
using dexa and IL-10, and assess the consequent characteristics of these 
macrophages in comparison to M2 macrophages.
• To investigate the hypothesis that susceptibility of porcine macrophages to 
PRRSV varies across macrophage sub-populations.
4.2. Differentiation of macrophages from peripheral blood monocytes
It is well established that monocytes are the precursor cells of macrophages 
and in vitro differentiation of peripheral blood monocytes is proposed to be a reliable 
model of in vivo macrophage differentiation (Kreutz et al., 1993; van Furth et al., 
1972). In vitro macrophage differentiation can be mediated by macrophage-colony 
stimulating factor (M-CSF), although various other methods without the requirement 
of M-CSF are reported (Becker et al., 1987; Geissmann et al., 2010). For the 
differentiation of porcine macrophages, there is a lack of studies using purified M- 
CSF, however, many use L929 conditioned media as a source of M-CSF (Genovesi 
et al., 1990; Mayer, 1983). One study, however, demonstrates the use of purified 
porcine M-CSF for differentiation of bone marrow cells to macrophages 
(Kapetanovic et al., 2012). For the present study, the observation of macrophage- 
like characteristics displayed by monocytes treated with recombinant purified human 
M-CSF in Chapter 3 (section 3.3.1) had suggested that purified human M-CSF could
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be used for the differentiation of porcine macrophages from peripheral blood 
monocytes. Based on the assessment of morphology and cell viability of monocytes 
following M-CSF treatment in Chapter 3, it was determined that 50 ng/ml of M-CSF 
was sufficient for activity on monocytes and resulted in cell morphology similar to 
the described macrophage morphology. Whilst this morphology was suggestive of 
macrophage differentiation, more in depth analysis of cell phenotype and functional 
characteristics was required to ascertain that M-CSF was adequate for differentiation 
of porcine macrophages from monocytes. This included the assessment of surface 
expression of lineage and antigen presentation markers, and the assessment of core 
macrophage function.
A review of the literature regarding porcine macrophages aided the selection 
of markers which were measured to confirm macrophage differentiation. These 
included Major Histocompatibility Complex Class II (MHCII), CD 14, SWC9 and 
CD 163. MHCII was selected because of its role in antigen presentation, a central 
function of macrophages. CD 14 is also important in the function of macrophages, 
and in the activation of macrophages, acting as a co-receptor for LPS binding. 
Regulation of Swine Workshop Cluster 9 (SWC9), recently identified as CD203 
(Petersen et al., 2007), and considered central for monocyte to macrophage 
differentiation due to its exclusive expression on porcine macrophages, was also 
measured (McCullough et al., 1999). Finally, the expression of the scavenger 
receptor CD 163 was measured as it is reportedly more readily expressed on 
macrophages in comparison to monocytes in both human and porcine systems 
(Chamorro et al., 2000; Sulahian et al., 2000), and also due to its significance with 
regard to PRRSV susceptibility.
121
Following analysis of the expression of surface molecules, the function of M- 
CSF treated monocytes was also assessed. Since the phagocytic action of 
macrophages is essential for their role as antigen presentation cells, phagocytosis 
assays were necessary to confirm macrophage differentiation.
4.2.1. Flow cytometric analysis of the expression of surface molecules on M- 
CSF treated monocytes
M-CSF treated monocytes were assessed after 4 days of culture using flow 
cytometry to analyse the percentage of cells expressing MHCII, CD14, SWC9, and 
CD 163, and the mean fluorescence intensity (MFI) of each molecule. Each of these 
markers were detected on >20% of cells (Figure 4.1 A).
A B
Figure 4.1. Phenotype of M-CSF treated monocytes. Freshly isolated porcine peripheral 
blood monocytes were cultured for 4 days in culture medium supplemented with 
recombinant human M-CSF and surface stained with anti-porcine mAbs for MHCII, CD 14, 
SWC9 and CD 163 for flow cytometry analysis of percentage expression of markers (A) and 
mean fluorescence intensity (MFI) (B). Bars represent mean +SD from 3 replicate 
experiments.
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4.2.2. Functional analysis of M-CSF treated monocytes
Since macrophages are mononuclear phagocytes, it was important to 
determine whether M-CSF treated monocytes were able to phagocytose in order to 
confirm that these monocytes had differentiated into macrophages. Flow cytometry 
was used to measure the association of cells with Florescein isothiocyanate (FITC)- 
labelled microsphere sulfate particles to represent phagocytic uptake. Microsphere 
particles were incubated with day 4 M-CSF treated monocytes for 3 hours at 4°C (as 
a negative control) or at 37°C before flow cytometric analysis.
As expected, there was little association of cells with particles at 4°C (2.3%) 
(Figure 4.2 B iii and D), however at 37°C, 42.7% of M-CSF treated monocytes were 
associated with FITC-labelled microsphere particles, suggesting particle uptake had 
occurred (4.2 C iii and D).
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Figure 4.2. Phagocytic activity of M-CSF treated monocytes. Peripheral blood derived 
monocytes were cultured for 4 days in tissue culture media supplemented with 50 ng/ml of 
M-CSF. Their phagocytic activity was assessed using 4 pm FITC-labelled microspheres, 
incubated with cells for 3 hours. Cells without beads were analysed as a negative control 
(A). As an additional negative control, cells were measured after incubation at 4°C (B) as 
well as at 37°C to represent phagocytosis (C). Cells were gated according to FSC/SSC (i) 
and dead cells were eliminated using a LIVE/DEAD Violet dye (ii) before gating on the 
percentage of cells expressing FITC (iii). Data are representative o f 3 replicate experiments, 
individual values o f which are shown in (D), where dots represent individual percentages o f 
cells associated with particles values at 4°C (blue) and 37°C (red) from 3 replicate 
experiments. Horizontal lines represent the mean percentage ±SEM.
124
4.3. Activation of porcine macrophages using typical M l and M2 activating 
factors
Following confirmation that M-CSF treatment of monocytes resulted in their 
differentiation towards a more macrophage like phenotype, these cells are further 
referred to as monocyte derived macrophages (MoM0s). The next aim was to 
characterise putative MoM0 subsets upon activation. Following the established 
human and mouse system, porcine MoM0s were activated using either classical 
activation with LPS and IFN-y (for Ml differentiation) or alternative activation with 
IL-4 (for M2 differentiation).
MoM0s were assessed for differences in their morphology, phenotype and 
function. For analysis of phenotype, the expression of surface markers on MoM0 
subsets were assessed using flow cytometric analysis of expression of a panel of 
markers selected from a list of genes shown to be differentially expressed on human 
Ml or M2 macrophages (Martinez et al., 2006). Since it was unknown whether pig 
and human macrophage subsets would be comparable, the expressions of other 
markers not described in the human system were also analysed to assess whether 
porcine macrophages exhibit unique differences between macrophage subsets.
The expression of pathogen recognition receptors and lineage markers were 
assessed. These included LPS receptor CD 14, reported to be up-regulated in Ml 
macrophages, and molecules reported to be up-regulated in M2 macrophages, such 
as mannose receptor CD206 and scavenger receptor CD 163. Since CD 163 is one of 
the proposed PRRSV receptors along with sialoadhesin (CD 169), and having shown 
the importance of these receptors in correlation with cell susceptibility in Chapter 3, 
CD 169 expression upon macrophage activation was also of particular interest.
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SWC9, a lineage marker exclusively expressed on porcine macrophage, was also 
measured.
Functional molecules, such as those involved in antigen presentation, and co­
stimulatory molecules were also measured upon macrophage activation. These 
included molecules that are hallmark of classical activation in humans and mice, 
such as antigen presenting molecule MHCII, CD80 and CD86, and the IL-2 receptor 
alpha CD25 (Gordon and Taylor, 2005; Martinez et al., 2006; Mosser, 2003). 
Adhesion molecule DC-SIGN (CD209) was assessed due to its association with M2 
macrophages (Relloso et al., 2002). CD83, another co-stimulatory molecule which 
has no defined role in macrophage activation, but relates to antigen presentation, was 
also measured.
In addition to assessing the morphologies and phenotypes of macrophage 
sub-populations, it was also important to measure differences in the biological 
functions of MoM0 subsets, given that differences in phenotype should correlate 
with differences in function. The effects of macrophage activation on such functions 
are unclear. Although it is assumed that activation of macrophages increases their 
ability to phagocytose, the literature is conflicting and is complicated by the fact that 
classically activated macrophages have decreased expression of mannose receptor 
CD206 and FcyR-II expression (Ezekowitz and Gordon, 1984; Mosser and 
Handman, 1992). Since endocytosis and phagocytosis are important functions of 
macrophages, and determine their role in eliminating pathogens, these functions 
were measured following activation in vitro using APC*-labelled ovalbumin (OVA) 
or FITC-labelled microsphere particles.
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4.3.1. Morphology of Ml and M2 MoM0s
Light microscopy was used to compare the morphology of unstimulated 
MoMos and MoMos treated with either Ml or M2 activating factors for 24 hours. 
Both Ml and M2 MoM0s (Figures 4.3 B, C) showed increased formation of clusters 
of cells compared to unstimulated MoM0s (Figure 4.3 A). Whilst LPS/IFN-y treated 
(M l) MoM0s occasionally appeared to link together as clusters, IL-4 treated MoM0s 
(M2) had noticeably more elongated projections protruding from individual cell 
surfaces (Figure 4.3 C).
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Figure 4.3. Morphology of M l and M2 MoMos. 4-day old MoMos were either left 
unstimulated, (A), or treated for 24 hours with either IFN-y and LPS to obtain M l MoMos 
(B) or with IL-4 to obtain M2 MoMos (C). Representative light microscopy photographs 
were taken after 24 hours with cytokines. Magnification is 20X.
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4.3.2. Phenotypical analysis of Ml and M2 MoM0s
MoMos were treated with either IFN-y and LPS (for Ml/classical activation), 
or with IL-4 (for M2/alternative activation) for 24 hours before flow cytometric 
analysis of a range of surface molecules relevant to macrophage activation. Ml or 
M2 activation of MoM0s did not induce any significant changes in the expression of 
pathogen recognition receptors/lineage markers CD 14, mannose receptor CD206, or 
PRRSV receptors CD 163 and CD 169 (Figure 4.4 A). However, the percentage of 
M2 MoMos expressing SWC9 was significantly higher than unstimulated MoM0s 
(pO.OOl) and Ml MoM0s (p<0.001) (Figure 4.4 A).
With regard to antigen presentation/co-stimulatory molecules, the expression 
of MHCII was detected on a significantly higher percentage of Ml MoM0s than on 
unstimulated MoM0s (pO.OOOl) and M2 MoM0s (pO.OOl) (Figure 4.4 B). The 
percentage of cells expressing CD80/86 was also significantly higher in M l MoM0s, 
when compared to unstimulated MoM0s (pO.OOl) and M2 MoM0s (pO.05) 
(Figure 4.4 B). Furthermore, some Ml MoM0s also expressed the IL-2 receptor 
alpha CD25, the percentage of which was significantly higher than the percentage of 
unstimulated MoM0s (pO.05) and M2 MoM0s (pO.OOl) expressing CD25 (Figure 
4.4 B), whereas significantly less Ml MoM0s expressed CD209 (DC-SIGN) than 
unstimulated MoM0s (pO.OOl), and M2 MoM0s (pO.OOl) (Figure 4.4 B). No 
statistical differences were observed between the mean fluorescence intensities of the 
molecules stained for (Figure 4.10 C, D).
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Figure 4.4. Phenotypical analysis of porcine M l and M2 M oM es. Freshly isolated 
peripheral porcine monocytes were treated with M-CSF for 4 days to obtain MoMos. 
MoMos were treated with IFN-y and LPS to generate M l macrophages (blue) or with IL-4 
to generate M2 macrophages (orange), or MoMos were left unstimulated (unfilled bars). 
After a further 24 hours MoMo were harvested and stained with various antibodies to assess 
their surface expression o f pathogen recognition receptor/lineage markers (A, C) or antigen 
presentation/co-stimulatory molecules (B, D) for flow cytometry analysis. Data represent 
mean percentage o f cells expressing markers +SD (A, B) or mean fluorescence intensity o f 
individual markers +SD (C, D) from 4 individual experiments. One-way ANOVA was used 
to assess significance followed by Bonferroni’s multiple comparison test ***p<0 0001 
**p<0.001, *p<0.05. '
4.3.3. Analysis of MoM0 function in M l and M2 sub-populations
Although modulation of CD206 expression was not observed in porcine Ml 
or M2 MoMos, changes in the percentage of cells expressing other markers, such as 
CD25 and CD209, were observed. It was therefore of interest to see whether such
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changes in phenotype were linked with changes in biological activity upon classical 
or alternative activation.
Endocytosis and phagocytosis of porcine MoMos were assessed in vitro 
following 24 hours of treatment with Ml or M2 activators, which were added on day 
4 of culture. Endocytosis was measured by percent association of MoMos with 
APC*-OVA following 1 hour of incubation at 4°C or 37°C. Phagocytosis was 
measured by percent association of MoMos with FITC-microsphere particles 
following 3 hours of incubation at both 4°C and 37°C. Both endocytosis and 
phagocytosis were analysed by flow cytometry.
Ml treated MoMos showed the highest percentage of cells associated with 
OVA (mean 60.3%), however, there were no significant differences between this and 
unstimulated (mean 59.8%) or M2 treated MoMos (mean 57.2%) (Figure 4.5 E, H, 
K, and Figure 4.6), indicating that neither Ml nor M2 MoMos changed in their 
abilities to endocytose.
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Figure 4.5. Endocytic Activity of MoM0 s following M l or M2 cytokine stimulation.
The ability of unstimulated MoMos (C-E) or MoMos treated with Ml cytokines (F-H) or 
M2 cytokines (I-K) to endocytose was assessed using APC*-labelled OVA. Cells were 
incubated with OVA at 4°C as a negative control, or at 37°C, for 1 hour before flow 
cytometric analysis of APC* fluorescence. Cells were first gated according to FSC/SSC 
(first column; A, C, F, I) and dead cells were eliminated using a LIVE/DEAD Violet dye 
(second column; D, G, J) before gating on the percentage of APC* positive events (third 
column; E, H, K). Some were analysed without OVA as an additional negative control (A- 
B). Data are representative of 3 replicate experiments.
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Figure 4.6. Data summarising flow cytometric analysis of M l and M2 MoMo 
endocytosis. The ability of unstimulated MoM0s or MoM0s treated with Ml or M2 
cytokines to endocytose was assessed using APC*-labelled OVA. Cells were incubated with 
OVA at 4°C as a negative control (blue dots), or at 37°C (red dots), for 1 hour before flow 
cytometric analysis of APC* fluorescence. Dots represent individual experiments, showing 
the percentage of cells fluorescing APC*, indicating endocytic OVA uptake. Lines represent 
mean percentage of cells associated with OVA-APC* ±SEM of 3 replicate experiments.
Similarly, when phagocytosis of Ml and M2 MoMos were assessed, no 
significant differences were observed between Ml and M2 MoMos and unstimulated 
MoMos. The mean percentages of cells associated with FITC labelled particles, 
representative of phagocytic uptake, remained approximately 40% in unstimulated, 
M l, and M2 MoMos (Figure 4.7 and Figure 4.8).
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Figure 4.7. Phagocytic activity o f  M oM es following M l or M2 cytokine stimulation The ability o f  unstimulated M oM es (A-F) or M oM os treated with 
M l cytokines (G-L) or M2 cytokines (M-R) to phagocytose was assessed using FITC-labelled 4pm  microsphere particles. Cells were incubated with FITC- 
particles for 3 hours at 37°C, or at 4°C as a negative control, before flow cytometric analysis o f  association o f cells with FITC-particles As an additional 
negative control, cells were analysed without FITC particles. MoM qs were gated according to FSC/SSC (shown for cells without particles first column; A, 
G, M, and cells with particles: (second column; B, H, N). Dead cells eliminated using a LIVE/DEAD Violet dye (third column, C, I, O) and FITC 
fluorescence was measured in cells without FITC particles (fourth column; D, J, P) and with FITC particles at 4°C (fifth column; E, K, Q) and at 37°C 
(sixth column; F, L, R). Percentages o f  cells fluorescing FITC are shown within pink boxes. Data are representative o f  4-5 replicate experiments.
134
Figure 4.8. Data summarising flow cytometric analysis of M l and M2 MoMo 
phagocytosis. The ability of unstimulated MoMos or MoMos treated with Ml or M2 
cytokines to phagocytose was assessed using FITC-labelled microsphere particles. Cells 
were incubated with particles at 4°C as a negative control (blue dots), or at 37°C (red dots), 
for 3 hours before flow cytometric analysis of FITC fluorescence. Dots represent individual 
experiments, showing the percentage of cells fluorescing FITC, indicating phagocytic 
uptake. Lines represent mean percentage of cells associated with FITC microsphere 
particles ±SEM from 3 replicate experiments.
4.4. D exam ethasone and IL-10 treatm ent o f M oM ds
Given the uncertainty of the role of glucocorticoids, such as dexamethasone 
(dexa) and of IL-10 with regard to macrophage modulation, and having observed 
interesting effects of dexa and IL-10 on monocytes in Chapter 3, both of these 
factors were also used to treat MoMos. In order to compare the effects with those of 
typical Ml (IFN-y + LPS) and M2 (IL-4) activating factors on MoMos, dexa and IL- 
10 were also applied for 24 hours and the same characterisation by morphology, 
phenotype and function was assessed using the same markers and functional tests.
4.4.1. Morphology of dexamethasone and IL-10 treated MoMos
Light microscopy was used to assess the morphology of MoMos following 
24 hours of treatment with either dexa or IL-10. Dexa treated MoMos (Figure 4.9 B) 
generally appeared more rounded, with some cells bigger in size than those seen in 
unstimulated MoMos (Figure 4.9 A). IL-10 treated MoMos noticeably clustered 
together more frequently, with more cells appearing as larger cells in cultures 
(Figure 4.9 C). Both dexa and IL-10 treated MoMos appeared unlike the M l and 
M2 MoMos described in section 4.3.1
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Figure 4.9. Morphology of dexa and IL-10 treated MoMos. 4 day old MoMos were 
either left unstimulated, (A) or treated for 24 hours with either dexa (B), or with IL-10 (C). 
Representative light microscopy photographs were taken after 24 hours with cytokines. 
Magnification is 20X.
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4.4.2. Phenotypical analysis of dexamethasone and IL-10 treated MoM0s
Dexamethasone (dexa) and IL-10 treatment of MoM0s on day 4 for 24 hours 
resulted in two distinct MoMo phenotypes, neither of which were similar to Ml and 
M2 MoMos. Data for untreated MoMos are carried over from the previous 
investigations of Ml and M2 MoMos, i.e. Figure 4.4 (data sets are separated for ease 
of interpretation). Dexa treated MoMos showed significantly higher percentages of 
cells expressing CD 163 than unstimulated MoMos (pO.OOOl), as did IL-10 treated 
MoMos (p<0.05) (Figure 4.10 A). The percentage of cells expressing CD 163, 
however, significantly higher in dexa MoMos than IL-10 MoMos (p<0.005). IL-10 
treated MoMos showed significantly higher percentages of cells positive for SWC9 
than unstimulated (pO.OOl) and dexa treated MoMos (p<0.05). No differences 
were observed in the percentage expression of MHCII, CD206 or CD 169 in dexa or 
IL-10 treated MoMos (Figure 4.10 A).
With regard to the expression of antigen presentation molecules, a lower 
proportion of IL-10 treated MoMos expressed CD80/86 compared with unstimulated 
(p<0.05) and dexa treated MoM0s (p<0.05) (Figure 4.10 B). Both dexa and IL-10 
treatment of MoMos resulted in decreased percentage of cells expressing CD83 
compared to unstimulated MoMos (both pO.OOl), and no differences were observed 
between the percentage of cells positive for MHCII, CD25 or CD209 (Figure 4.10 
B). No statistical differences were observed between the mean fluorescence 
intensities of the molecules stained for (Figure 4.10 C, D).
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F ig u re  4.10. P h e n o ty p ic  an a ly s is  o f  d e x a  a n d  IL -1 0  tr e a te d  M o M o s. Freshly isolated 
peripheral porcine monocytes were treated with M-CSF for 4 days to obtain MoMos. 
MoMos were treated with dexa (b lu e) or IL-10 (o ra n g e )  or left unstimulated (u n fille d  
b a rs ) . After a further 24 hours MoMos were harvested and surface stained for pathogen 
recognition receptors/lineage markers (A , C) or antigen presentation/co-stimulatory 
molecules (B , D ) for flow cytometric analysis. Data represent mean percentage of cells 
expressing markers +SD (A, B ) or mean fluorescence intensity of individual markers +SD 
(C, D ) from 3 replicate experiments. One-way ANOVA was used to assess significance 
followed by Bonferroni’s multiple comparison test ***p<0.0001, **p<0.001, *p<0.05.
4.4.3. Functional activity of dexamethasone and IL-10 treated MoMos
Since dexa and IL-10 treatment of MoMos had resulted in phenotypical 
changes that were not consistent with those seen in Ml and M2 MoMOs, the effects 
of dexa and IL-10 on the functional activity of MoMos were also of interest. 
Endocytosis and phagocytosis of dexa and IL-10 treated MoMos were measured as
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in 4.3.3, using the same method as with M l or M2 MoMos, with APC*-labelled 
ovalbumin (OVA) and FITC-labelled sulphate microsphere particles. In addition to 
analysis off these functions using flow cytometric analysis, phagocytosis was also 
analysed using confocal microscopy.
4 4.3.1. Analysis of MoMo function using flow cytometry
Flow cytometric analysis determined that a significantly higher percentage of 
cells were associated with OVA, demonstrating increased endocytosis, in IL-10 
treated MoMos (75.8%) compared with dexa treated MoMos (56.5%), (p<0.05) 
(Figure 4.11 H, K and Figure 4.12). The percentage of IL-10 treated MoMos 
associated with OVA was also significantly higher than that observed in M2 MoMos 
(57.2%) (p<0.05) (Figure 4.6).
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Figure 4.11. Endocytic Activity o f MoMos is following dexa or IL-10 treatment. The
ability of unstimulated MoMos (C-E) or MoMos treated with dexa (F-H) or IL-10 (I-K) to 
endocytose was assessed using APC*-labelled OVA. Cells were incubated with OVA at 
4°C as a negative control, or at 37°C, for 1 hour before flow cytometric analysis of APC* 
fluorescence. Cells were first gated according to FSC/SSC (first column; A, C, F, I) and 
dead cells were eliminated using a LIVE/DEAD Violet dye (second column; D, G, J) 
before gating on the percentage of APC* positive events (third column; E, H, K). Some 
were analysed without OVA as an additional negative control, for which FSC/SSC (A) and 
APC*/OVA fluorescence are shown (B). Data are representative of 3 replicate experiments.
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Figure 4.12. Endocytic Activity of MoMos following dexa and IL-10 treatment. The
ability of unstimulated MoMcs or MoMos treated with dexa or IL-10 to endocytose was 
assessed using APC*-labelled OVA. Cells were incubated with OVA for 1 hour at 4°C 
(blue) or 37°C (red) before flow cytometric analysis of percentages of cells associated with 
APC*-OVA. Dots represent individual experiments; lines represent mean percentages ± 
SEM of 3 replicate experiments. One-way ANOVA was used to assess significance 
followed by Bonferroni’s multiple comparison test, *p<0.05.
The mean percentage of cells associated with FITC-labelled microsphere 
particles, indicating phagocytosis, was significantly increased in MoM0s treated 
with dexa compared with unstimulated MoMos (p<0.05) (Figure 4.13 F, L and 
Figure 4.14), although replicate experiments showed a large spread of data (Figure 
4.8). While dexa treated MoM0s appeared higher than levels observed in M l and 
M2 macrophages, this difference was not significant.
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Figure 4.13. Phagocytic Activity o f  M oM os following dexa or IL-10 stimulation. The ability o f unstimulated M oM os (A-F) or M oM os treated with dexa 
(G-L) IL-10 (M -R) to phagocytose was assessed using 4pm FITC-labelled microsphere particles. Cells were incubated with FITC-particles for 3 hours at 
37°C, or at 4°C as a negative control, before flow cytometric analysis o f association o f cells with FITC-particles. As an additional negative control, cells 
were analysed without FITC particles. M oM os were gated according to FSC/SSC (shown for cells without particles: first column; A, G, M, and cells with 
particles: (second column; B, H, N). Dead cells eliminated using a LIVE/DEAD Violet dye (third column, C, I, O) and FITC fluorescence was measured in 
cells without FITC particles (fourth column; D, J, P) and with FITC particles at 4°C (fifth column; E, K, Q) and at 37°C (sixth column; F, L, R). 
Percentages o f cells fluorescing FITC are shown within pink boxes. Data are representative o f 4-5 replicate experiments.
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Figure 4.14. Phagocytic Activity of Dexa and IL-10 MoMos. The ability of unstimulated 
MoMos or MoMos treated with dexa or IL-10 to phagocytose FITC-labelled microsphere 
particles was measured after 24 hours of treatment with these factors. Cells were incubated 
with microsphere particles for 3 hours, both at 4°C (blue) or 37°C (red) before flow 
cytometric analysis. Dots represent individual experiments, lines represent mean 
percentages ±SEM (n=4-5). One-way ANOVA was used to assess significance followed by 
Bonferroni’s multiple comparison test, *p<0.05.
4 4.3.2. Confocal microscopy to confirm internalisation of FITC labelled 
microsphere particles
Although flow cytometric analysis showed an association of MoMos with 
microsphere particles by FITC fluorescence, further analysis was required to 
eliminate the possibility that microsphere particles were attached to the surface of 
MoM0s rather than inside the cell. Confocal microscopy was used, therefore, to 
provide images of individual sections of the cells to assess where the FITC-particles 
were located. As the highest levels o f association with FITC-particles were observed 
in dexa treated MoM0s, confocal microscopy was carried out using these cells.
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After 3 hours of incubation with FITC-particles at 37°C, dexa treated MoM0s were 
fixed and stained with a propidium iodide (PI) nucleic acid dye to enable cell nuclei 
to be distinguished from the FITC-particles. Confocal images showed that all o f the 
FITC-particles were all closely associated with the cells, and some cells were 
associated with up to 5 particles (Figure 4.15). Z-stacks of the confocal images were 
performed at 1.0 pM section slices throughout the cells, which showed the brightest 
FITC fluorescence in the mid-sections of cells in comparison to the lower or higher 
(bottom or top) sections of cells (Figure 4.15). This supported the assumption that 
dexa treated MoM0s had internalised the FITC-particles.
Figure 4.15. Confocal microscopy of dexa treated MoMos with FITC-particles. Dexa 
treated MoMos were incubated with FITC-labelled microsphere particles (green) for 3 hours 
at 37°C before being fixed and stained with PI nucleic acid dye (red). Z-stacks were 
performed at 1.0 pM section slices throughout the cells to show where the FITC-particles 
were located within the cells.
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4.5. PRRSV infection of MoM0 subsets
The identification of several different phenotypes of porcine macrophage 
subsets suggested that macrophage subsets might also show variations in their 
susceptibility to PRRSV infection. As well as investigating Ml and M2 MoMo sub­
populations, treatment of MoMos with dexa and IL-10 was further analysed, as these 
factors had resulted in distinct MoMo phenotypes, and positive effects on monocyte 
susceptibility to PRRSV was observed in Chapter 3 (3.4.2). Cells were treated with 
IFN-y and LPS (for M l), IL-4 (for M2), or with dexa or IL-10, for 24 hours as 
before, and infected with PRRSV Lena at a multiplicity of infection (m.o.i) of 0.1. 
At various time-points post infection (p.i), qPCR was used to analyse viral 
replication using RNA extracted from cells or from cell culture supernatant. Flow 
cytometric analysis was also used to assess the production of viral proteins at 20 
hours p.i.
4.5.1. Assessment of PRRSV replication within cells (MoMos)
Firstly, the replication of PRRSV was measured at the cellular level using the 
MoMos themselves to either extract viral RNA for RT-qPCR or for flow cytometric 
analysis by intracellular staining using the anti-PRRSV antibody SDOW-17. To 
ensure the comparison of equal cell numbers across different MoMo subsets, the 
qPCR data was normalised against 18S rRNA as endogenous control. To calculate 
virus production, cells were harvested at a range of time-points between 16 and 72 
hours following infection.
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4.5.11. PRRSV replication in MoMos measured by qPCR analysis
Classical (Ml) or alternative (M2) macrophage activation did not result in 
any changes in PRRSV replication at 16 hours p.i as there were no significant 
differences in the AACt values between unstimulated, Ml or M2 MoMos (Figure 
4.16 A). Dexa treated MoMos, in contrast, showed a significant increase in PRRSV 
replication with a mean AACt value of 8.7, which was significantly higher than 
unstimulated MoMos, of which showed a mean AACt of 3.28 (p<0.05). Replication 
in dexa MoMos was also significantly higher than Ml (pO.Ol), M2 (pO.Ol), and 
IL-10 treated MoM0s (p<0.05) (Figure 4.16 A).
After 16 hours p.i, PRRSV replication in dexa treated macrophages did not 
seem to increase further, as the AACt value remained unchanged. In contrast, other 
MoMos reached similar levels of replication only by around 72 hours p.i. At 24 
hours p.i, Ml MoMos showed negative values of AACt, significantly lower than 
unstimulated MoMos (p<0.05) and dexa treated MoMos (pO.Ol) (Figure 4.16 B). 
Ml MoMos remained negative for replication at 48 hours p.i, and were significantly 
lower than dexa MoMos and IL-10 MoMos (p<0.05) (Figure 4.16 C), however, 
PRRSV was detected in M l cells after 72 hours p.i (Figure 4.16 D).
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Figure 4.16. PRRSV replication in MoMos following different activation stimuli.
Monocytes were treated with M-CSF for 4 days to generate MoMos, and either left 
unstimulated or activated with LPS & IFN-y (Ml), IL-4 (M2), dexa or IL-10 for 24 hours 
before infection with PRRSV Lena using an m.o.i of 0.1. RNA was extracted from cells at 
either 16 (A), 24 (B) 48 (C) or 72 hours p.i (D), and a TaqMan qPCR was used to quantify 
PRRSV RNA. AACt represents difference between Ct at 2 hours p.i (time zero) and Ct at 
each time point p.i after normalisation against 18S RNA. Bars represent mean AACt +SD. 
One-way ANOVA was used to assess significance followed by Bonferroni’s multiple 
comparison test (A-C, n=3-4, D, n=2, each biological repeat was tested in duplicate), 
**p<0.001, *p<0.05.
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Upon comparison across time, no significant differences were observed 
between the AACt values in any of the MoM0 subsets between p.i time-points 
(Figure 4.17).
Unstimulated
Figure 4.17. PRRSV replication over time in MoMo subsets. Monocytes were treated 
with M-CSF for 4 days to generate MoMos, and either left unstimulated or activated with 
LPS & IFN-y (Ml), IL-4 (M2), dexa or IL-10 for 24 hours before infection with PRRSV 
Lena. Viral RNA was extracted from cells at 16, 24 or 48 hours pi, and a TaqMan qPCR 
was used to obtain Ct values. AACt represents difference between Ct at 2 hours p.i (time 
zero) and Ct at each time point p.i, shown at 16, 24, and 48 hour time-points in unstimulated 
(red), Ml (grey) M2 (green), dexa (orange) or IL-10 (blue) treated MoMos. Dots 
represent mean AACt ± SD. One-way ANOVA was used to assess significance followed by 
Bonferroni’s multiple comparison test (n=3-4, other than 72 hr where n=2, each biological 
repeat was tested in duplicate).
4.5.1.2. The assessment of PRRSV protein production in MoMos using flow 
cytometry
The production of PRRSV protein was assessed in MoMos at 20 hours p.i, 
to investigate whether the production of viral protein correlated with the qPCR data 
of PRRSV replication. The anti-PRRSV N protein antibody SDOW-17 was used to
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stain MoMtes intracellularly after infection with PRRSV Lena as described in section 
2.6.5. All MoMos showed low percentages of SDOW-17 positive cells and only be 
dexa treated MoMtes could considered infected, which showed mean values of 5.2% 
cells positive for SDOW-17 (Figure 3.18).
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Figure 4.18. Intracellular PRRSV staining using SDOW -17 in M oM o subsets. Monocytes were treated with M-CSF for 4 days to generate 
M oMos, and either left unstimulated or activated with LPS & IFN-y (M l), IL-4 (M2), dexa or IL-10 for 24 hours before infection with PRRSV 
Lena. At 20 hours p.i cells were harvested and stained with a LIVE/DEAD Violet stain before being permeabilised and fixed for intracellular 
staining with a-PRRSV antibody SDOW-17 and secondary G l-A PC* for detection by flow cytometry. Cells were gated on FSC/SSC (A ) before 
dead cells were eliminated according to LIVE/DEAD Violet stain (B). For negative controls, cells were stained with secondary G l-A PC * only (C) 
and with a mouse IgGl isotype and secondary G l-A PC * (D). SDOW-APC* staining is shown in mock infected M oM os (E) and in unstimulated 
(F), M l (G), M2 (H), dexa (I), IL-10 (J) treated M oM0s. Data are representative o f three replicate experiments.
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4.5.2. Measurement of MoMo subset PRRSV replication into cell culture
supernatant
In addition to comparing the viral RNA extracted from MoM0 cells, it was 
also assumed that differences between MoM0 subsets would be observed in the 
amount of virus produced by the cells into the cell culture supernatant. Therefore, 
viral RNA was extracted from cell culture supernatant at 16, 20, 24, 36, 48 and 72 
hour time-points p.i. At 16 hours p.i, ACt values were low in all MoM0 subsets, all 
were lower than the ACt values observed in RNA extracted from the cells, and no 
differences were observed between ACt values of MoM0 subsets (Figure 4.19 A). 
At 20 hours p.i, although ACt values still did not reach levels observed in replication 
in cells at 16 hours p.i, dexa treated MoM0 supernatant showed significantly higher 
ACt values than Ml MoM0 supernatant (Figure 4.19 B). At 24 hours p.i. Ml 
MoM0s still showed negligible ACt values, significantly lower than dexa (p<0.05) 
and IL-10 (p<0.001) treated MoM0s (Figure 4.19 C). Whilst all cells continued with 
the production of virus, Ml MoM0s clearly produced less virus for the first 48 hours. 
No significant differences were seen at 36, 48, or 72 hours p.i (Figure 4.19 D, F).
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Figure 4.19. PRRSV replication in MoMo supernatant between 16 and 72 hours p.i.
Monocytes were treated with M-CSF for 4 days to generate MoMos, and either left 
unstimulated or activated with LPS & IFN-y (Ml), IL-4 (M2), dexa or IL-10 for 24 hours 
before infection with PRRSV Lena. Viral RNA was extracted from cell supernatant at either 
16 (A), 20 (B), 24 (C), 36 (D), 48 (E) or 72 (F) hours p.i, and TaqMan qPCR was used to 
obtain Ct values. ACt represents difference between Ct at 2 hours p.i (time zero) and Ct at 
each time point p.i. Bars represent mean ACt +SD in 3 replicate experiments, (n=2 at 72 hr 
p.i), each biological repeat tested in duplicate. One-way ANOVA was used to assess 
significance followed by Bonferroni’s multiple comparison test, *p<0.05 **p<0.001.
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Individual MoM0 subsets were compared in their replication in cell 
supernatant across over time in order to visualise differences in the speed of 
replication. Unstimulated MoMos only showed a significant increase in ACt 
between 16 and 48 hours (p<0.05), and whilst no significant increases were observed 
over time in M2 MoMos, these cells followed a similar trend to unstimulated 
MoMos (Figure 4.20). It was clear that Ml MoMos have a particularly long lag 
phase of replication, where the end of the primary replication could not be 
determined, as replication levels remained low until 72 hours p.i (Figure 4.20). In 
contrast, dexa treated MoMos showed a rapid replication, by which the rounds of 
replication could not be captured. IL-10 treated MoMos showed several significant 
differences in ACt over time, notably ACt between, between 16 and 36 hours 
(p<0.05), between 16 and 48 hours (pO.OOl), between 20 and 36 hours (pO.05), 
and most significantly between 20 and 48 hours p.i (pO.OOl) (Figure 4.20), which 
may represent rounds of replication.
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Figure 4.20. PRRSV replication in MoMo subset supernatant over time. Monocytes 
were treated with M-CSF for 4 days to generate MoM0s, and either left unstimulated or 
activated with LPS & IFN-y (Ml), IL-4 (M2), dexa or IL-10 for 24 hours before infection 
with PRRSV Lena. Viral RNA was extracted from cell supernatant at 16, 20, 24, 36, or 48 
hours p.i, and a TaqMan qPCR was used to obtain Ct values. ACt represents difference 
between Ct at 2 hours p.i (time zero) and Ct at each time point p.i shown at 16, 20, 24, 36, 
48, or 72 hour time-points in unstimulated (red), Ml (grey) M2 (green), dexa (orange) or 
IL-10 (blue) treated MoM0s. Lines represent mean ACt ± SD in 3 replicate experiments, 
each biological repeat tested in duplicate (n=2 at 72 hr p.i). One-way ANOVA was used to 
assess significance followed by Bonferroni’s multiple comparison test, **p<0.001, *p<0.05.
4.5.3. Preliminary experiment assessing the function of MoMo subsets
following PRRSV infection
Viruses often inhibit the primary functions of cells as a mechanism of 
evading the host immune response, and it has previously reported that PRRSV also 
does this in alveolar macrophages (Thanawongnuwech et ah, 2000). It was assessed, 
therefore, whether PRRSV Lena infection affected the ability of MoMo subsets to 
phagocytose microsphere particles. MoMo subsets, generated as described earlier in 
this chapter, were treated with media alone, PRRSV Mock (PAM supernatant), or 
infected with PRRSV Lena at an m.o.i o f 0.1. At 20 hours p.i, the phagocytosis o f
FITC-labelled microsphere particles was measured as before. Although no 
significant differences were observed between the percentage of cells associated with 
microsphere particles in media, mock, or PRRSV infected MoMos, there is a trend in 
the data that suggests that PRRSV infected cells are less associated with particles 
than media treated cells in all MoMo subsets, and in some cases PRRSV infected 
cells were less associated with particles than mock infected cells (Figure 4.21).
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Figure 4.21. The effect of PRRSV on the phagocytosis o f MoMo subsets. The ability of 
unstimulated MoMos or MoMos treated with dexa or IL-10 to phagocytose FITC-labelled 
microsphere particles was measured following 20 hours of treatment with media (red) or 
mock (blue), or 20 hours p.i of PRRSV Lena (black). Cells were incubated with 
microsphere particles for 3 hours at 37°C before flow cytometric analysis. Dots represent 
mean percentages of cells associated with particles ±SD from 3 replicate experiments. One­
way ANOVA was used to assess significance between media, mock or PRRSV, followed by 
Bonferroni’s multiple comparison tests.
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4.6. Discussion
This chapter aimed to establish a system where porcine macrophages, derived 
from monocytes, could be used as a model to test the interaction of PRRSV with 
porcine macrophages at various states of activation. Consequently, macrophage 
differentiation and activation systems were established, and were used to explore and 
understand the kinetics of PRRSV infection of porcine macrophage sub-populations.
4.6.1. M-CSF is sufficient for porcine monocyte-macrophage differentiation
Earlier studies of macrophage differentiation claimed that the adherence of 
monocytes to plastic in tissue culture medium alone was sufficient for macrophage 
differentiation (McCullough et al., 1997). However, more recent reports frequently 
describe the use of granulocyte macrophage-colony stimulating factor (GM-CSF) 
and M-CSF (in combination with one another and also individually) to differentiate 
macrophages from monocytes, although resulting macrophages have variable 
phenotypes (Lacey et al., 2012). Serum factors are also reported to permit 
macrophage differentiation from monocytes in porcine and human models, and are 
often considered essential for in vitro differentiation (Andreesen et al., 1990; 
McCullough et al., 1999). One other report indicates that macrophages differentiated 
from bone marrow cells using GM-CSF display characteristics of classically 
activated macrophages and those differentiated using M-CSF display characteristics 
closer to alternatively activated macrophages (Fleetwood et al., 2009). The above 
systems, however, commonly use poorly defined factors which are not easily 
reproducible, such as serum from conditioned medium. The use of tested media 
(which is free of LPS) and recombinant cytokines in recent key studies in both
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human and mouse systems need to be continued in veterinary species in order to 
achieve reproducible conditions and harmonise studies of macrophage activation 
(Martinez et al., 2006; Villalta et al., 2009).
In this study, experiments were carried out to optimise the differentiation of 
macrophages from monocytes so that the most representative and reproducible 
model of in vivo macrophages could be achieved. Recombinant human M-CSF was 
selected for macrophage differentiation, firstly due to its known role in human and 
mouse monocyte to macrophage differentiation, and secondly because investigations 
in Chapter 3 confirmed the positive activity of recombinant M-CSF on porcine 
monocytes. M-CSF is described as a factor that is essential for the survival and 
differentiation of macrophages in vivo, and hence was presumed likely to drive 
macrophage differentiation in vitro alone.
In addition to using M-CSF for macrophage differentiation, the effects of 
porcine serum on monocytes were also compared (data not shown). Although 
porcine serum induced similar changes to the phenotype of treated monocytes as M- 
CSF did, its effects on morphology were quite variable, and not identical with the 
effects of M-CSF. Furthermore, the inability to replicate experiments given the 
genetic differences between pigs from which the serum was obtained, and the 
difficulty to obtain autologous serum for each replicate experiment, was a 
fundamental problem in using this method. It was also difficult to determine the 
active components present in the serum. Recombinant human M-CSF was chosen, 
therefore, for macrophage differentiation throughout the study, with full tissue 
culture medium containing 10% foetal bovine serum (FBS), as described in section 
2 .2.1.
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After 4 days of culture, the phenotype of M-CSF treated monocytes was 
consistent with what was expected of a porcine macrophage-like phenotype. Firstly, 
the expression of SWC9, which is a marker reported to be exclusively expressed on 
porcine macrophages and absent on porcine monocytes (Dominguez et a l ,  1998), 
was expressed on -40%  of cells. While slightly surprising that only 40% of M-CSF 
treated monocytes expressed SWC9, the high values of mean fluorescence intensity 
(MFI) suggested that the expression was substantial on those which were expressing 
it. This result reflects the heterogeneity of porcine macrophages which was to be 
further investigated later in the study. Furthermore, it is not unusual to see 
incomplete differentiation of the entire monocyte population. McCullough et al 
(1999) described a sub-population of monocytes which did not increase their 
expression of SWC9 and morphologically remained monocyte like (McCullough et 
al., 1999). In this study, the morphology of M-CSF treated monocytes also showed 
some heterogeneity, with some cells remaining smaller than others and possibly 
more monocyte like. In hindsight, the removal of non-adherent cells from cultures 
after 2-3 days may have been advantageous to avoid this, but it is assumed that non 
differentiated cells may die after some time anyway. The low average percentage of 
SWC9 expression could be due to variability between animals. Although all cultures 
received equivalent amounts of M-CSF, the amount o f autocrine M-CSF production, 
important during macrophage differentiation, has been shown to be donor dependent 
(Popova et al., 2011). This may suggest that in some experiments, differentiation 
was slower than in others.
M-CSF treated monocytes also expressed markers involved in macrophage 
function after 4 days, including antigen presentation molecule MHCII and LPS 
receptor CD 14. MHCII expression was observed on half of the M-CSF treated
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monocytes, which is in line with the study of Basta et al which reports 30% of cells 
are MHCII negative after 4 days undergoing differentiation (Basta et al., 2000). It 
has been reported that porcine monocytes do not behave like their human 
counterparts, in particular with regard to CD molecules (McCullough et al., 1997). 
The role of CD 14 in macrophage differentiation is somewhat controversial, with 
reports of human macrophages showing an up-regulation in CD 14 expression 
(Kreutz et al., 1992) and others which report a down-regulation (Andreesen et al., 
1990). With regard to porcine macrophage differentiation, most studies show a 
down-regulation of CD 14 expression following macrophage differentiation, although 
expression is considered to be low (Basta et al., 1999; Chamorro et al., 2000). Since 
the method of monocyte isolation from PBMCs is done by positive CD 14 selection 
in this study, at least 80% of monocytes would have been CD14+ before M-CSF 
treatment, so the result of 64% expression in this study is a significant decrease, 
albeit this would perhaps not be considered to be low. The MFI of CD 14 expression 
is low, however, suggesting that individual cells do not express much CD 14. In 
contrast, Basta et al report that by day 4, 20% of differentiated macrophages are 
CD 14', slightly less than observed in this study (Basta et al., 1999). Finally, M-CSF 
treated monocytes also expressed CD 163, which was expected as CD 163 is 
considered important in monocyte populations and is suggested to be linked with 
their stages of maturation and or differentiation and requirement for scavenger 
function (Chamorro et al., 2005; Ezquerra et al., 2009).
Phagocytosis assays of M-CSF treated monocytes after 4 days showed that 
-40% of cells were able to phagocytose microsphere particles. This was slightly 
lower than expected, however, could be linked with the observation that only -40%  
of cells expressed the porcine macrophage marker SWC9. Monocyte derived
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macrophages have not been shown to phagocytose the same particles in any other 
studies, and although all macrophages should be able to phagocytose foreign 
material, it could be considered that the microsphere particles used here do not fully 
represent the foreign bacterial or viral material that macrophages would bind and 
internalise in vivo using the specific pathogen recognition receptors. As increasing 
the period of incubation of cells with microsphere particles did not increase the 
percentage of cells phagocytosing microsphere particles, it is likely that these 
particles were not suitable for maximum uptake. In combination with the 
morphology, the evidence of some phagocytic activity and their macrophage-like 
phenotype, however, was sufficient to suggest that a significant proportion of cells 
had differentiated into monocyte derived macrophages (MoMos).
4.6.2. Classical and alternative activation of monocyte derived macrophages
(MoMos)
MoM0s were activated with the stimulators of classical and alternative 
activation, IFN-y and LPS, or IL-4 respectively. Porcine Ml and M2 MoMos were 
morphologically and phenotypically distinguishable from one another, and from 
unstimulated MoM0s, which confidently assured that two forms of activation had 
occurred. Consequently, they were classified as Ml and M2 porcine MoM0s, 
however, due to the limited number of studies investigating macrophage activation in 
the pig, these cells could only be compared with other species such as humans and 
mice. Porcine MoMos were therefore assessed upon differentiation for their 
expression of markers identified as classical and alternative activated macrophages 
in humans and mice, in addition to some other markers considered important in
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porcine macrophage heterogeneity and PRRSV susceptibility. Surprisingly, data 
suggested that porcine MoMos do not behave entirely like the well-defined human or 
mouse macrophages following classical or alternative activation.
It is unclear whether the different pro and anti -inflammatory roles of 
classical and alternative activated macrophages would require different specialised 
cell morphologies. There are few studies that discuss the morphology of activated 
macrophages in vitro, and some claim that human Ml and M2 macrophages do not 
exhibit any particular morphology (Porcheray et al., 2005). However, some 
morphological differences are observed in murine macrophages, along with changes 
within the cytoskeleton of activated macrophages, where alternatively activated 
macrophages showing an ability of increased motility (Vereyken et al., 2011), In 
the present study, many cell clusters were observed in both IFN-y/LPS and IL-4 
treated MoMos in comparison to unstimulated MoMos. Whilst cell clusters 
appeared tightly packed together in IFN-y/LPS treated MoMos, occasionally 
resulting in the fusion of two or more cells, IL-4 treated MoM0s showed smaller cell 
clusters which were linked together by long projections protruding from cell 
surfaces. The morphology of IFN-y/LPS MoM0s suggests a low adherence, which is 
in line with the study of Rey-Giraud et al where IFN-y/LPS treatment increased the 
detachment of human macrophages (Rey-Giraud et al., 2012). The long cellular 
elongations seen in M2 MoM0s are a typical effect of IL-4, well documented during 
dendritic cell differentiation, and are consistent with other descriptions of IL-4 
treated mouse macrophages (Vereyken et al., 2011). In humans, however, M2 
macrophages are not commonly associated with any morphological changes (Rey- 
Giraud et al., 2012). The cellular elongations observed in the present study may 
contribute to increased motility, which would aid their migration to sites of
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inflammation in order to repair damaged tissues, which would be in line with their 
presumed role in vivo (Gordon, 2003).
Classically activated porcine Ml MoMos showed the most dramatic change 
in phenotype, which is consistent with the study of Martinez et al, which shows the 
most dramatic change in transcriptome is following classical activation (Martinez et 
al., 2006). Changes were predominantly by up-regulation of cells expressing antigen 
presentation and co-stimulatory molecules, including MHCII, CD80/86 and IL-2 
receptor alpha CD25. This is fitting with the increased antigen presentation role 
described of classically activated macrophages (Gordon and Taylor, 2005). An up- 
regulation of MHCII is a known effect of IFN-y (Schroder et al., 2004), and is 
described in classically activated macrophages in humans and mice (Gordon and 
Taylor, 2005; Mosser, 2003; Whyte et al., 2011). MHCII expression is also 
described in alternative activation of macrophages, but whether it is expected to be 
highly expressed is uncertain, as is its significance (Gordon and Martinez, 2010). In 
the present study, MHCII was expressed in -40% of M2 MoMos, however this value 
was identical to unstimulated MoMos.
The expression of CD86 in human and mouse macrophages stimulated with
IFN-y and LPS is also well reported (Gordon and Taylor, 2005; Mosser, 2003), and
CD80 is described as the most robust phenotypic marker for human macrophages
stimulated with IFN-y (Ambarus et al., 2012). This could be true of porcine
macrophages alike, since CD80/86 expression showed the highest percentage in
comparison to other markers on Ml MoM0s. More recent research has described the
importance of suppressor of cytokine signalling (SOCS) proteins in macrophage
activation. SOCS proteins are released in inflammatory diseases and are able to
regulate macrophage activation. It is thought that the changes in MHCII and CD86
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in particular are regulated by S0CS1, as Whyte et al show that SOCS1 knockout 
mice have enhanced Ml induction of MHCII and CD86 (Whyte et al., 2011). 
Having observed changes in MHCII and CD86 here, further analysis might reveal a 
significant role of SOCS proteins in porcine macrophage activation.
In addition to antigen presentation molecules, porcine MoMos stimulated 
with IFN-y and LPS also showed significantly increased percentage of IL-2 receptor 
alpha CD25 positive cells. This finding is strongly supported by the up-regulation of 
CD25 genes observed in the transcriptional profiling of human M l macrophages by 
Martinez et al, and is proposed to be a hallmark marker of Ml macrophages in vitro 
(Martinez et al., 2006). CD25 is usually associated with the activation of T-cells, so 
the significance of CD25 expression on macrophages is uncertain. IL-2 receptor 
expression and up-regulation by LPS is, however, noted in human monocytes, with 
higher expression in activated macrophages than in monocytes (Scheibenbogen et 
al., 1992). Given that IL-2, considered a Th-1 cytokine, plays roles in T-cell 
differentiation and proliferation, perhaps CD25 expression accommodates for the 
increased antigen presentation activity of classically activated macrophages. This 
could also be in line with the suggestion that classical and alternative activation 
mirrors the Thl and Th2 polarization of T-cells (Mills et al., 2000).
Dendritic cell-specific ICAM-3 grabbing non-integrin (DC-SIGN/CD209) is
usually associated with DCs, and is important in DC migration and DC-T-cell
interactions (Geijtenbeek et al., 2000a). Its expression is IL-4 dependent and,
therefore, is also associated with M2 macrophages (Martinez et al., 2006). Vice
versa, the negative regulation of DC-SIGN by IFNs is reported on human monocytes
(Relloso et al., 2002), which correlates with the observation in the present study
where the percentage of cells expressing CD209 was significantly down-regulated in
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porcine IFN-y/LPS stimulated Ml MoMos. Surprisingly, however, porcine MoM0s 
stimulated with IL-4 did not show a significant up-regulation of CD209 positive 
cells. This could be a species specific difference, given that some other markers 
expected on M2 MoMos also did not occur as predicted.
The only marker significantly up-regulated by IL-4 treatment was porcine 
macrophage lineage marker SWC9. SWC9 has recently been identified as a 
homologue to the human nucleotide pyrophosphatase/phosphodiesterase enzyme I 
(NPPl/CD203a), but its function in the porcine macrophage is uncertain (Petersen et 
al., 2007). In humans and mice, however, NPPl/CD203a is a regulator of 
mineralization in articular cartilage and arterial tissues, (Bollen et al., 2000; Coding 
et al., 2003), which may relate to the role of M2 macrophages in tissue repair and 
hence may explain why a significant up-regulation in cells expressing this molecule 
was observed. Although there are no other reports of the effect of IL-4 on CD203a 
expression on macrophages, contrastingly it has been shown that IL-4 decreases 
expression of NPPl/CD203a (here named PC-1) on fibroblast-like synoviocytes, 
(Kehlen et al., 2001). These cells, however, are not an ideal comparison to be made 
with macrophages.
Alternative activation of porcine MoMos surprisingly did not affect the
percentage of cells expressing mannose receptor CD206, a well defined marker of
alternative activation of macrophages in humans and mice, which is often linked
with increased endocytic activity required for the clearance of damaged material
(Linehan et al., 2003; Martinez et al., 2006; Stein et al., 1992). The absence of
CD206 up-regulation in porcine M2 MoMos, however, also correlates with
unchanged endocytic or phagocytic activity. The reasons as to why porcine
macrophages do not express high levels of mannose receptor are uncertain, but an
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explanation could lie in the potential lack of cross-reactivity and hence affinity of the 
human antibody used to detect CD206 expression. The limited availability of a 
porcine specific anti-CD206 antibody is reflected in the literature, as the expression 
of CD206 on porcine cells is not reported elsewhere. It may be that others have also 
attempted using anti-human CD206 to no avail.
The putative PRRSV receptors CD 163 and CD 169 remained unchanged 
during classical Ml or alternative M2 activation of MoM0s. It was slightly 
surprising not to see any up-regulation of cells expressing CD 163 in M2 MoM0s, 
given that this is reported in many other studies of alternative macrophages in 
humans and mice, and as a scavenger receptor it is assumed to aid the clearance of 
damaged cells (Gordon, 2003). Experiments in the previous chapter of this thesis 
showed that the anti-CD 163 antibody worked well, and also identified IL-10 as a 
strong driver of CD 163 expression on monocytes. Although not measured in this 
study, M2 macrophages reportedly produce high levels of IL-10, which would be 
expected to enhance CD 163 expression on macrophages also. On the other hand, the 
result is in fact consistent with other data in Chapter 3 where IL-4 showed negative 
effects on CD 163 expression on monocytes. The result is, therefore, perhaps 
unsurprising, given that IL-4 may override the effects of low levels of autocrine IL- 
10. Furthermore, this result is supported by Ambarus et al (2012), where a similar 
methodology was used (treatment of human monocytes with M-CSF for 4 days 
before activation with IL-4), and no change in numbers of cells expressing CD 163 
was observed (Ambarus et al., 2012). In the same study, original experiments were 
also carried out with direct activation of monocytes, without prior differentiation, 
which highlights the variability of methodologies used across studies and the 
differences in data that can ensue.
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4.6.3. Dexa and IL-10 treatment of MoMos results in two further states
Morphological changes were observed following dexa and IL-10 treatment of 
MoMos, which were different to IFN-y/LPS and IL-4 induced changes. Although 
cell clusters also formed in both dexa and IL-10 treated MoMos, cellular elongations 
were absent. Dexa treated MoMos appeared more rounded, and although some large 
cells were observed, there were also a few smaller cells. In addition, fewer clusters 
were observed than those in IL-10 treated MoMos. This appearance, along with the 
reduced viability observed during flow cytometric analysis, is comparable to the 
‘condensed’ morphology of dexa treated human macrophages, which is proposed to 
be suggestive of increased cellular damage, caused by dexa through apoptosis and 
resulting in immune suppression, i.e. by reduction of macrophage numbers 
(Porcheray et al., 2005). This is perhaps consistent with the proposed deactivation 
state described of dexa treated macrophages (Gordon, 2003).
Despite the suggestion that IL-10 is another stimulator of alternative 
macrophage activation, it is recognised elsewhere that it induces different effects on 
the morphology of macrophages than IL-4/IL-13; IL-10 is described to induce more 
rounding of cells than fusion (Gordon, 2003). The morphology observed in this 
study are in agreement in that IL-10 treated MoM0s were certainly more rounded 
than the IL-4 treated, but cells are closely clustered and perhaps fusing. In contrast, 
Rey-Giraud et al do not report any changes in the morphology of IL-10 treated 
human macrophages (Rey-Giraud et al., 2012).
In contrast to classical and alternative activation, the percentage of CD 163 
expressing cells was significantly up-regulated by both dexamethasone and IL-10 
treatment of porcine MoM0s. This is consistent with data in the Chapter 3 which
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showed both of these factors increased the percentage of porcine monocytes 
expressing CD 163, supported by Ambarus et al as discussed (Ambarus et al., 2012). 
An over-expression of CD 163 was also, however, described on differentiated 
macrophages treated with dexa and IL-10, albeit this study used a different 
differentiation approach of M-CSF and GM-CSF together to treat 3 day old 
monocytes and considering them to be differentiated by day 8 (Porcheray et al., 
2005).
Both dexa and IL-10 treated MoM0s showed significantly lower percentages 
of cells expressing CD83, whilst only IL-10 induced a decrease in the percentage 
expressing CD80/86. The decrease of these maturation markers is interesting, given 
that dexa (and other glucocorticoids) and IL-10 are often considered to cause the 
‘deactivation’ of macrophages. Deactivation of macrophages is still a poorly 
understood concept, however, is thought to be the final stage of activation, where the 
inflammatory functions of macrophages are suppressed, halting inflammation and 
tissue damage (Gordon, 2003), and the macrophage undergoes functional changes to 
help clear debris (Gordon and Martinez, 2010). The decrease in cells expressing 
such co-stimulatory markers observed here, which are important in antigen 
presentation, may relate to this, as the lack of such markers would reduce antigen 
presentation.
IL-10, perhaps more so than dexa, is often confused with IL-4 as a driver of 
alternative macrophages. In this study, the only similarity of IL-10 treated MoMos 
with IL-4 treated MoM0s was the up-regulation of cells expressing SWC9. This has 
not been shown before, and is not a known feature attributed to alternative activation 
of macrophages. Since IL-10 treated MoMos are otherwise phenotypically 
distinguishable from the IL-4 treated MoMos, this study is in agreement with
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previous suggestions that IL-4 and IL-10 should be distinguished from one another. 
Interestingly, IL-10, like IL-4, is said to increase CD206 mannose receptor 
expression (Martinez-Pomares et al., 2003), and decrease MHCII expression 
(Montaner et al., 1999). Although the data of this study are not consistent with these 
reports, IL-10 was found to significantly increase endocytosis activity regardless of 
unchanged mannose receptor expression, suggesting that uptake here is not 
dependent of CD206.
4.6.4. Dexa and IL-10 treated MoMos showed enhanced uptake function
Whether differences in endocytic and phagocytic activity should be expected 
between classical and alternative activation is uncertain. M2 macrophages are said 
to display high endocytic activity in order to fulfil their role in the clearance of 
damaged or apoptotic cells (Gordon, 2003). Whilst many reports support that 
alternative activation of macrophages is associated with increased phagocytic 
activity, both in the earlier original studies on mice and more recent human ones 
(Rey-Giraud et al., 2012; Stein et al., 1992), phagocytic activity has also shown to be 
higher in classically activated mouse macrophages (Vereyken et al., 2011). In the 
present study, neither IFN-y/LPS nor IL-4 treatment induced any changes in 
endocytosis or phagocytosis, which may suggest that the porcine MoM0s were not 
entirely activated and may have required a further stimulus to function as activated 
macrophages. There are no other reports to date, however, on the endocytic or 
phagocytic activity of porcine monocyte derived macrophages that this data can to be 
compared to.
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Endocytosis and phagocytosis are mediated by the mannose receptor CD206, 
but no changes were observed here in the expression of CD206 across different 
macrophage treatments. Despite this, both uptake functions were affected by dexa 
and IL-10 treatment, where dexa enhanced phagocytosis and IL-10 enhanced 
endocytosis. IL-10 has previously been shown to enhance the endocytic activity of 
macrophages (Montoya et al., 2009), and also in monocyte derived DCs (Longoni et 
al., 1998). In contrast, however, IL-10, along with IFN-y, were both shown to 
decrease mannose-mediated uptake of macrophages, in comparison to IL-4 and IL- 
13, which up-regulated uptake (Montaner et al., 1999).
Dexa treated MoMos showed the highest phagocytic activity, which was later 
confirmed by confocal microscopy, where up to 5 particles could be seen inside 
cells. Although early reports suggest that dexa suppresses the phagocytic activity of 
macrophages (Becker and Grasso, 1985), this result is in line with the more recent 
studies using human monocyte derived macrophages showing that dexa enhances 
phagocytosis (Zahuczky et al., 2011). Increased uptake is not a feature associated 
with the proposed ‘deactivation’ of macrophages suggested by dexa and other 
glucocorticoids, and also by IL-10. As anti-inflammatories, glucocorticoids are 
known inhibitors of various immune reactions (Stone et al., 1990). Glucocorticoids 
are also thought to skew macrophage activation to a M2 phenotype, by increasing the 
stimulation of IL-4 production and inhibiting IFN-y production by T-cells, which 
would bias the inflammatory response to an M2 type (Blotta et al., 1997; DeKruyff 
et al., 1998). Given that IL-4 treated MoM0s did not show increased phagocytic 
activity and showed a different morphology, it would appear that porcine 
macrophages do not skew to an M2 phenotype following dexa treatment.
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The lack of CD206 modulation by dexa and IL-10 could suggest that forms 
of uptake not mediated by mannose receptor, such as pinocytosis, had occurred. 
However, since ovalbumin and the microsphere particles were the correct sizes for 
endocytosis and phagocytosis respectively, it is more likely that the problem lies 
with the CD206 staining.
In order to compensate for what might have not been fully representative 
methodology, the analysis of microarray data would have been advantageous here. 
RNA was extracted from MoM0 subsets and applied to a porcine pan-genome 
microarray, however the analysis of this data is ongoing. Once complete, however, 
this data will be used to compare the regulation of genes identified to distinguish 
human activated macrophages, such as those responsible for CD206 and CD25 
expression (Martinez et al., 2006). The analysis will strengthen the characterisation 
carried out so far, and give further insight into the pathways induced upon activation. 
Genes associated with phagocytosis have been identified in human macrophages; 
sphingosine, known to inhibit phagocytosis, and ceramide kinase, known to enhance 
phagocytosis, were identified in M l and M2 macrophage transcriptomes respectively 
(Martinez et al., 2006).
4.6.5. PRRSV susceptibility varies across different MoMo subsets
Previous studies of viral and bacterial pathogens have suggested that 
differences between susceptibility of pig breeds or individuals within pig breeds are 
correlated with differences in macrophage activation states (Ait-Ali et al., 2007). It 
is suggested that PRRSV has strongly restricted tropism for only certain populations 
of monocytes/macrophage and that specific differentiation and activation states
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considerably affect their susceptibility (Duan et al., 1997a). As well as PRRSV, it is 
suggested that susceptibility to African Swine Fever Virus is likely to be related to 
monocyte/macrophage phenotype (McCullough et al., 1993).
Dexa was able to significantly enhance the replication of PRRSV in MoMos, 
an effect also observed on monocytes in Chapter 3, but values of AACt in MoM0s 
were relatively low in comparison to that observed in monocytes; AACt values of 
dexa treated MoM0s were almost half of what was observed in dexa treated 
monocytes. In support of the data in Chapter 3, the effect of dexa on the 
permissiveness of MoM0s to PRRSV was associated with a positive effect on 
CD 163 expression also. However, in contrast to monocytes, dexa did not induce a 
significant increase in CD 169 expression on MoM0s, albeit levels of cells expressing 
CD 169 were already high and similar to those expressing CD 163. CD 163 is 
considered essential for PRRSV genome release (Calvert et al., 2007), although 
PRRSV entry reportedly also requires CD 169 (Vanderheijden et al., 2003). The fact 
that dexa could still significantly increase PRRSV replication with a significant 
effect on CD 163 alone, could suggest that CD 169 plays a less significant role in 
PRRSV infection than CD 163, as was proposed also in Chapter 3 when IL-10 
increased PRRSV replication following up-regulation of cells expressing CD 163 
only. This is supported by the recent work of Prather et al, stating that CD 169 is not 
required for PRRSV attachment (Prather et al., 2013). Dexa treated MoM0s were 
also characterised by increased phagocytic activity, although this is unlikely to be 
linked with their enhanced susceptibility to PRRSV since PRRSV is reported to enter 
cells via receptor mediated endocytosis (Van Breedam et al., 2010a).
Although the difference between dexa treated MoM0s and unstimulated 
MoM0s was significant when measured at 16 hours post p.i, the difference was not
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maintained throughout additional time-points, suggesting that dexa is only effective 
after one round of viral replication. Surprisingly, however, none of the MoM0 
subsets increased in their replication in cells over time.
Having observed no changes in the expression of PRRSV receptors CD 163 
and CD 169 following classical and alternative activation of MoMos, it was not 
expected for M l or M2 to show any enhanced susceptibility to PRRSV. However, it 
was not expected that Ml macrophages would show such low AACt values, reaching 
negative values up to 48 hours p.i. Remarkably, at 72 hours p.i, replication of Ml 
MoM0s returned to levels similar to all other subsets. These changes could be 
linked with the effects of IFN-y used to activate MoM0s. A strong anti-viral effect is 
expected of IFN-y, and its relevance in PRRSV for the clearance of virus and 
avoidance of immune response is well documented. Similarly to this study, IFN-y 
has been shown to inhibit PRRSV replication in vitro (Bautista and Molitor, 1999; 
Rowland et al., 2001). Furthermore, PRRSV has been shown to increase the number 
of IFN-y producing yô-T-cells (Olin et al., 2005), and increased IFN-y m-RNA has 
been reported in the blood of Lena infected pigs (Weesendorp et al., 2013). The 
detection of PRRSV replication in Ml MoM0s after 72 hours could be related to a 
change in the anti-viral effect of IFN-y, which is expected to change in its activity 
over time. In Chapter 3, a negative effect of IFN-y on CD 163 expression and on 
PRRSV replication in monocytes was suggested, although not confirmed by 
statistical significance. Classically activated Ml macrophages are also characterised 
by increased production of a number of pro-inflammatory cytokines, including IL-6. 
This may have some relevance to this finding, since IL-6 was shown in Chapter 3 to 
inhibit PRRSV replication in monocytes.
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Porcine M2 MoMos, treated with IL-4 for alternative activation, did not 
show any differences in PRRSV replication in cells with unstimulated MoMos. This 
was perhaps surprising, given that alternatively activated macrophages reportedly 
produce high levels of IL-10, shown to enhance PRRSV replication in monocytes in 
Chapter 3. Conversely, IL-4 was shown to down-regulate the percentage of 
monocytes expressing CD 163 and CD 169, and so it may also have had a negative 
effect on the susceptibility of M2 MoMos to PRRSV.
IL-10 treated MoMos themselves, despite showing increased percentage of 
CD 163 positive cells, did not show increased PRRSV replication in cells. However, 
IL-10 MoMos were the only subset to increase their replication in cell supernatant at 
each time-point p.i, up to 48 hours. There are few reports which discuss the release 
of PRRSV from infected cells, but it is clear here that IL-10 encourages the release 
of virions into cell supernatant, an effect which is not previously described of IL-10. 
At 72 hours p.i, PRRSV replication in IL-10 MoMos decreased, suggesting that 
many of the cells had died by this point. On the other hand, it could be that IL-10 
prolongs the survival of MoMos better than the other factors could. In hindsight, it 
would have been advantageous to measure the effect of all activating factors used to 
treat MoMos on cell viability following infection at each time-point. As discussed in 
Chapter 3, PRRSV has many associations with IL-10, with some PRRSV strains 
inducing IL-10 production in order to evade the immune response (Flores-Mendoza 
et al., 2008; Suradhat et al., 2003). The role of IL-10 could potentially be to increase 
the release of virus from cells in order to avoid detection and hence presentation to 
T-cells, which may provide an additional theory as to why some PRRSV strains 
induce IL-10 as an evasion strategy.
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PRRSV detection in the cell supernatant of all MoM0 subsets was lower than 
that in cells at 16 hours p.i, but following longer periods of infection (>24 hours p.i), 
more replication was observed in supernatant than in cells. All MoM0 subsets 
appeared to increase their replication in cell supernatant over time, however the only 
significant differences observed between time-points were with IL-10, as discussed, 
and also with dexa MoM0s, which showed a significant increase between 16 and 48 
hours p.i, suggesting that an additional round of replication had taken place. It was 
noticed that the qPCR data from cell supernatants was more variable than that of 
cells, and it could not be normalised to an endogenous control like cell data was, 
which may have compromised the significance of data. The increased replication in 
cell supernatant compared to that of cells shows that PRRSV is quickly eliminated 
from cells. Although many studies have investigated the entry of PRRSV into cells, 
there are few studies describing virus shedding from cells, but it is thought that 
progeny virus is released first by exocytosis and eventually by cell lysis. It is 
reported that in alveolar macrophages, one round of PRRSV replication takes 9-12 
hours, but this is variable between virus strains (Morilla, 2002). This suggests that 
further replication rounds have occurred within the time-points measured in this 
study, although since we did not see an increase in replication within cells, perhaps 
virus release is quicker with each new round of replication. It should also be 
remembered that the supernatant of infected cells will have contained other factors 
such as cytokines and other soluble mediators which may have affected the amount 
of virus in the supernatant, and this is likely to have varied between MoM0 subsets 
given the factors used to activate them.
Dexa treated MoM0s were the only MoM0 subset in which any PRRSV 
protein was detected by SDOW-17 flow cytometric staining, which was surprisingly
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low in unstimulated and all other MoM0s subsets. The low levels of SDOW-17 
staining of PRRSV infected MoM0 was surprising, because monocytes were stained 
well using the same method in Chapter 3. It is therefore more likely that the low 
levels of staining are due to the low levels of replication in MoM0s in comparison to 
monocytes, highlighted by the differences in AACt by qPCR. Since macrophages are 
considered the favourable cell in PRRSV tropism, and that monocytes alternatively 
are considered refractory to PRRSV, it was not expected that MoM0s would be less 
permissive to PRRSV. Furthermore, also using SDOW-17 staining, Thacker et al 
detected up to ~38% of PRRSV infected monocyte derived macrophages, however 
this study used a higher m.o.i of 1 (Thacker et al., 1998). It could be suggested that 
PRRSV replication is slower in macrophages than in monocytes, but since 
replication in MoM0s did not significantly increase over time, this is uncertain. It 
should be considered, however, that using monocyte derived macrophages in vitro is 
perhaps less closely related to in vivo macrophages as fresh monocytes are to in vivo 
monocytes, and the methods used may therefore not fully recapitulate PRRSV 
infection of macrophages in vivo. Having characterised these cells as macrophage­
like cells through phenotyping and functional tests, however, it could be more simply 
that they require a higher viral load to kick-start successful infection. Using a higher 
multiplicity of infection (m.o.i) to infect cells would certainly have been 
advantageous to enable detection of viral protein in PRRSV infected MoM0s and 
hence identify differences between MoM0 subsets. However, this would have also 
compromised the aim of this thesis with regard to comparing PRRSV replication 
across different myeloid cells, i.e. monocytes, macrophages and dendritic cells.
Finally, preliminary experiments suggested that PRRSV infection may be 
able to suppress the phagocytosis function of macrophages. Whilst this requires
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further work, particularly using a higher m.o.i, it could suggest another mechanism 
of PRRSV evasion of the host immune response. It would also be interesting to 
assess whether the capacity of antigen presentation to T-cells would is also decreased 
following PRRSV infection.
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5. PORCINE DENDRITIC CELLS AND THEIR INTERACTION
WITH PRRSV
5.1. Rationale and aims
The interaction of PRRSV with dendritic cells (DCs) is less studied than with 
other myeloid cells. While the importance of DCs in PRRSV is indefinite, it is 
unlikely that their role is solely a minimal one given that they are highly important 
APCs in innate and adaptive immunology (Banchereau and Steinman, 1998). 
Despite this, reports informing the understanding of European PRRSV-1 interaction 
are often conflicting, whereas it is well known that the North American genotype, 
PRRSV-2, infects DCs.
Like other myeloid cells, DCs are a variable population and many distinct 
subsets are thought to exist (Guilliams et al., 2010; Shortman and Liu, 2002) . DC 
subsets can be distinguished by differentiation and maturation, and are defined in 
humans as early stage immature DC (iDC) and mature DC (mDC) (O'Doherty et al., 
1994). Following the successful generation of DCs from mouse and human 
monocytes, resulting in monocyte derived dendritic cells (MoDC) (Peters et al., 
1996; Sallusto and Lanzavecchia, 1994; Schreurs et al., 1999), there have been some 
attempts to generate porcine MoDCs (Bautista et al., 2007; Carrasco et al., 2001; 
Johansson et al., 2003; Paillot et al., 2001). Different methods have been described 
however, including one using porcine autologous serum, a method not reproducible 
in other species and was not followed up further by others. Therefore, as the 
investigation of MoDC subsets in pigs remained elusive, the first aim of this chapter
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was to describe porcine monocyte derived DCs (MoDCs) in vitro, distinguishing 
immature (iMoDCs) and mature (mMoDCs) by phenotypical and functional analysis. 
Moreover, since previous findings have suggested a correlation of CD 163 and 
CD 169 with PRRSV infection of myeloid cells, the expression of these receptors 
was also assessed. Furthermore, having demonstrated a potential importance of 
dexamethasone and IL-10 for the replication of PRRSV in myeloid cells, MoDCs 
were also treated with these factors. Finally, MoDC subsets were infected with 
PRRSV-1 to investigate the hypothesis that PRRSV-1 replicates in these MoDCs 
treated with a variety of factors and MoDC susceptibility correlates with CD 163 and 
CD 169 expression.
5.2. MoDC differentiation from monocytes using GM-CSF and IL-4
DCs can be differentiated in vitro from peripheral monocytes using the 
cytokines GM-CSF and IL-4, a method well described as a sophisticated DC model 
human and mouse systems (Chapuis et al., 1997; Kiertscher and Roth, 1996; 
Schreurs et al., 1999). For the pig, MoDCs have been generated in vitro from both 
bone marrow (Carrasco et al., 2001; Peng et al., 2009) and from blood monocytes 
(Carrasco et al., 2001; Paillot et al., 2001), for which various methods have been 
described. Bautista et al pointed out that IL-13 should replace IL-4 in swine MoDC 
differentiation, because IL-4 is not a prominent cytokine in some breeds (Bautista et 
al., 2007). However, as earlier studies showed porcine IL-4 to be biologically active 
on freshly isolated monocytes from the Large White Cross Landrace pigs used in this 
study, the use of IL-4, along with GM-CSF, for MoDC differentiation was 
continued.
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Due to the variety of cytokine concentrations used in other studies, it was 
necessary to optimise porcine MoDC differentiation. This was achieved by using 
morphological and phenotypic approaches to identify the correct concentrations of 
cytokines, and the ideal duration of cytokine treatment, for obtaining optimal 
dendritic cell-like features.
5.2.1. Morphology of monocytes treated with GM-CSF and IL-4
Porcine monocytes were isolated from peripheral blood mononuclear cells 
(PBMCs) using CD14+ isolation, as described in Chapter 2 section 2.2.1. Monocytes 
were cultured in full tissue culture medium supplemented with recombinant porcine 
GM-CSF and IL-4. A range of concentrations of GM-CSF and IL-4 were used, and 
compared in their effects on cell morphology, using light microscopy. The most 
dendritic cell like morphology was observed after 4 days of culture with 10 ng/ml of 
GM-CSF and 10 ng/ml of IL-4. It was clear that monocytes treated with GM-CSF 
and IL-4 had undergone considerable morphological changes in comparison to 
freshly isolated monocytes and monocytes untreated for 4 days (Figure 5.1 A-C). 
GM-CSF/IL-4 treated monocytes presented many typical structural features of DCs; 
MoDC were joined together in large clusters of cells and many cells expressed 
elongated projections from their surface (Figure 5.1 C).
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Figure 5.1. Morphology of GM-CSF/IL-4 treated monocytes. Fresh CD 14+ monocytes 
were obtained from peripheral blood (A), and were cultured for 4 days in media alone (B) or 
in media supplemented with porcine GM-CSF and IL-4 (C). Magnification is 20X.
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5.2.2. A nalysis o f G M -C SF and IL-4 treated  m onocytes phenotype
In order to demonstrate the notion that porcine monocytes treated with GM- 
CSF and IL-4 for 4 days had differentiated into MoDCs, flow cytometry was used to 
analyse the expression of cell surface molecules associated with DCs, and of some 
other markers of interest, such as the putative PRRSV receptors CD 163 and CD 169. 
GM-CSF/IL-4 treated monocytes expressed Major Histocompatibility Complex 
Class II (MHCII) (88% of cells), CD14 (41%), CD80/86 (62%), CD83 (56%), 
Dendritic cell-specific ICAM-3 grabbing non-integrin (DC-SIGN/CD209) (20%) 
and CD1 (33%) (all mean values), but displayed negligible expression of CD163 and 
CD169 (Figure 5.2), which could have a major impact on their ability to support the 
infection of PRRSV.
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Figure 5.2. GM-CSF and IL -4  treated monocyte expression of DC associated 
molecules. Peripheral blood monocytes were cultured for 4 days in medium supplemented 
with recombinant porcine GM-CSF and IL-4 before surface staining with anti-porcine or 
anti-human mono/polyclonal antibodies for flow cytometric analysis. Bars show mean 
percentage of cells expressing each marker +SD from 5 replicate experiments.
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5.3. In vitro maturation of MoDC
Morphological and phenotypical analysis confirmed that porcine monocytes 
treated with GM-CSF and IL-4 for 4 days represented cells with morphology and 
phenotype of immature MoDCs. Subsequently, it was important to assess the 
maturation of porcine MoDCs in vitro. DC maturation occurs in vivo in response to 
cytokines and other factors in the surrounding environment, released following 
recognition of ‘danger signals’ in the form of pathogen derived molecules (Mellman 
and Steinman, 2001; Sallusto and Lanzavecchia, 1994). In order to represent this in 
vitro, a cytokine maturation cocktail was used to treat MoDCs. This contained 
purified cytokines (IFN-y, IL-6, TNF-ot, IL-lp), lipopolysaccharide (LPS) and 
prostaglandin E2 (PGE2), known to be activators of DCs, as described for both 
human and equine MoDCs (Jonuleit et al., 2000; Moyo et al., 2013). The DC 
maturation cocktail was added to 4 day old MoDCs for 24 hours. The effects of the 
maturation cocktail were assessed according to MoDC morphology and phenotype, 
and compared with untreated/immature MoDCs (iMoDCs). Flow cytometric 
analysis was again used to measure the expression of various surface molecules on 
MoDCs, including some associated with human and mouse DC maturation. 
Molecules involved in antigen presentation, such as MHCII, CD80/86, CD83 and 
CD1 were measured, in addition to other co-stimulatory molecules and lineage 
markers. Putative PRRSV receptors, CD 163 and CD 169 were also measured, as 
carried out in previous chapters investigating other myeloid cells.
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5.3.1. M orphology o f  M aturation C ocktail Treated M oD C s
Light microscopy was used to assess any morphological differences 
following 24 hours of culture with the cytokine maturation cocktail. No obvious 
differences were observed with regard to the size or shape of MoDCs, however, it 
did appear that maturation cocktail treated MoDCs were less adherent, as the 
majority of cells in presented in more clusters than untreated MoDCs (Figure 5.3 A, 
B)
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Figure 5.3. Morphology of untreated MoDCs and maturation cocktail treated MoDCs.
Four day old MoDCs were either left untreated, (A), or treated for 24 hours with a 
maturation cocktail containing LPS, IFN-y, IL-6, TNF-a, IL-ip and PGE2 (B). Light 
microscopy photographs are representative of 3 biological replicates. Magnification is 20X.
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5.3.2. Phenotype of Maturation Cocktail Treated MoDCs
Flow cytometric analysis showed that the DC maturation cocktail induced 
some significant changes to MoDC phenotype. With regard to functional molecules, 
the percentage of cells positive for MHCII expression remained high in treated 
MoDCs (mean 91%). A significant increaese was observed in the expression of both 
CD80/86 (p<0.001) and CD83 (p<0.001) following maturation cocktail treatment, 
expressed on 75% and 70% of cells respectively (mean values) (Figure 5.4 A). The 
expression of CD1 was unchanged, with 33% of both iMoDC and treated MoDCs 
staining positive for expression (Figure 5.4 A).
With regard to other co-stimulatory molecules and DC lineage markers, the 
percentage of maturation cocktail treated MoDCs expressing CD 14 (mean 30%) was 
significantly lower than iMoDC (p<0.001). Whilst CD25 expression was relatively 
high, there was no change between untreated and treated MoDCs, of which 63% and 
65% expressed CD25 respectively (Figure 5.4 B). Other molecules CD206 and 
CD209 (DC-SIGN) remained low, as did porcine macrophage lineage marker 
SWC9. Finally, the percentage of cells expressing CD 163 and CD 169 was 
negligible in both untreated and treated MoDCs (Figure 5.4 B).
Despite the above changes in the percentage of cells expressing certain 
molecules, the mean fluorescence intensity of makers was not significantly changed 
by the maturation cocktail (Figure 5.4 C, D).
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Figure 5.4. The effect of maturation cocktail on porcine MoDC. 4 day old MoDC were 
treated with a maturation cocktail for 24 hours before flow cytometric analysis of surface 
molecules involved in DC maturation or antigen presentation (A, C) and other co­
stimulatory molecules and lineage markers (B, D) in untreated iMoDC (white bars) and 
cytokine maturation cocktail treated (blue bars) MoDCs. Bars show mean percentage of 
cells expressing each marker +SD (A, B) or the mean fluorescence intensity of markers (C, 
D) from 5 replicate experiments. Two-way ANOVA was used to assess significance 
followed by Bonferroni’s multiple comparison test, **p<0.001.
5.4. Dexamethasone and IL-10 treatm ent of MoDCs
The absence of putative PRRSV receptors CD 163 and CD 169 on both 
untreated MoDC and maturation cocktail treated MoDC was unexpected, especially 
since preliminary experiments had shown PRRSV infection of MoDC, as did one 
study by Silva-Campa et al (Silva-Campa et al., 2010). Having acknowledged that
dexamethasone (dexa) and IL-10 significantly increased both CD 163 and CD 169 on 
porcine monocytes and CD 163 on macrophages in Chapters 3 and 4, their effect on 
DCs was also assessed.
5.4.1. Morphology of dexa and IL-10 treated MoDCs
Immature MoDCs were treated with dexa or IL-10 for 24 hours before their 
morphology was analysed. Dexa treated MoDCs appeared to have fewer and less 
dense clusters than untreated MoDCs, but still expressed some cellular elongations 
(Figure 5.5 B). In contrast, IL-10 treated MoDCs appeared more similar to untreated 
MoDCs, with similar clusters although fewer cellular elongations (Figure 5.5 C).
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Figure 5.5. Morphology of untreated MoDCs and dexa or IL-10 treated MoDCs. Four 
day old MoDCs were either left untreated, (A), or treated for 24 hours with dexa (B) or IL- 
10 (C). Light microscopy photographs are representative of 3 biological replicates. 
Magnification is 20X.
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5.4.2. Phenotype of Dexa and IL-10 Treated MoDCs
As observed with treatment of MoDCs with the maturation cocktail, the 
percentage expression of MHCII on MoDCs remained high following dexa and IL- 
10 treatment. The percentage of cells expressing CD80/86 was also unchanged, and 
although IL-10 induced some down-regulation of cells expressing CD83, the 
difference was not significant. The percentage of cells expressing CD1 was up- 
regulated by dexa treatment, a difference which was significant from the percentage 
of IL-10 treated MoDCs expressing CD1 (p<0.05) but not from the percentage of 
iMoDCs (Figure 5.6 A).
More interesting changes in MoDC phenotype were observed with other co- 
stimulatory molecules and DC lineage markers. Dexa treatment significantly 
enhanced the percentage of MoDCs expressing CD 14 to 68% (mean value) 
(pO.OOOl), whilst percentage of IL-10 treated MoDCs expressing CD14 remained 
the same as in iMoDCs (Figure 5.6 B). In addition to increasing the percentage of 
cells expressing CD 14, dexa also significantly enhanced the mean fluorescence 
intensity of CD14 (p<0.001) (Figure 5.6). The percentage of cells expressing CD25, 
however, was decreased to 54% (mean value) following dexa treatment, significantly 
lower than iMoDC and IL-10 treated MoDC (p<0.0001). Dexa also had a significant 
effect on mannose receptor CD206, inducing a 2-fold increase in the number of cells 
expressing it on iMoDCs (p<0.0001), albeit levels were still relatively low (mean 
16%) in comparison to MoMos in Chapter 4, section 4.3.2. Finally, dexa also 
significantly increased the percentage of cells expressing CD209 (DC-SIGN) to 35% 
(p<0.05). (Figure 5.6 B). In contrast to previous findings with monocytes and 
MoM0s, neither dexamethasone nor IL-10 treatment affected the expression of
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CD 163 and CD 169 on MoDCs; the percentage of cells expressing these molecules 
remained less than 10% (Figure 5.6 B).
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Figure 5.6. The effects of dexamethasone and IL-10 treatment on the phenotype of 
porcine MoDCs. 4 day old MoDCs were treated with either dexamethasone or IL-10 for 24 
hours before surface staining with various anti-porcine or anti-human mono/poly-clonal 
antibodies for flow cytometric analysis of surface molecules involved in antigen presentation 
and maturation (A, C) or against other co-stimulatory molecules and myeloid lineage 
markers (B, D) in untreated MoDCs (unfilled bars), dexa treated MoDCs (blue bars), or 
IL-10 treated MoDCs (orange bars). Bars show mean percentage of cells expressing each 
marker +SD (A, B) or mean fluorescence intensity +SD (C,D) from 5 replicate experiments. 
One-way ANOVA was used to assess significance followed by Bonferroni’s multiple 
comparison test ***p<0.0001, **p<0.001, *p<0.05.
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5.5. Function of MoDC Subsets
Given that the major role of DCs is to present antigen to T-cells, the 
functional abilities of porcine MoDCs were also of interest. Having now generated 
four MoDC subsets, which were different in morphology and more so in their 
phenotypes, it was conceivable that such differences would also be reflected in their 
ability to endocytose and phagocytose particles, APC*-labelled ovalbumin (OVA) 
and FITC-labelled microsphere particles were used to investigate this uptake as per 
methods established in Chapter 4. Having identified a phenotype consistent with 
maturation, maturation cocktail treated MoDCs are consequently referred to as 
mature MoDCs (mMoDCs). The additional two MoDC subsets, treated with dexa or 
IL-10, are referred to as dexa MoDCs and IL-10 MoDCs.
5.5.1. The effects of maturation cocktail, dexa and IL-10 on MoDC endocytosis
Flow cytometric analysis showed that as expected, levels of endocytosis were 
much lower in MoDCs than those observed in MoMos in Chapter 4. The 
percentages of cells associated with OVA-APC*, as an indication of endocytosis, 
were unchanged between iMoDC and mMoDCs. In contrast, both dexa and IL-10 
treatment of MoDCs, appeared to increase endocytosis (Figure 5.7 Q, R). However, 
replicate experiments were variable, and therefore when summarised, only the dexa 
treated MoDCs showed a statistically significant increase in endocytic activity 
(p<0.05) (Figure 5.8).
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Figure 5.7. Flow cytometric analysis o f endocytosis in MoDC subsets. The ability of 
iMoDCs (untreated; first column), mMoDCs (maturation cocktail treated; second 
column), dexa treated MoDCs (third column), and IL-10 treated MoDCs (fourth column) 
to endocytose APC*-labelled OVA was assessed. Cells were incubated with OVA at 4°C as 
a negative control, or at 37°C, for 1 hour, before flow cytometric analysis of APC* 
fluorescence. Cells were first gated according to FSC/SSC (second row; C-F) and dead 
cells were eliminated using a LIVE/DEAD Violet dye (third row; G-J) before gating on the 
percentage of cells fluorescing APC*, at 4°C (fourth row; K-N), or 37°C (fifth row; O R) 
Percentages of cells fluorescing APC* are shown within pink boxes. MoDCs were analysed 
without OVA as an additional negative control (first row; A-B). Data are representative of 
3 replicate experiments.
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Figure 5.8. The effect o f dexa treatment on MoDC levels of endocytosis. The ability of 
immature/iMoDC (untreated), mature/mMoDC (maturation cocktail treated) to endocytose 
APC*-labelled OVA was assessed. Cells were incubated with OVA at 4°C as a negative 
control (blue dots), or at 37°C (red dots), for 1 hour before flow cytometric analysis of 
APC* fluorescence. Each dot represents the percentage of cells fluorescing APC*, 
indicating endocytic OVA uptake, in individual experiments. Lines represent mean 
percentages of cells associated with OVA-APC* ±SEM of 3 replicate experiments. One­
way ANOVA was used to assess significance followed by Bonferroni’s multiple comparison 
test, *p<0.05.
5.5.2. The effects of maturation cocktail, dexa and IL-10 on MoDC 
phagocytosis
Levels of phagocytosis in MoDC subsets also appeared to be less than those 
observed in MoMos in Chapter 4, and only slight differences between levels at 4°C 
and 37°C. Whilst maturation cocktail treatment of MoDCs did not induce any 
changes, IL-10 treated MoDCs showed significantly higher percentages of cells 
associated with FITC-labelled particles compared to iMoDCs and mMoDCs 
(p<0.05) (Figure 5.9 and Figure 5.10).
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Figure 5.9. Flow cytometric analysis of MoDC phagocytosis. The ability of untreated 
immature/iMoDCs (first column), maturation cocktail treated mature/mMoDCs (second 
column), dexa treated MoDCs (third column) and IL-10 treated MoDCs (fourth column) 
to phagocytose FITC-labelled 4pm microsphere particles was assessed. Cells were 
incubated with FITC-particles at 4°C as a negative control, or at 37°C, for 3 hours before 
flow cytometric analysis of FITC fluorescence. Cells were first gated according to FSC/SSC 
(second row; C-F) and dead cells were eliminated using a LIVE/DEAD Violet dye (third 
row; G-J) before gating on the percentage of cells fluorescing FITC following incubation at 
4°C (fourth row; K-N) or at 37°C (fifth row; O R). Percentages of cells fluorescing FITC 
are shown within pink boxes. Data are representative of 4-5 replicate experiments. MoDCs 
were analysed without particles as an additional negative control (first row; A-B).
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Figure 5.10. The effect of IL-10 treatment on MoDC levels of phagocytosis. The ability 
of untreated immature/iMoDC, maturation cocktail treated mature/mMoDC, dexa treated 
MoDC and IL-10 treated MoDC to phagocytose FITC-labelled microsphere particles was 
assessed. Cells were incubated with particles at 4°C as a negative control (blue dots), or at 
37°C (red dots), for 3 hours before flow cytometric analysis of FITC fluorescence. Each 
dot represents the percentage of cells fluorescing FITC, indicating phagocytic uptake, in 
individual experiments. Lines represent the mean percentage of cells associated with FITC 
microsphere particles ±SEM from 4-5 replicate experiments. One-way ANOVA was used to 
assess significance followed by Bonferroni’s multiple comparison test *p<0.05.
5.6. PRRSV Infection of MoDC Subsets
The assessment of MoDC morphology, phenotype and uptake following 
treatment with a cytokine maturation cocktail, dexa, or IL-10, showed that four 
MoDC subsets could be generated in vitro; iMoDC, mMoDC, dexa MoDC and IL- 
10 MoDC. Given that a variety of differences with regard to phenotype and function 
were observed between MoDC subsets, the final hypothesis to be investigated was 
that the interaction of these subsets with PRRSV would also differ. To assess MoDC 
interactions with PRRSV, three different aspects of infection were assessed. Firstly, 
viral replication within MoDCs, using viral RNA extracted from cells for qPCR
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analysis. Secondly, viral production by MoDCs in cell supernatants, using viral 
RNA extracted from cell supernatant for qPCR analysis. Finally, production of viral 
protein by MoDCs was assessed, using PRRSV monoclonal antibody (mAb) 
SDOW-17 to stain MoDCs intracellularly for flow cytometric analysis. Given the 
uncertainty of the time required for one PRRSV replication cycle in MoDCs, and to 
allow a parallel comparison with MoM0 studies, MoDCs were infected for a range 
of incubation periods between 16 and 72 hours. Also to maintain parallels with 
monocyte and MoM0 studies, MoDCs were infected with the same PRRSV strain 
Lena and using the same multiplicity of infection (m.o.i) of 0.1.
5.6.1. Assessment of PRRSV Replication in Cells (MoDCs)
The first aim was to assess the susceptibility of MoDC subsets to PRRSV on 
a cellular level, using qPCR to analyse RNA extracted from MoDCs, or flow 
cytometric analysis using the PRRSV mAb SDOW-17. To ensure comparisons 
between MoDC subsets were of equal cell numbers, qPCR data was normalised to an 
18S rRNA endogenous control using the AACt comparative method.
5.6.1.1. PRRSV replication in MoDCs measured by qPCR analysis
At 16 hours p.i, qPCR analysis showed that viral replication was relatively 
low in MoDC subsets, represented by low AACt values. All AACt values in MoDCs 
were less than 5 at this time point, with the highest value of 4.8 shown in mMoDCs. 
This was significantly higher than that observed in dexa MoDC (p<0.05), but no 
significant differences were observed between other MoDC subsets (Figure 5.11 A).
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At 24 hours p.i, viral replication in untreated/iMoDCs appeared to increase in AACt 
from 3.4 to 6.2, although surprisingly this was not a significant difference (Figure 
5.12). Viral replication in other MoDC subsets did not show increased AACt and 
remained below 5, and no significant differences were shown between subsets 
(Figure 5.11 B). After 48 hours p.i, viral replication in some MoDC subsets showed 
slight increases in AACt to mean values of 5.9 (mMoDC), 5.3 (dexa MoDC) and 5.8 
(IL-10 MoDC), although these differences were not significant (Figure 5.11 C). 
After 72 hours p.i, viral replication in all MoDC subsets decreased in replication and 
AACt levels were less than 4 in all MoDC subsets. Surprisingly, viral replication in 
mMoDCs showed negative AACt values, indicative of no replication after this time 
point (Figure 5.11 D). There were no differences between AACt values across 
MoDC subsets.
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Figure 5.11. qPCR detection o f PRRSV replication in MoDC subsets at 16, 24, 48 and 
72 hours post infection. Monocytes were treated with GM-CSF and IL-4 for 4 days to 
generate MoDCs, and four subsets were generated; untreated immature/iMoDC, maturation 
cocktail treated mature/mMoDC, dexa treated MoDC and IL-10 treated MoDC, before 
infection with PRRSV Lena using an m.o.i o f 0.1. Viral RNA was extracted from cells at 
either 16 (A), 24 (B), 48 (C) or 72 hours p.i (D), and a TaqMan qPCR with an 18S 
endogenous control was used to obtain Ct values. AACt represents difference between Ct at 
2 hours p.i (time zero) and Ct at each time point p.i, both normalised to 18S. Bars represent 
mean AACt +SD. One-way ANOVA was used to assess significance followed by 
Bonferroni’s multiple comparison test (n=3), each biological repeat was tested in duplicate), 
*p<0.05.
When MoDC subsets were compared over time, no significant differences 
were observed in AACt values for viral replication in any of the MoDC subsets 
(Figure 5.12).
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Figure 5.12. PRRSV replication over time in MoDC subsets. Monocytes were treated 
with GM-CSF and IL-4 for 4 days to generate MoDCs, and four subsets were generated; 
untreated Immature/iMoDC (red), maturation cocktail treated mature/mMoDC (green), dexa 
treated MoDC (orange) and IL-10 treated MoDCs (blue) before infection with PRRSV Lena 
using an m.o.i of 0.1. Viral RNA was extracted from cells at 16, 24, 48 or 72 hours p.i, and 
a TaqMan qPCR was used to obtain Ct values. AACt represents difference between Ct at 2 
hours p.i (time zero) and Ct at each time point p.i, both normalised to an 18S endogenous 
control. Dots represent mean AACt values ± SD from 3 replicate experiments. One-way 
ANOVA was used to assess significance followed by Bonferroni’s multiple comparison test 
(n=3), each biological repeat was tested in duplicate.
5.6.1.2. Assessment of MoDC susceptibility to PRRSV using flow cytometric 
SDOW-17 staining
MoDCs were stained intracellularly at 20 hours p.i for the detection of 
PRRSV protein using the SDOW-17 mAb as used in previous chapters. Although 
PRRSV replication in MoDCs was detected by qPCR analysis, infection could not 
yet be detected by flow cytometry (Figure 5.13).
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Figure 5.13. Flow cytometric analysis of PRRSV infected MoDCs. Four subsets of porcine 
MoDCs (untreated immature/iMoDC [first column], maturation cocktail treated 
mature/mMoDC [second column], dexa treated MoDC [third column] and IL-10 treated MoDC 
[fourth column])were infected with PRRSV Lena using an m.o.i of 0.1. At 20 hours p.i, MoDCs 
were harvested and stained intracellularly with PRRSV mAb SDOW-17 and secondary anti­
mouse APC*. MoDCs were first gated according to FSC/SSC (first line; A D), then dead cells 
eliminated by LIVE/DEAD Violet stain (second line; E-H), before gating on cells fluorescing 
APC*, percentages of which are shown within the pink boxes, shown for negative controls G1 - 
APC* secondary only (third line; I-L) and anti-mouse IgGl isotype control (fourth line; M-P), 
and for SDOW-17 APC* staining of Lena infected cells (fifth line; Q-T) and o f mock infected 
cells (sixth line; Lf-X). Data are representative of three replicate experiments.
5.6.2. Assessment of PRRSV Replication in MoDC cell supernatant
In addition to measuring PRRSV replication in MoDCs, the amount of virus 
produced in the cell supernatant was also measured using qRT-PCR, but without the 
same 18S normalisation applied for analysis of cells. However, an equal volume of 
supernatant was taken from all cell subtypes, so their replication will have been 
normalised to some extent. At 16 hours p.i, PRRSV replication in MoDC 
supernatant was negligible in all subsets (Figure 5.14 A), and remained so at 20 
hours p.i, with the exception of IL-10 treated MoDCs which showed a ACt value of 
1.8 (Figure 5.14 B). At 24 hours p.i, only dexa and IL-10 treated MoDCs showed 
ACt values greater than 1, but these only reached 1.3 and 1.1 respectively (Figure 
5.14 C). A slight increase was observed at 36 hours p.i in all MoDC subsets other 
than iMoDCs (Figure 5.14 D). At 48 hours p.i, however, no obvious changes were 
observed in ACt (Figure 5.14 E). Similar to that observed in the assessment of 
PRRSV replication in MoDCs cellular RNA at 72 hours p.i, the mean ACt value of 
mMoDC supernatant was negative, indicating no PRRSV replication, whilst all other 
MoDCs did not show any changes (Figure 5.14 F). Although statistical tests were 
performed, data between biological repeats were variable and no significant 
differences were observed between MoDC subsets at individual time-points.
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Figure 5.14. PRRSV replication in MoDC supernatant between 16 and 72 hours p.i.
Monocytes were treated with GM-CSF and IL-4 for 4 days to generate MoDCs, and four 
MoDC subsets were generated; untreated/immature iMoDC, maturation cocktail treated 
mature mMoDC, dexa treated MoDC and IL-10 treated MoDC for 24 hours before infection 
with PRRSV Lena using an m.o.i o f 0.1. Viral RNA was extracted from cell supernatant at 
either 16 (A), 20 (B), 24 (C), 36 (D), 48 (E) or 72 (F) hours p.i, and TaqMan qPCR was 
used to obtain Ct values. ACt represents difference between Ct at 2 hours p.i (time zero) and 
Ct at each time point p.i. Bars represent mean ACt +SD from 3 replicate experiments, each 
biological repeat tested in duplicate. One-way ANOVA was used to assess significance 
followed by Bonferroni’s multiple comparison test.
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Each MoDC subset was compared across time-points p.i. Statistical tests 
were performed, although no significant differences were observed (Figure 5.15).
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Figure 5.15. PRRSV replication over time in the supernatant of MoDC subsets.
Monocytes were treated with GM-CSF and IL-4 for 4 days to generate MoDCs, and four 
subsets were generated; untreated immature/iMoDC (red), maturation cocktail treated 
mature/mMoDC (green), dexa treated MoDC (orange) and IL-10 treated MoDCs (blue) 
before infection with PRRSV Lena using an m.o.i of 0.1. Viral RNA was extracted from 
cell supernatants at 16, 20, 24, 36, 48 or 72 hours p.i, and a TaqMan qPCR was used to 
obtain Ct values. ACt represents difference between Ct at 2 hours p.i (time zero) and Ct at 
each time point p.i. Dots represent mean ACt values ± SD from 3 replicate experiments. 
One-way ANOVA was used to assess significance followed by Bonferroni’s multiple 
comparison test (n=3), each biological repeat was tested in duplicate.
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5.7. Discussion
In this chapter, porcine monocyte derived DCs (MoDCs) were used as a 
model system to characterise porcine myeloid dendritic cells. In addition to 
analysing MoDCs by morphology, phenotype and function, the interaction of 
MoDCs with PRRSV was investigated. Similar to monocytes and monocyte derived 
macrophages (MoM0s), recent studies have highlighted some heterogeneity 
regarding DCs, with reference to changing maturation states. This chapter, 
therefore, aimed to generate and compare immature (iMoDC) and mature (mMoDC) 
subsets. Having investigated the effects of dexa and IL-10 on monocytes and 
MoMos, these factors were also used to stimulate MoDCs. Consequently, the 
susceptibility of MoDCs to PRRSV was addressed, and compared across immature 
MoDC, mature MoDC, dexa treated MoDC and IL-10 treated MoDC.
5.7.1. GM-CSF and IL-4 treatment of monocytes results in MoDC 
differentiation
Given that studies of porcine MoDC are few, and different methods of 
generating MoDC in pig were reported, it was necessary to first optimise the 
differentiation of porcine MoDCs from monocytes. DC morphology was observed 
using equal amounts of GM-CSF and IL-4; 10 ng/ml of each, for 4 days. This 
morphology was typical of human DC morphology, in that cells were clustered 
together and elongated projections protruded from cell surfaces (Chapuis et al., 
1997), and is fitting with the morphology of porcine MoDCs described by others 
(Carrasco et al., 2001; Paillot et al., 2001). Equal amounts of these cytokines are not 
always used in MoDC differentiation protocols, however, as ultimately it is not the
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amount of cytokine applied but the bioactivity which is important. Whilst some 
other studies waited up to 7 days for differentiation of iMoDC, it was considered in 
the present study that 4 days was sufficient for differentiation and it appeared that 
prolonged culture increased cell death (not shown).
Phenotypical analysis demonstrated the expression of DC associated markers 
on GM-CSF/IL-4 treated monocytes including MHCII, CD 14, CD80/86, CD83, CD1 
and CD209 (Dendritic cell-specific ICAM-3 grabbing non-integrin [DC-SIGN]), 
which compares well with the review by Summerfield et al concluding that porcine 
MoDCs are CD1+ CD14+ CD16+ CD80/86+ CD172a+ M H C lf (Summerfield and 
McCullough, 2009). In the present study, CD 16 and CD 172a were not measured, 
although CD 172a is a pan-myeloid marker with little relevance for DCs. The fact 
that the mean value of cells expressing MHCII here (89%) was identical to that of 
porcine MoDCs reported by Park et al (Park et al., 2008), despite using a shorter 
culture period and lower cytokine concentrations indicates that a full differentiation 
was achieved in this system. The percentage of GM-CSF/IL-4 treated monocytes 
which expressed MHCII, a molecule essential for antigen presentation, was twice 
that observed on MoM0s in Chapter 4. Furthermore, the expression of CD 14, 
involved in LPS detection and phagocytosis, was less than that observed in MoMos. 
Since the primary function of DCs is to present antigen, in comparison to 
macrophages which are predominantly involved in phagocytosis, the differences in 
MHCII and CD 14 expression confirmed that two different cell types were generated 
from porcine monocytes, and expressed molecules fitting their individual diverse 
functions.
More than 50% of GM-CSF/IL-4 treated monocytes expressed CD80/86 and
CD83, which are considered maturation markers in the human system in particular
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(Weissman et al., 1995; Zhou and Tedder, 1996). However, it has been suggested 
that such a distinct difference between iMoDC and mMoDC does not exist in all 
species, as is shown in horses where immature MoDCs express CD83 (Mauel et ah, 
2006, Moyo et al., 2013). GM-CSF and IL-4 treated monocytes also expressed DC 
specific molecules CD1 and CD209/DC-SIGN. DC-SIGN expression confirmed 
MoDC differentiation as it is IL-4 dependent and hence MoDC specific, with 
reported roles in DC migration and in DC-T-cell interactions (Curtis et al., 1992; 
Geijtenbeek et al., 2000b; Geijtenbeek et al., 2000c). Unlike DC-SIGN, the CD1 
system of livestock species, specifically in pigs, is presumed different to that 
described in humans (Chun et al., 1999). It is, therefore, difficult to interpret the 
expression of CD1 by porcine MoDCs, however, it has been suggested that porcine 
CD1 behaves like the CD la  molecule expressed by human DCs (Carrasco et al., 
2001). With regard to the majority of molecules measured, phenotypical analysis of 
GM-CSF/IL-4 treated monocytes, together with morphological analysis, showed 
several DC-features, indicating that these cells are likely to have differentiated to 
monocyte derived DCs (MoDCs).
5.7.2. Porcine MoDCs show maturation in response to a cytokine maturation
cocktail
Having established porcine MoDC differentiation from monocytes, it was 
subsequently important to assess the maturation of MoDCs. The maturation cocktail 
used to treat MoDCs contained a variety of factors able to initiate an up-regulation of 
downstream inflammatory genes in cells, in order to represent ‘danger signals’ in 
vivo, and was similar to the ‘gold standard’ maturation cocktail used in many DC
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based vaccination studies. The reported gold standard cocktail contains TNF-a, IL- 
1-P, IL-6 and PGE2 (Jeras et al., 2005), which was used with the addition of IFN-y 
and LPS in this study . IFN-y and TNF-a are often used together in DC maturation 
due to the mixed Thl and Th2 type phenotypes that result in the up-regulation of 
downstream inflammatory genes, and LPS has been shown to induce porcine MoDC 
maturation when used with TNF-a and IFN-a (Guzylack-Piriou et al., 2006).
The cytokine maturation cocktail treated MoDCs did not induce significant 
morphological changes that could be detected by light microscopy, other than a 
slight increase in the number of cell clusters. Increased cell clusters are also reported 
in human MoDC (Jeras et al., 2005), however, other studies also report increased cell 
size and increased dendritic elongations in both human and of porcine MoDC, which 
were not so obvious in the present study using light microscopy, in contrast to the 
scanning electron microscopy used in other studies (Lagaraine et al., 2005; Pilon et 
al., 2009).
Whilst the effects of the maturation cocktail were minimal on the 
morphology of MoDCs, its effects on MoDC phenotype were far more significant. 
The induction of MoDCs to express molecules involved in antigen presentation 
confirmed maturation of MoDCs. The percentage of MoDCs expressing MHCII 
remained high on maturation cocktail treated MoDCs, but could not be considered 
significantly different to untreated/immature MoDCs (iMoDCs) given that 89% 
(mean) of iMoDCs already expressed MHCII prior to treatment. MHCII expression 
is commonly associated with DC maturation, and results from the redistribution of 
molecules from the intracellular vesicular compartments to the cell surface (Winzler 
et al., 1997). An up-regulation of MHCII expression has been shown in porcine
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MoDC following LPS treatment (Pilon et al., 2009) and LPS and TNF-a treatment 
(Carrasco et al., 2001).
CD80/86 represents the human equivalent of murine B7 molecules, which 
when expressed on DCs provide the additional signals required to co-stimulate and 
activate T-cells, a functional feature of mature DCs (Winzler et al., 1997). Increased 
CD80/86 positive cells was observed upon maturation cocktail treatment, which is in 
agreement with other studies of porcine MoDC following various forms of 
stimulation, including LPS alone (Carrasco et al., 2001; Facci et al., 2010; Flores- 
Mendoza et al., 2008), and LPS/IFN-y/TNF-a cocktail (Pilon et al., 2009).
Whilst CD83 expression is a known marker DC maturation in humans (Zhou 
and Tedder, 1996) and mice (Berchtold et al., 1999), this is the first report of CD83 
expression by porcine MoDCs. Recent studies highlight species differences 
regarding MoDC CD83 expression (Moyo et al., 2013). Although the number of 
porcine MoDCs expressing CD83 was significantly up-regulated following 
maturation cocktail treatment, its expression by iMoDCs suggest that the porcine 
species also behaves differently to humans and mice which do not express CD83 on 
iMoDCs.
In contrast to other molecules involved in antigen presentation, the 
percentage of cells expressing CD1 was unchanged following maturation. This 
finding agrees with Carrasco et al, who denote low CD1 expression following LPS 
and TNF-a treatment of porcine MoDC (Carrasco et al., 2001). Although CD1, 
diverged evolutionally from MHC molecules, is considered to play a significant role 
in immune responses by way of antigen presentation, associated with lipids and
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gylcolipids (Dascher and Brenner, 2003), its expression does not depend on MoDC 
maturation in humans (Cao et al., 2002).
While CD 14 is generally viewed as a marker of monocytes and macrophages 
rather than DCs and is not expressed on blood DCs in humans (Thomas et al., 1993), 
its expression on porcine MoDCs was perhaps surprising. However, CD 14 is 
expressed by a subset of dermal DCs with impaired allostimulatory properties 
(Nestle et al., 1993) and was described on porcine MoDCs by others, and on MoDCs 
from other species, including cat, cattle and dog (Miranda de Carvalho et al., 2006). 
The significant decrease in cells expressing CD 14 following maturation is in line 
with other porcine MoDC studies by Paillot et al and Chamorro et al (Chamorro et 
al., 2004; Paillot et al., 2001), but disagrees with the study of Carrasco et al, who 
report increased CD 14 following MoDC maturation (Carrasco et al., 2001). This 
discrepancy could be due to the significant differences in the differentiation protocol. 
Carrasco et al used autologous porcine serum for the differentiation of DCs, the 
same factor often used for the differentiation of macrophages rather than fetal bovine 
serum (PBS). Therefore, it is possible that these cells maintained a degree of 
MoM0 characteristics despite their DC function. As MoDCs are reported to lose 
their phagocytic ability following maturation and do not need to sense danger again, 
it is perhaps more conceivable that CD 14 would no longer be required by mMoDC.
A high percentage of cells expressing CD25 was observed on both immature
and maturation cocktail treated porcine MoDC. It could be expected that the
immune regulatory role of CD25, as an IL-2 receptor, would be linked with
maturation and this was indeed shown by Pilon et al in porcine MoDCs (Pilon et al.,
2009), however, there are no other reports which support this theory, neither in pig
or human studies. It is interesting to note, however, that in mice studies, it is
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suggested that the IL-2 receptor on DCs is non-functional, due to the lack of the IL-2 
receptor p chain on these cells (Kronin et al., 1998). Therefore, the suggested role of 
CD25 in MoDC maturation may not have any significant relevance.
Another interesting observation regarding the expression of molecules 
involved in DC function was the unchanged expression of mannose receptor CD206 
on both immature and maturation cocktail treated MoDC. CD206 expression is 
reported to be hallmark of immature DC, as it is not expressed on monocytes or the 
mature DCs (Cochand et al., 1999; Mellman et al., 1998; Sallusto and Lanzavecchia, 
1994), but it would appear that this is not the case with porcine MoDCs, which 
similarly to CD83 could be another species difference. Alternatively, as previously 
discussed with regard to MoM0s in section 4.6.2, potential lack of cross-reactivity 
and hence reduced affinity of the human antibody used to detect CD206 expression 
may explain the unchanged expression on porcine MoDCs.
Despite modulation of several other functional molecules, no significant
changes were observed in the percentage of cells expressing CD209/DC-SIGN
following MoDC maturation. Given that DC-SIGN is a critical mediator of the
migratory and T-cell interaction capacities of DCs, it is, perhaps, surprising that it
was unchanged upon maturation, particularly as it is mature DCs that are specialised
for migration (Cunningham et al., 2010). Nonetheless, there are few reports that
describe the role of DC-SIGN in DC maturation, other than that of Cheong et al
(Cheong et al., 2010). They described a 10-fold increase in DC-SIGN on mouse
MoDC following LPS stimulation, but LPS is used for in vivo differentiation from
monocytes rather than maturation of differentiated DCs, so the study is not
comparable with the present one. In contrast, and possibly more relevant to this
study, due to its presence in the maturation cocktail, TGF-p is reported to reduce
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DC-SIGN on Langerhans cells (Borkowski et al., 1996). Moreover, it is reported 
that DC-SIGN is highly expressed on immature DCs in peripheral tissues rather than 
mature DCs (Curtis et al., 1992; Geijtenbeek et al., 2000b).
It can be concluded by the changes listed above that the maturation cocktail 
resulted in a phenotype consistent with DC maturation. However, it would seem that 
regardless of MoDC maturation, CD 163 and CD 169 expression by MoDCs remained 
negligible, despite two factors of the maturation cocktail, IL1-P, and IFN-y, 
individually increased numbers of monocytes expressing CD 163 and CD 169, shown 
in Chapter 3. It was, therefore, interesting to determine whether the same result 
would be observed following dexa and IL-10 treatment, identified as the most 
significant drivers of CD 163 and CD 169 expression.
Despite the modulated phenotype upon maturation, there were no significant 
differences in the endocytic or phagocytic activity of mMoDCs. Other groups 
describe decreased macropinocytosis in mature MoDC (reviewed by Summerfield et 
al (Summerfield and McCullough, 2009), and although a large percentage of porcine 
MoDCs are shown to phagocytose by Bautista et al (Bautista et al., 2007), the effects 
of MoDC maturation were not investigated in this study. The present study, 
however, showed less than 20% of iMoDCs to phagocytose or endocytose, and the 
data were variable between replicates. This could be related to the difference in the 
methodologies used as Bautista et al use 2 pm particles for phagocytosis, in contrast 
to the 4 pm particles used in this study. It could be suggested, therefore, that MoDCs 
more readily take up smaller particles. Furthermore, reduced endocytic activity is 
reported in human mMoDC, following maturation with TNF-a/LPS (Bimczok et al., 
2007) or TNF-a/LPS/TLR ligand (Rau et al., 2006).
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5.7.3. Porcine MoDCs respond to exogenous factors by modulation of
phenotype and function
Prior to this study, little was known about the effects of dexa on porcine 
MoDCs, but several reports suggested that glucocorticoids could impair MoDC 
differentiation and maturation (Bengtsson et ah, 2004; Woltman et al., 2000; Xia et 
al., 2005). With regard to IL-10, Velten et al described that IL-10 induced a 
regulatory subset of DCs (Velten et al., 2004). Both factors have been described to 
skew MoDC differentiation to a more macrophage-like cell, but this is unlikely to be 
observed past the stage of differentiation which is what is measured in this study 
(Allavena et al., 1998; Matasic et al., 1999).
Initial investigations showed that the morphology of dexa treated MoDCs 
(dexa MoDCs) were not macrophage like but still very much represented DCs; cells 
were clustered and expressed cellular elongations. This finding agrees with 
Duperrier et al in that dexa does not influence human MoDC morphology after 
differentiation (Duperrier et al., 2005).
Whilst the effects on morphology were minimal, dexa induced significant 
changes to MoDC phenotype. The dexa MoDC phenotype was different to both 
iMoDC and IL-10 treated MoDC. MHCII expression remained to be expressed by 
high percentages of dexa MoDCs, which was also shown by Duperrier et al 
(Duperrier et al., 2005). As described earlier, such high MHCII expression is 
associated with DC maturation, and suggested that these cells would better prime 
antigen presentation.
The effects of dexa on MoDC phenotype, however, were not otherwise 
consistent with maturation. With regard to CD80/86 and CD83, percentages of dexa
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MoDCs expressing these markers were slightly decreased, albeit not statistically 
significantly to iMoDC. Decreased CD80/86 expression on dexa treated MoDCs is 
reported in the same human MoDC study by Duperrier et al, along with decreased 
CD83 expression (Duperrier et ah, 2005). Whilst the reported decrease in CD83 is 
supported by Matasic et al in another human MoDC study (Matasic et al., 1999), it is 
also contradicted by results using a murine DC cell line by Kitakima et al where 
CD86 was increased by dexa (Kitajima et al., 1996). The difference between 
CD80/86 and CD83 positive cells in mMoDCs and dexa MoDCs in the present study 
support the theory that dexa inhibits maturation, as does the finding that dexa 
MoDCs showed significantly enhanced CD 14 expression, where percentage 
expression exceeded that described on MoMos in the previous chapter. This finding 
agrees with several others (Canning et al., 2000; Duperrier et al., 2005; Piemonti et 
al., 1999), and strengthens the suggestion of increased phagocytic activity of dexa 
MoDCs.
Interestingly, dexa was the only factor to modulate the percentage expression 
of CD1 by MoDCs. This was surprising, since many groups report a suppressive 
effect of dexa on CD la  expression in humans (Canning et al., 2000; Mainali et al., 
2005; Piemonti et al., 1999; Xia et al., 2009). Xia et al, however, described the 
effect of dexa to be dose dependent, but it was recognised in Chapter 3 that only 
minimal concentrations of dexa were required to affect monocytes.
Notably, the percentage of MoDCs expressing CD25 was decreased
following dexa treatment. Since the role of CD25 on DCs is discussed
controversially, it is perhaps not surprising that there are no MoDC studies which
discuss the influence of dexa on the expression of CD25 on DCs, instead only those
which describe the effects of dexa on T-cells, for which negligible effects of dexa are
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reported (Kitajima et al., 1996). The fact that CD25 was not altered on maturation, 
but by dexa, which has anti-inflammatory properties, argues perhaps for an active 
role of dexa in the interaction with T-cells.
Expression of DC-SIGN was observed on a significantly higher percentage of 
dexa treated MoDCs than IL-10 MoDCs, and was not reduced compared to iMoDCs. 
The slight increase in DC-SIGN itself, however, is surprising, given that Relloso et 
al report that dexa blocks the GM-CSF and IL-4 acquisition of DC-SIGN by 
blocking IL-4 triggered intracellular signalling (Relloso et al., 2002). However, the 
study by Relloso et al incorporates dexa alongside GM-CSF and IL-4 in the MoDC 
differentiation step, rather than following differentiation as in this study. As DC- 
SIGN is associated with immature DCs, and its ligation actively primes DCs to 
induce T-regs (Smits et al., 2005) its expression on dexa MoDCs is not consistent 
with a deactivation state. Additionally, dexa is reported to inhibit the NF-Kp 
pathway (Auphan et al., 1995; Scheinman et al., 1995), by which DC-SIGN is 
positively regulated (Neumann et al., 2000), so it is surprising that this effect was not 
observed on porcine MoDCs.
With regard to another important molecule with some role in DC function, 
dexa significantly increased the percentage of cells expressing mannose receptor 
CD206, which is important for antigen uptake of DC (Reis e Sousa et al., 1993). 
This effect of dexa is similarly reported on human MoDCs (Piemonti et al., 1999). 
As previously discussed, CD206 is associated with iMoDC in human and mouse 
studies, and therefore, this finding supports the argument that the dexa MoDC 
phenotype is one that is immature rather than mature.
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Like glucocorticoids, IL-10 is an important effector of the immune system, 
and while its effects are usually described as immunosuppressive (Saraiva and 
O'Garra, 2010), IL-10 has originally been identified as a Th2 cytokine which 
stimulates B cells. In contrast to dexa, IL-10 failed to significantly modulate MoDC 
phenotype in this study, which is in line with the reported inhibition of DC 
maturation by IL-10 in humans (Buelens et al., 1997). IL-10 treated MoDC also 
induced very minimal changes to MoDC morphology, and showed similarities to 
iMoDC morphology. When IL-10 is used during the differentiation pathway of 
human MoDCs (alongside GM-CSF and IL-4), cells lack DC morphology and have a 
CD la ' and MHCIIlow phenotype (Allavena et al., 1998). As with dexa, this study 
suggests that these effects of IL-10 are not apparent on differentiated MoDCs
Despite variability in the endocytosis and phagocytosis data, possibly due to 
variability between pigs, a significant difference was observed between the 
endocytic activity of dexa MoDC and iMoDC. Although the variability 
compromises the data, it was in line with the observed increased percentage 
expression of CD 14 and CD206, and is in agreement with other studies of human 
MoDCs (Piemonti et al., 1999; Xia et al., 2005). Hodrea et al (Hodrea et al., 2012) 
report that dexa also has a positive effect on the MoDC phagocytic activity, but data 
in the present study did not show a significant increase. A higher acquisition 
capacity is also described of dexa treated MoDCs by Banchereau et al, which is said 
to be fitting with properties of immature MoDC (Banchereau et al., 2000).
IL-10 also showed a positive effect on MoDC uptake by increased
phagocytic activity. This is in line with Morel et al (Morel et al., 1997), where
increased antigen capture ability is described in IL-10 treated MoDCs, which
maintain iMoDC characteristics. An increase in endocytic activity is also described
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by Longoni et al (Longoni et al., 1998), but although data in this study showed a 
trend to this effect, the difference was not statistically significant. It is likely that 
endocytosis and phagocytosis use similar pathways, however, so it may be that IL-10 
enhances uptake in general but the data was not sufficient to show this in both tests 
of uptake.
Despite significant effects on MoDC phenotype and function by dexa, and on 
MoDC function by IL-10, neither factor was able to modulate putative PRRSV 
receptors CD 163 or CD 169. This was unexpected following the effects of these 
factors observed during studies on porcine monocytes and macrophages, and 
suggested that unlike the other myeloid cells, porcine MoDCs do not express these 
PRRSV receptors in any state of activation or maturation. Similarly, it is reported 
that human MoDCs express very low levels of CD 163 (Sulahian et al., 2000), and 
that CD 169 is expressed only following human rhinovirus infection (Kirchberger et 
al., 2005). The lack of CD 163 and CD 169 expression queried the susceptibility of 
these cells to PRRSV infection.
Ideally, it would have been ideal to proceed with functional tests to include 
the ability of MoDCs to present antigens to T-cells either by studying mixed 
leukocyte reaction (MLR) tests or primary antigen presentation. However, since 
time was limited and the focus of this study is the interaction of myeloid cells with 
PRRSV, these investigations were prioritised.
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5.7.4. Infection of porcine MoDCs with PRRSV-1
Following the acknowledgment that porcine MoDCs did not express PRRSV 
receptors CD 163 and CD 169 in any state, several questions were raised regarding 
their susceptibility to PRRSV. The first essential question was whether MoDC 
subsets could be infected with European PRRSV at all, and if so, whether their 
susceptibility would be modulated with dexa, or IL-10 treatment.
Levels of PRRSV replication in iMoDCs remained very low throughout the 
observation period of 72 hours with AACt values of 5 at all time points other than a 
peak at 24 hours post infection (p.i) of 6.2. In the cell supernatant, PRRSV 
replication was also very low and failed to reach levels measured in monocytes and 
MoMos. Furthermore, replication was too low for detection of PRRSV N protein 
production. Despite the low levels of replication, morphological analysis of MoDCs 
in this study did not suggest a significant amount of cell death, which is in line with 
the low m.o.i used and a low replication rate. While low levels of replication in 
MoDCs are not reported elsewhere, similarly Park et al report a peak in PRRSV 
infection of MoDCs at 24 hours p.i, and a decline in replication until 72 hours p.i due 
to a loss of cell viability following 24 hours (Park et al., 2008). However, Park et al 
infect MoDCs with PRRSV-2, well known for its increased pathogenicity in 
comparison to PRRSV-1 used in the present study.
Another porcine MoDC study using PRRSV-1 also describes a peak of 
infection at 24 hours p.i, and highlights the variation between virus strains (Silva- 
Campa et al., 2010), which could not be studied here, but it may be a particular 
feature of Lena to replicate poorly in MoDC. Interestingly, the same study suggests 
that DCs remain in an immature state following infection, as was shown for PRRSV-
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2 strains (Flores-Mendoza et al., 2008; Wang et al., 2007). This denotes that PRRSV 
favours replication in immature MoDCs, which could also be said of the data 
obtained in this study. Although PRRSV replication was shown in both iMoDC and 
mMoDC, mMoDCs were more refractory to infection. It should be considered, 
however, that the cocktail used for maturation of MoDCs contained IFN-y, the anti­
viral effects of which were discussed and demonstrated in MoMos in Chapter 4.
Whilst dexa had increased the susceptibility of other myeloid cells to 
PRRSV, it did not affect the susceptibility of MoDCs. This is interesting in that 
dexa treatment also failed to induce expression of putative PRRSV receptors CD 163 
and CD 169, and suggests that its effects on the susceptibility of monocytes and 
MoM0s is solely via the modulation of these molecules and not by any additional 
effects.
Given the low replication in comparison to monocytes and MoMos, it is clear 
that a higher multiplicity of infection (m.o.i) would have been desirable for infection 
of MoDCs. Changing the m.o.i, however, would have made comparisons with other 
myeloid cells impossible, and in addition, an m.o.i of 0.1 has been used successfully 
for PRRSV-1 MoDC infection studies before (Silva-Campa et al., 2010). Given the 
recognised genetic diversity of PRRSV, however, it is likely that replication time in 
MoDCs would be strain-dependent.
In addition to detecting PRRSV infection of MoDCs by viral RNA extracted 
from cells, extracellular virus was also detected by qPCR analysis of viral RNA 
extracted from MoDC supernatant. As with MoM0s in chapter 4, these data show 
more variance due to the absence of normalisation of qPCR data, but the study was 
still able to show some interesting findings.
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As expected from the cellular assessment of MoDC susceptibility to PRRSV, 
extracellular production of PRRSV showed lower levels than those observed with 
monocytes and MoMos. Virus was not detected until 24 hours p.i, which mirrored 
the time-point where a peak infection was measured in cells, which suggested it is at 
this time point that virus is produced by cells into the cell supernatant, albeit at low 
levels.
Interestingly, dexa treated MoDCs and IL-10 MoDCs showed the highest 
levels at 36 and 48 hours p.i, which was surprising since no significant differences 
between MoDC subsets were observed on a cellular level. This increased production 
was not measurable at 72 hours and could suggest that the released virus re-infected 
further MoDCs. IL-10 was also shown to increase virus production by MoMos in 
Chapter 4.
In summary, it appears that PRRSV is able to infect MoDCs in all subsets, its 
replication is much slower than in other myeloid cells. The lack of CD 163 and 
CD 169 might be linked to the lower uptake and replication, but the virus seems to be 
able to use alternate mechanisms for infection. This, however, can only be tested 
using a higher m.o.i and demonstrating viral proteins in MoDCs in combination with 
staining for CD 163 and CD 169.
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Chapter VI
Conclusions 
and Future 
Work
6. CONCLUSIONS AND FUTURE WORK
6.1. Introduction
The current understanding of PRRSV pathogenesis lacks a comprehensive 
characterisation of the innate immunological mechanisms that follow infection. 
Since innate immunity drives the adaptive immune response, which PRRSV has 
been suggested to interfere with, the elucidation of these mechanisms would be 
crucial to the development of improved disease control. The present study, 
therefore, attempted to thoroughly characterise porcine myeloid innate immune cells 
using in vitro techniques, in order to predict the roles of these cells upon PRRSV 
infection in vivo. The hypothesis that porcine myeloid cells show distinct 
heterogeneity, not only in phenotype and function but is further reflected by 
variations in susceptibility to PRRSV, was investigated.
6.2. Characterisation of porcine myeloid cells
The in vitro study of porcine monocytes, immediately following isolation 
without the requirement of a differentiation step, could be considered the most 
representative model of all the myeloid cells in terms of resembling their behaviour 
in vivo. When in circulation, however, monocytes are exposed to various other 
factors, forming a specific environment which is impossible to replicate in vitro. 
The availability of recombinant purified cytokines does, however, allow the in vivo 
environment to be modelled in vitro. The effects of macrophage-colony stimulating 
factor (M-CSF), likely to be present in the circulation with monocytes (Popova et al.,
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2011), were investigated using a recombinant source of this factor, which led to the 
conclusion that porcine monocytes are able to proliferate in the presence of M-CSF. 
Monocyte proliferation until recently was a controversial concept, but has been 
suggested in other species so may not be unique to pigs (Clanchy et al., 2006). In 
addition it has been suggested that IL-34, which is similar to M-CSF and acts by the 
same CSF-1 receptor, also induces proliferation of monocytes (Lin et al., 2008). M- 
CSF is produced by cells of the monocyte/macrophage lineage, and also by B and T - 
cells that are activated (Popova et al., 2011). Since infection would trigger the 
activation of these cells, the autocrine production of M-CSF may support the 
availability of increased numbers of monocytes and consequently macrophages in 
the case of an infection in pigs.
M-CSF was also able to differentiate monocytes in to macrophage-like state. 
Porcine monocyte derived macrophages (MoMos) proved to be an appropriate 
representation of in vivo macrophages, as they expressed relevant macrophage 
specific molecules and showed endocytic and phagocytic uptake of foreign synthetic 
particles. Porcine MoMos also demonstrated their heterogeneity, as described in 
human and mouse macrophages, with the capacity to exist in four different states of 
activation following treatment with various inflammatory/activating factors. In 
addition to characterising porcine MoMos in the two described activation states (i.e. 
classical and alternative) as Ml (MHCII*" CD80/86hl CD25hl) and M2 (SWC9hl), two 
further MoM0 states were characterised following both dexa and IL-10 treatment, 
neither of which induced the deactivation states that are proposed in the literature 
(Gordon and Martinez, 2010). Whilst both dexa and IL-10 induced phenotypes 
suggestive of decreased antigen presentation ability, they also resulted in enhanced 
macrophage uptake, suggesting that deactivation is not the correct term for porcine
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macrophages and that these cells may play a role in the clearance of 
pathogens/damaged cells, similar to M2 cells. The array of MoMo phenotypes, 
including variability in the expression of several functional molecules, highlighted 
the impact external inflammatory mediators might have in vivo, and the functional 
consequences that might follow. The limited number of markers available for 
porcine macrophages prevented the full characterisation of cells, thus further 
analysis using more sophisticated technologies, such as microarray or quantitative 
proteomics, should be used to elude the differences in macrophages further. These 
will be able to confirm how well the porcine system compares to the human or 
mouse immunology.
Porcine dendritic cells (DCs) were represented in the study by monocyte 
derived DCs (MoDCs), recently demonstrated to resemble inflammatory DCs, which 
would appear in infections like PRRSV (Geissmann et al., 2008). MoDCs in vitro 
demonstrated similar characteristics described in human and mouse DCs, and 
displayed some heterogeneity following treatment with a described maturation 
cocktail and also with dexamethasone or IL-10. MoDCs could be characterised as 
four stages of differentiation and activation, which lacked expression of CD 163 and 
CD 169, even following dexa or IL-10 treatment which enhanced expression on both 
monocytes and MoM0s. This confirmed that the effects of dexa and IL-10 are not 
identical across myeloid cells.
6.3. PRRSV susceptibility across different myeloid cells
PRRSV replication in myeloid cells is reported to require both scavenger 
receptor CD 163 and sialic-acid binding lectin sialoadhesin (CD 169) (Van Breedam
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et al., 2010a). This study confirmed the hypothesis that PRRSV is able to replicate 
in myeloid cells in their various states of activation or maturation. While changes in 
susceptibility to PRRSV were influenced by immunomodulators which occur in vivo, 
patterns in the infection of myeloid cells did not always relate to CD 163 and CD 169 
expression.
6.4. Monocytes
Contrary to previous reports, monocytes were susceptible to PRRSV, and 
showed higher/faster levels of replication than MoMos and MoDCs. Whilst 
monocytes displayed significant modulation in their expression of CD 163 and 
CD 169 upon treatment with various recombinant pro and anti-inflammatory factors, 
only in some cases did this result in altered PRRSV replication. For example, 
PRRSV replication was enhanced following up-regulation of both CD 163 and 
CD 169 by dexa, but also following up-regulation of CD 163 only by IL-10. 
Conversely, M-CSF enhanced both receptors without affecting PRRSV replication. 
This argues the case that infection requires more than just the described receptors, 
however, it could be assumed that each of these factors also induced other changes in 
the transcriptome and proteome of the cells which may have modulated viral 
replication. This suggestion requires further investigation, however, perhaps by 
microarray analysis.
The higher levels of replication in monocytes, in comparison to other 
myeloid cell types, may be advantageous to the success of PRRSV given the less 
significant role of monocytes in the immune response. Unlike differentiated 
macrophages and DCs, monocytes are not equipped to process and present antigen to
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T-cells, so their responses upon infection are likely to result in reduced activation of 
adaptive immune responses in the early stages of infection. Additional approaches, 
such as microarray analysis of monocytes, may provide interesting insights into the 
role of these cells upon infection, and may identify key features such as the 
production of chemokines in order to attract other immune cells.
Furthermore, elevated replication by monocytes also suggested that 
monocytes could be used as a reliable method for PRRSV-1 propagation as an 
alternative to PAMs, which are difficult to obtain and require the killing of animals. 
The use of immortalised dexa treated monocytes is a possibility, therefore, and is 
currently under further investigation by colleagues at AHVLA. A suitable cell-line 
for PRRSV-1 propagation would enable large volumes of uniform virus isolates to 
be produced and thus enhance the quality of PRRSV in vitro studies. Moreover, this 
would prevent the unnecessary killing of pigs required for the continuous supply of 
alveolar macrophages.
6.5. Monocyte derived macrophages (MoM0s)
The analysis of MoMos confirmed the hypothesis that PRRSV susceptibility 
varies across myeloid cell subsets. It was clear that differences in PRRSV tropism 
also varied with time, for example, at early time-points p.i, classically activated 
macrophages were refractory to infection but replicated at a later stage, possibly due 
to the anti-viral effects of IFN-y used to stimulate MoMos. Although not 
demonstrated, enhanced antigen presentation was suggested of M l macrophages by 
their expression of particular surface molecules such as MHCII and CD80/86. The 
reduction in PRRSV replication in these cells with potential increased antigen
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presentation is consistent with the delayed T-cell mediated immunity described with 
PRRSV (Bautista and Molitor, 1997). The stimulation of classical activation upon 
PRRSV infection should also be considered; IFN-y is known to be produced 
following PRRSV infection (Olin et al., 2005; Weesendorp et al., 2013), and it is 
likely that uninfected macrophages in vivo may undergo the phenotypical changes 
that are described here, driving them to a state refractory to PRRSV infection. 
Moreover, following the first priming signal of IFN-y, macrophages can be activated 
by exogenous TNF-a, reportedly induced following PRRSV infection (Ait-Ali et al., 
2007; Park et al., 2008), enabling the classical activation of macrophages 
independently of LPS (Mosser, 2003). All of these suggestions might in turn explain 
why only so few tissue macrophages in vivo were found to be PRRSV positive after 
in vivo infection (Morgan et al., 2013).
Both dexa and IL-10 increased CD 163 expression on MoMos, again 
strengthening the correlation of this receptor with PRRSV. The relevance of CD 169 
was queried here, however, due to the lack of a significant increase by IL-10. This 
does not conform to the proposed requirement of CD 169 in the attachment of 
PRRSV (Van Breedam et al., 2010a).
6.6. Monocyte derived dendritic cells (MoDCs)
Unlike other myeloid cells, PRRSV replication by MoDCs, which were all 
CD 163 and CD 169 negative, was unaffected by dexa and IL-10. This might argue 
that the main effects of dexa and IL-10 on replication are by the regulation of CD 163 
and CD 169. Conversely, the lack of CD 163 and CD 169 on MoDCs and the ability 
to infect such cells in principle, proposes that PRRSV infection of DCs involve
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receptors which have not yet been identified. Furthermore, it could also be 
considered that DCs could become infected by the uptake of bystander infected 
apoptotic cells, for which it would not require PRRSV specific receptors. This 
theory, which is also supported by a recent study by Frydas et al (Frydas et al., 
2013), however, would require further investigations where MoDCs would be 
infected alongside other susceptible cell types.
The reduced susceptibility of mature MoDCs, however, is likely to be due to 
the anti-viral effect of IFN-y in the maturation cocktail, as observed in Ml MoM0s. 
This was the only difference observed in susceptibility to PRRSV across MoDC 
subsets. Given that DCs are considered the most professional APCs, the slow and 
inefficient replication of PRRSV by MoDCs may also explain the delay in the T-cell 
response to PRRSV and conversely might provide PRRSV with an elegant immune 
evasion mechanism.
6.7. The influence of dexamethasone and IL-10 on PRRSV
Dexa and IL-10 were both shown to promote PRRSV replication at some 
stage throughout the study of monocytes and macrophages. Both factors were able 
to drive replication by monocytes individually, and while dexa promoted replication 
by MoM0s at early time points, IL-10 played a role in the later stages of infection, 
perhaps by a downstream effect on viral release, which significantly increased over 
time. However, it could also be suggested that IL-10 improves cell viability, thereby 
delaying viral release by apoptotic cells.
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The failure to influence MoDCs in the same manner isolates the effects of 
dexa and IL-10 to actions via CD 163 and CD 169 modulation only, and raises 
questions regarding the intracellular pathways involved in the effects of dexa and IL- 
10. DCs are known to express IL-10 receptors, and while dexa does not bind 
specifically to a cell surface receptor, it is expected to act via nuclear receptors 
(Castrillo and Tontonoz, 2004). The effect of IL-10 on DCs is important, given the 
increasing number of reports describing IL-10 production by PRRSV as a 
mechanism of evasion of the immune response, usually associated with immune 
suppression (Diaz et al., 2006; Suradhat et al., 2003). This study does not support a 
direct effect of IL-10 on the suppression of DCs, but does suggest an additional role 
of IL-10 in replication of virus, which might potentially result in the increased 
infection to bystander cells.
Unlike the vast number of reports that suggest that PRRSV induces IL-10, 
there are very few reports investigating the role of cortisol in PRRSV infection. 
Those that do, however, are consistent in their reports of a down-regulation of the 
cortisol response following the first week of exposure to PRRSV infection, which is 
associated with no change in pro-inflammatory cytokine production by PRRSV 
(Borghetti et al., 2011; Sutherland et al., 2007). Given that the significant effect of 
dexa on monocyte and MoM0 replication in the early stage of infection, it would be 
interesting to determine whether cortisol is suppressed immediately upon infection. 
Perhaps it is produced early on to enhance susceptibility and spread rapidly, but is 
decreased at a later stage to delay the anti-inflammatory effects.
Findings regarding dexa became even more interesting upon the realisation 
that significant effects occurred when treating cells with only minute amounts. This 
strongly suggests a link between cortisol levels and PRRSV susceptibility, pointing
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towards a significant influence of stress of the animal on vulnerability to infection. 
The effect of dexa on susceptibility to PRRSV may also be relevant in the latency of 
PRRSV infection, since it is reported that dexa treatment reactivates latent 
herpesvirus in cattle (Winkler et al., 2000). Furthermore, the effects observed on the 
phenotype of myeloid cells may represent further downstream implications which 
could also be related to susceptibility to infection, as dexa has the ability to suppress 
JAK-STAT signalling (Bianchi et al., 2000) and inhibits NFkB (Auphan et al., 1995; 
Scheinman et al., 1995).
6.8. Future work
There are a number of additional techniques that can be used in the future to 
characterise macrophages and DCs more extensively. Firstly, microarray analysis 
would enable the comparison of myeloid cell subsets on a transcriptome level, and 
would help identify which pathways are activated following activation or maturation. 
This would permit a more comprehensive comparison with other species, which may 
enlighten whether the pig is a good model of human immune responses as suggested 
by Fairbaim et al (Fairbaim et al., 2011). Microarray experiments have been carried 
out for the comparison of macrophage subsets, and analysis is on-going, however, 
further work could involve the same application to MoDC subsets which would 
allow subsequent comparison of the two cell types. More simple techniques, such as 
measuring cytokine production, particularly beneficial in the assessment of 
macrophage activation, and mixed leukocyte reactions (MLRs) would also be 
beneficial to assess antigen presentation capacities of MoMos and MoDCs.
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Although Lena has shown to be more pathogenic than other type-1 PRRSV 
strains (Kamiychuk et ah, 2010), it would be advantageous to infect the same 
myeloid cells with other PRRSV-1 virus strains to investigate whether same patterns 
occur with strains displaying a range of pathogenicities. Moreover, the suggestion 
that IL-10 production varies between PRRSV strains, and the effects of IL-10 shown 
in this study, underline the importance of testing multiple strains (Diaz et ah, 2006).
Whilst this study has provided a perspective of the time frames involved in 
PRRSV replication in individual myeloid cells, and demonstrated the effects of 
inflammatory mediators, it could have been enhanced through increased m.o.i during 
infection studies. While not necessary for the infection of monocytes, given their 
rapid replication, this would have provided an enhanced visualisation of the 
replication cycles in macrophages and DCs in the early time-points that were 
measured.
Having characterised the important myeloid cells in an uninfected state, the
same analysis could have been applied following infection of these cells. This would
help suggest the functional consequences of PRRSV infection of these myeloid cells,
perhaps providing a further insight into PRRSV-host interactions and might confirm
some of the assumptions made throughout this study. Particular aspects of interest
would include the measurement of autocrine production of M-CSF given its effects
on the monocyte proliferation and monocyte-macrophage differentiation. It is
conceivable that PRRSV may induce M-CSF production, given the described IL-34
increase in macrophages infected with equine infectious anaemia virus (EIAV)
(Covaleda et al., 2010). Moreover, M-CSF is produced via stimulation of the NFkB
pathway, which PRRSV reportedly activates (Fu et al., 2012; Wang et al., 2011).
Although unlikely to encourage replication of PRRSV-1, the proliferation of
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monocytes and the differentiation of macrophages but M-CSF may contribute to the 
survival and rapid replication of PRRSV.
Also of particular interest following infection would be the phenotype of 
cells, with regard to molecules involved in antigen presentation, such as MHCII, and 
those that might enhance replication further (CD 163, CD 169 or others which might 
be highlighted in the process). The phenotypes expressed upon infection may 
correlate with those already characterised in this study, which may determine 
whether PRRSV induces the modulation of myeloid cell activation and maturation 
states.
Finally, in order to answer one of the most significant questions initiated by 
this study, further work is required to identify which molecules are involved in 
PRRSV entry and replication, particularly in MoDCs which are susceptible despite 
expressing neither CD 163 nor CD 169. First approaches would involve the 
elimination of selected surface receptors on myeloid cells and assessing their 
consequent susceptibility to PRRSV. This could be done using specific antibodies to 
blocking receptors, or siRNA for the knock-down of receptor gene expression.
6.9. Summary
In summary, this study has provided an interesting model for PRRSV 
infection in vitro, exhibiting some interesting patterns of PRRSV infection across 
different myeloid cell subsets, which potentially provide some clues as to which 
inflammatory factors influence the success of PRRSV in vivo. The hypothesis that 
porcine myeloid cells show distinct heterogeneity and that this is reflected in their
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susceptibility to PRRSV was confirmed. Findings suggest that monocytes are highly 
effective replicators of PRRSV and MoDCs are far less effective. Macrophages fall 
between these two myeloid cells in terms of susceptibility to PRRSV, as similarly to 
MoDCs, replication is slow and cells require high viral loads in the early stages of 
infection in order to initiate significant infection. When viral loads are low, 
however, as suggested in latent periods of infection, replication is slow, particularly 
in MoDCs. The overall suggestion would be that PRRSV infects monocytes, and is 
able to kill them due to high levels of replication. This would consequently reduce 
the supply chain for myeloid cells during infection, and enables PRRSV to avoid the 
cells that significantly induce immunity. It could be suggested that instead of 
infecting macrophages and DCs, PRRSV could infect other cells which have a less 
significant role in the immune response, such as bone marrow cells. If so, PRRSV 
would be hidden from sensing cells and therefore protected by the lack of initiation 
of the immune response
The impact of external inflammatory mediators on myeloid cells was 
highlighted, in terms of phenotype and cell function. Whilst changes were often 
induced in the expression of CD 163 and CD 169, these were not always correlated 
with PRRS replication. Whilst it is undoubted that these molecules play significant 
in the downstream events following infection, it would seem that the expression of 
these putative receptors is not the sole correlate to the efficacy of PRRSV 
replication.
The common factors able to strongly influence the susceptibility of myeloid
cells to PRRSV include IFN-y, dexa and IL-10; the latter two factors are able to
enhance replication, whereas IFN-y strongly inhibits replication. IFN-y, reportedly
produced in PRRSV infection but delayed, clearly has a significant role reducing
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viral loads in myeloid cells, whereas the role of dexa and IL-10 appear to be less 
straightforward.
It could be suggested that whilst dexa/cortisol encourages the early stages of 
replication, IL-10 influences PRRSV much later by the increased transmission to 
bystander cells via enhanced viral release. The effects of IL-10 on DCs, therefore, 
are more complicated than the proposed immunosuppression. The ability of dexa to 
immediately enhance infection strengthens the suggestion that cortisol levels in 
animals that are stressed play a significant role in virus replication, perhaps 
immediately upon stress.
Whilst the findings of this study are only limited in the contribution to the 
wider objective of understanding the immune response to PRRSV in order to 
improve control of the disease, there are some important messages that can be taken 
from the study. In particular, the significance of dexa and hence cortisol 
demonstrate that the welfare of animals should be considered imperative to the 
control of infection of PRRSV, and potentially with regard to other infections also.
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